

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Birth defects and associated risk factors in a Saudi population: a cohort study from pregnancy to age 2 years

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026351
Article Type:	Research
Date Submitted by the Author:	28-Aug-2018
Complete List of Authors:	Kurdi, Ahmed; Prince Sultan Military Medical City, Majeed-Saidan, Muhammad Ali; Prince Sultan Military Medical City, Paediatrics Al Rakaf, Maha; Prince Sultan Military Medical City, Obstetrics & Gynecology AlHashem, Amal; Prince Sultan Military Medical City Botto, Lorenzo; University of Utah, Pediatrics Baageel, Hassan; King Saud bin Abdulaziz University for Health Sciences Ammari, Amer; Pediatrics
Keywords:	Birth defects, Prevalence, Risk factors, Prevention, Outcome

SCHOLARONE™
Manuscripts

1
2
3
4 **Birth defects and associated risk factors in a Saudi population: a**
5 **cohort study from pregnancy to age 2 years**
6
7
8
9

10 Ahmed M Kurdi¹, Muhammad A Majeed-Saidan², Maha S Al Rakaf¹,
11 Amal M AlHashem², Lorenzo D Botto³, Hassan S Baaqeel⁴, Amer N
12 Ammari².
13
14
15

16
17
18
19 ¹ Division of Maternal and Fetal Medicine, Department of Obstetrics
20 and Gynaecology, Prince Sultan Military Medical City (PSMMC), P.O.
21 Box 7897, Riyadh, 11159, Saudi Arabia.
22
23
24

25
26
27 ² Department of Paediatric, Division of neonatal medicine, PSMMC.
28
29

30
31 ² Department of Paediatric, Division of medical genetics, PSMMC
32
33
34

35
36 ³ Department of Paediatric, Division of medical Genetics, 295 Chipeta
37 way, Suite 25010, University of Utah school of medicine, Salt Lake
38 City, UT, USA,
39
40
41
42
43

44
45 ⁴ Department of Obstetrics and Gynaecology, King Saud Bin
46 AbdulAziz University for Health Sciences, Jeddah, Saudi Arabia,
47
48
49

50
51 **Running title:** Birth Defects and Risk Factors in a Saudi population
52
53

54 **Corresponding author:**
55
56
57
58
59
60

1
2
3 **Dr. Ahmed M. Kurdi, MD, German Board, DFM**

4
5 Consultant Maternal and Fetal Medicine

6
7 Avenue Medical Center

8
9 Kingdom of Saudi Arabia

10
11 Telephone: work +966-112000099 Ext. 158

12
13 Mobile: +966505451701

14
15 Fax: 0096611-4500185

16
17 Email: ahmedkurdi1950@gmail.com

18
19
20
21
22
23
24
25
26
27
28
29 **Abstract**

30
31
32
33
34 **Background:** Birth defects (BD) are a recognized global health priority
35 because of their increasing impact on childhood survival and health
36 worldwide. However, information on the three key areas of risk factor
37 prevalence, BD occurrence, and BD-related outcomes are limited in
38 low and middle-income countries, where most BD occurs.

39
40
41
42
43 **Objective:** To assess the three key issues for birth defect prevention
44 and care, namely risk factor prevalence, birth defects occurrence, and
45 survival, in a well-defined longitudinal cohort in Riyadh, Saudi Arabia.

46
47
48
49
50 **Design:** Longitudinal, prospective cohort study with a nested case-
51 control study.

52
53
54 **Setting:** Prince Sultan Military Medical City, Riyadh Saudi Arabia.

1
2
3
4 **Participants:** Pregnant Saudi women enrolled over three years, and
5
6 their 28646 eligible births. The nested case-control study evaluated
7
8 the underlying cohort's birth defects risk factor profile. All cases (1
9
10 179) and the unaffected controls (1 262) were followed through age 2
11
12 years.

13
14 **Main outcome measures:** Frequency of birth defects related risk
15
16 factor, the prevalence and pattern of major birth defects, and survival
17
18 through age 2 years.

19
20
21 **Results:** In this cohort of women, the burden of potentially modifiable
22
23 risk factors included high rates of diabetes (7.3%), maternal age >40
24
25 years (7.0%), consanguinity (54.5%), and lack of periconceptional folic
26
27 acid use (90.8%). The birth prevalence of birth defects was 41.2/1,000
28
29 births, driven mainly by congenital heart disease (14.8 per 1000), renal
30
31 malformations (11.3), neural tube defects (1.9), and chromosomal
32
33 anomalies (2.7). Mortality for live births with BD at 2 years of age was
34
35 15.8%.

36
37
38 **Conclusions:** This study documented specific opportunities for
39
40 primary prevention and for better care. Folic acid fortification (the rate
41
42 of neural tube defect was more than 3 times higher than what might
43
44 be achieved with full fortification), preconception diabetes screening
45
46 and consanguinity-related counseling could have significant health
47
48 benefits, in this cohort and arguably in the larger Saudi population.
49
50
51
52
53
54

55 **Article summary:**
56
57
58
59
60

Strengths and limitations of this study

- Babies with birth defects are diagnosed prospectively; prenatally, postnatally, and followed up to 2 years of age.
- Involvement of multidisciplinary teams in establishing the final diagnosis.
- Inclusion of elective termination of pregnancies with lethal birth defects and stillbirth.
- Single center study. The pregnancy cohort was mainly from families of Saudi army personnel dependents. could present a limiting factor.

The original protocol of the study: See supplementary file.

Funding statement: This project was supported by a generous grant from King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21.

Disclaimer: The funding institution has no role in the study design, data collections, analysis, interpretation of data and the writing of the various reports or the decision for submission for publications. All authors have full independence from the funder and have full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the analysis.

Competing interests statement:

All authors have completed the ICMJE uniform disclosure form at www.icmje.org-coi_disclosure.pdf and declare: no support from any organization for the submitted research article; no financial relationship with any organization that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Key Words: Birth defects, Prevalence, Risk factors, Prevention, and outcome

**Birth defects and associated risk factors in a Saudi population:
a cohort study from pregnancy to age 2 years****Introduction**

Birth defects (BD) are increasingly recognized as a global health priority because of their lifelong impact on health and survival^{1,2}. As causes of early mortality such as infections are being brought under control, BD are becoming increasingly important drivers of child survival and health also in low- and middle-income countries^{1,3}. BD affect approximately an estimated 1 in 33 newborns, contribute each year to 300,000 deaths in the first month of life, and are associated with 3.2 million birth-related disabilities³. Accordingly, the World

1
2
3 Health Assembly has emphasized the urgent need for action to help
4 prevent, diagnose, and provide timely intervention ¹.
5
6
7
8
9

10 However, local action, whether focused on primary prevention or on
11 improving care, is most effective when based on by reliable
12 information on key indicators on causes and outcomes of BD in the
13 underlying population. These data are typically scarce outside a few
14 high-resource countries. In this study, we implemented an integrated
15 approach to generate these data in well-defined cohort of women,
16 tracked from mid-gestation through the second year of life of their
17 children, to assess concurrently the burden of potentially modifiable
18 risk factors, the occurrence of BD, and survival of affected children, as
19 a basis for better prevention and care ⁴.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Methods**

35
36
37
38 **Setting.** The Prince Sultan Military Medical City (PSMMC) is a tertiary
39 teaching institution with 1250 beds and approximately 10,000 annual
40 deliveries. PSMMC primarily serves Saudi army personnel and their
41 families and is a referral center for the other 16 military hospitals in
42 the Kingdom of Saudi Arabia. The fetal medicine unit includes
43 advanced imaging facilities, including 3D and 4D scanning. The
44 paediatric department includes all major subspecialties, including
45 medical genetics, paediatric surgery, and paediatric cardiology.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Study Design** (Figure 1). Observational, prospective cohort design
5
6 with a nested case-control study. The eligible cohort included
7
8 pregnancies of women who had their antenatal care and their routine
9
10 antenatal anomaly ultrasound scan examination (USS) between 18
11
12 weeks and 22 weeks of gestation at PSMMC from 1 July 2010
13
14 through 30 June 2013.

15
16 In addition, Saudi women who are eligible for their antenatal care at
17
18 PSMMC but did not have antenatal screening ultrasound examination
19
20 and later delivered at PSMMC are included in the study.
21
22
23
24
25

26 **Inclusions and Exclusions.** Pregnancy outcomes included in the study
27
28 were live births, stillbirths (fetal deaths at 20 weeks' gestation or
29
30 later), and pregnancies electively terminated because of fetal
31
32 anomalies (ETOPFA). The study excluded spontaneous abortions,
33
34 pregnancies referred from other hospitals because of a diagnosis of a
35
36 fetal anomaly, and babies with BD delivered elsewhere and referred
37
38 to PSMMC for evaluation and management.
39
40
41
42

43 **Evaluations.** Initial antenatal screening tests included a complete
44
45 blood count, liver and kidney function tests, blood group and
46
47 antibodies screening, rubella and toxoplasma status, hepatitis B
48
49 screen, random blood sugar and HbA1c level, VDRL, sickle cell screen
50
51 and urine analysis. A glucose tolerance test was done at 24-28 weeks
52
53 of gestation.
54
55
56
57
58
59
60

1
2
3
4
5
6 When a structural birth defect was diagnosed or suspected
7
8 antenatally, mothers were counseled by one of the investigators
9
10 (MSR, AMK), demographic and exposure information was gathered,
11
12 and both parents were scheduled within 2-4 weeks in a dedicated
13
14 clinic developed for the study. At that time, a detailed diagnostic and
15
16 care plan was developed, which may have included further blood
17
18 tests and fetal imaging, or amniocentesis, chorionic villous and/or
19
20 fetal blood sampling for genetic studies. Consent was requested for
21
22 cord blood collection for future molecular testing.
23
24
25

26
27 On the first day of life, all newborns in the cohort (with and without
28
29 birth defects) were examined by a pediatrician as part of the first
30
31 clinical screening examination. Babies with BD, whether identified
32
33 antenatally or postnatally, underwent diagnostic investigations as
34
35 clinically indicated (e.g., echocardiogram, cardiac catheterization, or
36
37 other imaging studies; metabolic and molecular testing) and were
38
39 referred to the appropriate subspecialists. A clinical geneticist
40
41 evaluated all babies with suspected syndromes or multiple birth
42
43 defects. A letter was distributed to all clinical departments describing
44
45 the study and requesting that they inform the study team about all
46
47 infants and children with BD born at PSMCC.
48
49
50
51

52
53
54 **Evaluations for specific BD.** If congenital heart disease (CHD) was
55
56 detected or suspected antenatally on USS examination, the mother
57
58
59

1
2
3 was referred to the paediatric cardiologist for a fetal echocardiogram.
4
5 All these infants were also re-evaluated after birth by a pediatric
6
7 cardiologist. Isolated atrial septal defects (ASD II) were reevaluated at
8
9 6 to 12 months of age, and if at that time the echocardiogram
10
11 showed no evidence of ASD II at the time, the infant was not
12
13 considered a case. Congenital hydronephrosis (HN) was graded using
14
15 the Society of Fetal Urology grading system ⁵. Babies with grade one
16
17 HN was given a repeat US examination within the first year of life; if it
18
19 had resolved, the baby was not considered a case. Chromosomal
20
21 analysis was done according to standard procedures, and a minimum
22
23 of 20 metaphases was analyzed (Applied imaging CytoVision
24
25 Karyotyping System). Reports followed the International System of
26
27 Human Cytogenetic Nomenclature (ISCN 2013). Molecular studies
28
29 were performed at Biocenthia health group in Germany
30
31 (<http://www.bioscientia.de/en/>), Mayo medical laboratories in the
32
33 United States, and Developmental Genetic laboratory at King Faisal
34
35 specialist hospital and research center in Saudi Arabia.
36
37
38
39
40
41
42

43 **Nested Case-Control Study.** The nested case-control study included
44
45 as cases all women in the cohort with a pregnancy diagnosed with a
46
47 birth defect, and as controls a random sample of women in the
48
49 cohort with a normal USS. The random sample was generated daily
50
51 by taking the morning list of scheduled USS and using a random
52
53 number generator (<http://www.random.org>) to select potential
54
55 controls, so that the control sample would be eventually at least as
56
57
58
59
60

1
2
3 large as the estimated total number of cases. If a woman initially
4 selected as a control had a pregnancy diagnosed with a birth defect
5 at the initial or later date, she was then included in the case group.
6
7 Investigators administered an in-person structured interview to case
8 and control mothers. The interview included information on age (for
9 both parents); weight before pregnancy; height; parity; family income
10 (father's income or combined parental income if the mother worked);
11 maternal education level (illiterate, primary school graduate,
12 secondary school graduate, or university graduate); parental
13 occupation (mother; housewife, teacher, student and others, father;
14 soldier, officer or civilian employee); folic acid (FA) supplement use
15 (regular use before and during 1st trimester of pregnancy; irregular or
16 only post-conception use; no use or uncertain use per mother report);
17 parental smoking (one or both parents smoking during current
18 pregnancy); maternal radiation exposure during first trimester;
19 maternal diabetes (overt or gestational) as defined by the
20 International association of diabetes and pregnancy study groups ⁶,
21 and HbA1c level; family history of BD (in previous pregnancies and in
22 maternal or paternal lineages); drug and medication use during the
23 first trimester; chronic maternal systemic illnesses (hypothyroidism,
24 epilepsy, depression, essential hypertension, and bronchial asthma).
25 Consanguinity was defined as women being first or second cousins to
26 their husbands.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Follow up.** Case-infants (with BD) and control-infants were examined
4 in the dedicated study clinic at 1, 6, 12, 18 and 24 months of age.
5
6 Two neonatologists and a clinical geneticist supervised the clinic.
7
8 Babies with BD also continued to be followed by the relevant
9 subspecialty clinics. The remaining cohort (babies without birth
10 defects not selected as controls) was re-examined at 4-8 weeks by
11 the pediatrician for a second screening examination. A head
12 ultrasound and a postductal pulse oximetry reading were completed
13 in all babies attending the clinics. If the O₂ saturation was below 95%,
14 the baby was referred to the pediatric cardiologist for evaluation. If
15 any BD were detected at the second screening examination, the
16 babies were referred to the genetics clinic for further evaluation and
17 diagnosis. If the second screening examination proved to be normal,
18 then no further follow up was arranged. However, if BD were
19 discovered later in babies up to 2 years of age, they were included in
20 the study.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Case review, coding, classification.** BD were coded following the
42 International Statistical Classification of Diseases and Related Health
43 Problems, 10th revision, (ICD10, WHO-2010) according to EUROCAT
44 recommended procedures ⁷. We did not include isolated minor
45 anomalies or prematurity-related conditions such as patent ductus
46 arteriosus or hydrocephalus complicating intraventricular hemorrhage
47 diagnosed in preterm babies (<37 completed weeks of gestation).
48
49 Data were entered in a version of EUROCAT Data Management
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Program (EDMP) modified to include control records and the
4 additional variables generated by the case-control study and the
5 follow up.
6
7
8
9

10
11
12 **Patient and public involvement:** Our long-time experience with the
13 families and their offspring has helped us to shape the research
14 question and the study design. All the families recruited were
15 informed about the study objectives. None of the parents were
16 involved in the study. The study results were disseminated to the
17 community and professional health care provider through social
18 media interviews, newspapers, presentation at various conference, and
19 scientific publications.
20
21
22
23
24
25
26
27
28
29

30
31
32 **Institutional Ethics Review.** The study approved by the Ethical
33 Committee of the PSMCC (Project No. 366, series of 2009).
34
35
36
37

38
39 **Statistical analysis.** Proportions were compared with Chi-square or
40 Fisher's exact tests. Odd ratios for BD were computed first via
41 univariate logistic regression, then with a multiple logistic model. The
42 latter was developed by first including uncorrelated significant factors
43 ($p < 0.05$) from the univariate analysis, then reducing the number of
44 variables by stepwise backward elimination for a more parsimonious
45 model. The final model included as covariates consanguinity,
46 maternal age group, education level, diabetes and history of sib with
47 congenital anomaly. Model fit was assessed with Hosmer and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Lemeshow goodness of fit ($p=0.08$). The Nagelkerke R^2 was 0.055
4 (explaining 6% of the effect on BD). Statistical analysis was done with
5 SPSS for Windows, version 15 (SPSS Inc., Chicago, Illinois).
6
7
8
9

10 11 12 **Results**

13
14 Of the 31 032 birth outcomes of the 30351 women followed since
15 pregnancy, 30753 (99.1%) occurred at PSMHC (Figure 2). Of these,
16 2107 were spontaneous abortions (6.9%) and were not included in
17 the study, leaving 28646 eligible births (27726 singleton births and
18 920 multiple births). The overall stillbirth rate was slightly less than 1
19 percent (Figure 2).
20
21
22
23
24
25
26
27
28
29

30 **Birth defect occurrence, detection, and mortality** (Table 1). Of the
31 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a BD,
32 for an overall prevalence of 412/10000 total births, or 1 in 24 births.
33 Of these 1179 cases, 38 (3.2%) were stillbirths and 18 (1.5%) were
34 electively terminated because of lethal malformations (13 with
35 anencephaly, 3 with severe hydrops fetalis and cystic hygroma, 1 with
36 Meckel-Gruber syndrome and 1 with bilateral renal agenesis). The
37 antenatal detection rate among women who has had antenatal
38 ultrasound screening examination was 70.6%(561/795), and in 90% of
39 these (505/561) the diagnosis was made by ultrasound scan at 22
40 weeks of gestation or later. Of the 618 babies diagnosed postnatally,
41 296 (47.9%) were diagnosed at birth; 239 (38.7%) between 1-7 days,
42 29 (4.7%) between 1-4 weeks, 52 (8.4%) between 1-12 months, and 2
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (0.3%) after one year of age. Mortality among livebirths with BD
4 (Table 1) was 14.1% in the first year, nearly half of which occurred in
5 the first week of life, with a total mortality of 15.8% by the end of the
6 second year of life. Mortality at two years was 0.9% in the unaffected
7 cohort.
8
9
10
11
12
13
14
15

16 **Contribution of specific BD (Table 2).** Approximately half of the
17 overall birth prevalence was due to congenital heart disease and
18 central nervous system anomalies. Neural tube defects occurred at a
19 rate of 1.9 per 1000 (1 in 526 births). Severe CHD occurred at a rate
20 of 3.2 per 1000 (1 in 313 births) and accounted for 21.4% of all CHD
21 cases. Chromosomal conditions whose risk is associated with
22 increased maternal age (trisomies 21, 18, and 13) occurred at
23 combined prevalence of 2.5 per 1000 (1 in 392 births), with trisomy
24 21 accounting for most of the cases (2.2 per 1000 or 1 in 456 births).
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Risk factors.** Figure 3 summarizes the frequency of selected maternal
39 or parental risk factors for BD among controls in the nested case-
40 control study. Among potentially modifiable factors, lack of
41 periconceptional folic acid supplement use, consanguinity, high body
42 mass index, advanced maternal age, smoking (first or second-hand)
43 and maternal diabetes were particularly frequent. Nearly 6% of non-
44 primiparous women had one prior child with a major BD. The nested
45 case-control study (Table 3) detected overall increased odds ratios for
46 all BD combined for consanguinity, advanced maternal age, high
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 parity, maternal diabetes, and positive family history of BD in a sib.
4
5 Increased odds ratios with confidence intervals including unity were
6
7 also found for maternal depression and hypertension (Table 3).
8
9
10
11
12
13
14
15
16
17
18

19 **Discussion**

20
21
22
23
24 This longitudinal study of BD in a pregnancy cohort in Saudi Arabia
25 followed from mid-gestation through age 2 years had three
26 integrated aims: describe the population's risk factor profile,
27 document the associated birth prevalence of BD, and assess survival
28 as critical health outcome ⁴. This information is crucial when planning
29 and then evaluating policies and interventions, be they aimed at
30 primary prevention (e.g., folic acid fortification) or at improving care
31 of those affected.
32
33
34
35
36
37
38
39
40
41
42

43
44 In terms of the burden of BD, the study documented a remarkably
45 high birth prevalence of 41.2 per 1000, or 1 in 24 total births. This
46 rate is higher than that in many high-income countries, as reported
47 by EUROCAT (26.1/1000 births)⁸, BINOCAR (20.6/1000 births)⁹ and the
48 Bradford (BIB) study (30.5/1000)¹⁰. It is also higher than previously
49 reported from Saudi Arabia (11.5 to 25.7 per 1000 live births)¹¹⁻¹³.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Sallout and colleagues reported an antenatal BD prevalence of
4 52.1/1000 pregnancy screened and 46.5/1000 LB¹⁴. These high
5 prevalences are biased because of the inclusion of mothers referred
6 from other institutions, which lead to an imprecise denominator. In
7 addition, none of their cases discovered postnatally, which reflect an
8 underestimation. In the current study findings could be related in part
9 to methodological factors leading to better detection – for example,
10 the follow-up starting in pregnancy and extending through the
11 second year of life; the inclusion of stillbirths and elective termination
12 of pregnancies for fetal anomalies (ETOPFA); and the inclusion of
13 some genetic conditions that tend to be diagnosed after the newborn
14 period.
15

16
17 However, the high prevalence is likely related also to the high
18 frequency of adverse risk factors in the underlying population, as
19 documented in the controls of the nested case-control study.
20 Focusing on factors that are potentially modifiable, three factors seem
21 to stand out. The first is insufficient folic acid use in this cohort
22 (<10% in the periconceptional period). Concurrently, the rate of
23 neural tube defects was 1.9 per 1000/births (Table 2), approximately
24 three times higher to the rate of 0.6 per 1000/births that seems
25 achievable by providing sufficient folic acid to women of childbearing
26 age ^{15,16} . Although legislation for mandatory flour fortification had
27 been in place in Saudi Arabia for years prior to this study (Kingdom
28 of Saudi Arabia, 2000; Food fortification initiative, 2013)^{17,18}, our data
29 suggests that there are gaps in coverage or effectiveness, which could
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 be better documented with nutrition or blood folate surveys as a first
5
6 step for improvement. Because of the inclusion of stillbirths and
7
8 pregnancy terminations, this study also provides a fuller estimate of
9
10 the potential benefits of primary prevention, compared to if only
11
12 livebirths had been identified (representing just over half of all cases,
13
14 30/54).
15

16
17
18 The second factor is maternal diabetes (Table 3). Diabetes is an
19
20 established risk factor for many BD and whose control before
21
22 conception is associated with a near normalization of BD risk ^{6,19,20}.
23
24 Several avenues for preventing diabetes and its health effects are
25
26 available, including population screening (many diabetic women are
27
28 undiagnosed), health care and counseling, and education on healthy
29
30 lifestyle and dietary choices starting from childhood. The current
31
32 reported prevalence in Saudi Arabia of overt diabetes in women
33
34 above age 40 years range from 7.7% – 21.7% ²¹⁻²³. In the study
35
36 cohort, overt diabetes was seen in 2% of women, and even higher in
37
38 women 30 years old or older. Al-Nozha and colleagues (Al-Nozha et
39
40 al., 2004) reported a prevalence of overt diabetes of 11.6% at 30-39
41
42 years and >22% at women of ≥ 40 years ²⁴ compared to 2.7% and
43
44 7.1% in our study respectively. Though lower than these estimates,
45
46 the prevalence of overt diabetes in the study cohort is alarmingly
47
48 high.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Third, we observed a high rate of parental consanguinity (54.5%),
5 especially first-cousin marriages (48.0%). These marriages are
6 common in many parts of the Middle East, Africa, and the Indian
7 subcontinent²⁵⁻²⁷, with one estimate suggesting that “one billion
8 people live in communities with a preference for consanguineous
9 marriage” (Hamamy, 2012)²⁶. This preference has deep social roots.
10 Nevertheless, education combined with preconception and premarital
11 counseling can be important prevention strategies, focusing on
12 increasing awareness to allow couples to make more informed
13 choices. Close consanguinity is a known risk factor for BD²⁶ as well as
14 Mendelian conditions such as inborn errors of metabolism (occurring
15 in 1 in 770 births in this study), confirmed prior reports from Saudi
16 Arabia and the world literature^{28,29}.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 Finally, the impact of BD in this population is reflected not
35 only in the birth prevalence but also in the associated early
36 mortality (Table 1), which was 15.8% by the second-year life
37 (nearly all in the first year). Supporting the high impact of BD in
38 early mortality is the study by Majeed-Saidan and colleagues,
39 which showed that 36% of deaths in a large neonatal intensive
40 care unit in Riyadh was due to lethal BD³⁰. These findings
41 highlight the need to improve care in addition to primary
42 prevention, in order to improve survival associated with BD.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The study has some limitations. Because of the cohort
4 design, the study sample did not allow a more detailed analysis
5 of specific BD groups. Some key risk factors such folic acid
6 insufficiency was based on maternal reports of supplement use
7 rather than biomarkers. The pregnancy cohort was mainly from
8 families of Saudi army personnel dependents. Although the
9 Saudi Army recruits from all sectors of the Saudi society, a more
10 generalized survey of the Saudi population would be ideal to
11 assess gaps and opportunities for prevention and care.
12
13
14
15
16
17
18
19
20
21
22
23

24
25 **Conclusion.** This longitudinal surveillance program that encompassed
26 the causal chain from risk factors to health outcomes documented
27 specific opportunities for primary prevention and for better care. Folic
28 acid fortification, preconception diabetes screening, and
29 consanguinity-related counseling could have significant health
30 benefits, in this cohort and arguably in the larger Saudi population,
31 particularly if associated with a national BD monitoring program to
32 support and track the impact of interventions.
33
34
35
36
37
38
39
40
41
42
43

44 **Acknowledgments**

45 We thank the Medical Services Directorate of the Saudi Armed Forces
46 and the PSMCC directorate for their support during the initiation and
47 execution of the study; the study's advisory board (Eduardo Castilla,
48 Pierpaolo Mastroiacovo, Esther Garne, Fowzan Alkuraya, and Wesam
49 Kurdi) for advice and guidance throughout the study; and the study
50
51
52
53
54
55
56
57
58
59
60

1
2
3 secretaries for their commitment and enthusiasm.
4
5
6
7
8
9
10
11

12 **Author's statement:**
13

14
15 **AMK** study conception and design, revised the manuscript. **MAMS**,
16 study conception and design, drafting and revising the manuscript.,
17
18 **MSR**, study design, data collection. **AMH**, data collection, revised the
19 manuscript. **LDB**, study design, critically revised the manuscript for
20 intellectual content. **HSB**, statistical analysis and revised the
21 manuscript. **ANA**, study design, data collection, revised the
22 manuscript. All authors approved the submission of the manuscript.
23
24
25
26
27
28
29
30
31
32
33

34 **Patient consent form:** n/a
35
36
37

38 **Data sharing statement:**
39

40 **Dataset can be obtained on request through a third party "King**
41 **Abdulaziz city for science and technology.**
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. World Health Organization. Sixty -Third World Health Assembly. Birth defects Report by the Secretariat, A63/10. Geneva, Switzerland: World Health Organization, 2010.

- 1
2
3
4
5
6 2. World Health Organization. Global Health Observatory
7 (GHO) data. Under-five mortality 2016.
8 [http://www.who.int/gho/child_health/mortality/mortality_und](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/)
9 [er_five_text/en/](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/) (accessed 12 December 2017).
10
11
12
13
14
15
16
- 17 3. Christianson AL, Howson CP, Modell B. Global report on
18 birth defects: the hidden toll of dying and disabled children.
19 White Plains (NY): March of Dimes Defects Foundation 2006.
20
21
22
23
24
25
- 26 4. Botto LD, Mastroiacovo P. Triple surveillance: a proposal for
27 an integrated strategy to support and accelerate birth
28 defect prevention. *Ann. N. Y. Acad. Sci* 2018; (1414):126-36.
29
30
31
32
33
34
- 35 5. Avni FE, Maugey-Laulom B, Cassart M, *et al.* Fetal
36 genitourinary tract. In: Callen PW, ed. *Ultrasonography in*
37 *Obstetrics and Gynecology*. 5th Ed. New York: W.B.
38 Saunders 2007; 640-75.
39
40
41
42
43
44
45
- 46 6. Metzger BE, Gabbe SG, Persson B, *et al.* International
47 association of diabetes and pregnancy study groups
48 recommendations on the diagnosis and classification of
49 hyperglycemia in pregnancy. *Diabetes Care* 2010; 33(3):
50 676–82. doi: 10.2337/dc09-1848.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 7. EUROCAT. Eurocat Guide 1.3. Instructions for registration
7 and surveillance of congenital anomalies. Belfast, Northern
8 Ireland University of Ulster 2005. [http://www.eurocat-](http://www.eurocat-network.eu/content/Section%202.4-%2027_Oct2016.pdf)
9 [network.eu/content/Section%202.4-%2027_Oct2016.pdf](http://www.eurocat-network.eu/content/Section%202.4-%2027_Oct2016.pdf)
10
11
12
13
- 14
15
16
17 8. EUROCAT. Prevalence Tables, 2011-2015.
18 [http://www.eurocat-](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx)
19 [network.eu/newprevdata/showPDF.aspx?winx=1896&winy=9](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx)
20 [40&file=allsubgroups.aspx](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx) 2015. (accessed 12 December
21 2017).
22
23
24
- 25
26
27 9. Springett A, Budd J, Draper ES, *et al.* Congenital Anomaly
28 Statistics 2012 England and Wales, London 2014.
29 [www.binocar.org/content/Annual%20report%202012_FINAL_](http://www.binocar.org/content/Annual%20report%202012_FINAL_nologo.pdf)
30 [nologo.pdf](http://www.binocar.org/content/Annual%20report%202012_FINAL_nologo.pdf).
31
32
33
34
35
36
37
- 38
39 10. Sheridan E, Wright J, Small N, *et al.* Risk factors for
40 congenital anomaly in a multiethnic birth cohort: an analysis
41 of the Born in Bradford study. *Lancet* 2013; 382(9901):
42 1350–9. doi: 10.1016/S0140-6736(13)61132-0.
43
44
45
46
47
48
- 49
50 11. Al Bu Ali WH, Balaha MH, Al Moghannum MS, *et al.* Risk
51 factors and birth prevalence of birth defects and inborn
52 errors of metabolism in Al Ahsa, Saudi Arabia. *Pan Afr Med*
53 *J* 2011; 8: 14.
54
55
56
57
58
59
60

- 1
2
3
4
5
6 12. Fida NM, Al-Aama J, Nichols W, *et al.* A prospective study
7 of congenital malformations among live born neonates at a
8 University Hospital in Western Saudi Arabia. *Saudi Med J*
9 2007; 28(9): 1367–73.
10
11
12
13
14
15
16 13. Refat MY, Al-Moghanem M, McDonald, *et al.* Major birth
17 defects at King Fahd Hofuf Hospital: Prevalence, risk factors
18 and outcome. *Ann Saudi Med* 1995; 15(4): 339–43.
19
20
21
22
23
24
25 14. Sallout B, Obedat N, Shakeel F, *et al.* Prevalence of major
26 congenital anomalies at King Fahad Medical City in Saudi
27 Arabia: a tertiary care centre-based study. *Ann Saudi Med*
28 2015; 35(5): 343–51.
29
30
31
32
33
34
35
36 15. Kancherla V, Oakley GP Jr, *et al.* Urgent global
37 opportunities to prevent birth defects. *Semin Fetal Neonatal*
38 *Med* 2014; 19(3): 153–60.
39
40
41
42
43
44
45 16. Youngblood ME, Williamson R, Bell KN, *et al.* Update on
46 global prevention of folic acid-preventable spina bifida and
47 anencephaly. *Birth Defects Res A Clin Mol Teratol* 2013;
48 97(10): 658–63. doi: 10.1002/bdra.23166. Epub 2013.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Kingdom of Saudi Arabia, Ministry of health, Nutritional
5 department directive. Number 652/1/26, 2000; 13/09/2000.
6
7
8
9
10 18. Food Fortification Initiative. (2013).
11 [http://www.ffinetwork.org/country_profiles/country.php?reco](http://www.ffinetwork.org/country_profiles/country.php?record=194)
12 [rd=194](http://www.ffinetwork.org/country_profiles/country.php?record=194) (accessed 12 December 2017).
13
14
15
16
17
18 19. Kitzmiller JL, Wallerstein R, Correa A, *et al*. Preconception
19 care for women with diabetes and prevention of major
20 congenital malformations. *Birth Defects Res A Clin Mol*
21 *Teratol* 2010; 88(10): 791–03. doi: 10.1002/bdra.20734.
22
23
24
25
26
27 20. Simeone RM, Devine OJ, Marcinkevage JA, *et al* Diabetes
28 and congenital heart defects: a systematic review, meta-
29 analysis, and modeling project. *Am J Prev Med* 2014; 48(2):
30 195–204. doi: 10.1016/j.amepre.2014.09.002.
31
32
33
34
35
36
37
38 21. Al-Nuaim AR, Al-Rubean K, Al-Mazrou Y, *et al*. Prevalence
39 of diabetes mellitus, obesity and hypercholesterolemia in
40 Saudi Arabia: national chronic disease survey. Riyadh (KSA):
41 Ministry of Health and King Saud University. ISBN: 1995;
42 9960-603-01-6.
43
44
45
46
47
48
49
50 22. El-Hazmi M, Warsy A, Al-Swailem AR, *et al*. Diabetes
51 mellitus as a health problem in Saudi Arabia. *East Mediterr*
52 *Health J* 1998 (4): 58–67.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 23. Warsy AS, el-Hazmi MA. Diabetes mellitus, hypertension
7 and obesity--common multifactorial disorders in Saudis.
8 East Mediterr Health J 1999; 5(6): 1236–42.
9
10
11
12
13
14 24. Al-Nozha MM, Al-Maatouq M, Al-Mazrou YY.] *et al.*
15 Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25(11):
16 1603–10.
17
18
19
20
21
22
23 25. El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, et al.
24 Regional variations in the prevalence of consanguinity in
25 Saudi Arabia. Saudi Med J 2007; 28(12): 1881–4.
26
27
28
29
30
31
32 26. Hamamy H. Consanguineous marriages: Preconception
33 consultation in primary health care settings. J Community
34 Genet 2012; 3(3): 185–92.
35
36
37
38
39
40
41 27. Majeed-Saidan MA, Ammari AN, AlHashem AM, *et al.*
42 Effect of consanguinity on birth defects in Saudi women:
43 results from a nested case-control study. Birth Defects Res
44 A Clin Mol Teratol 2015; 103(2): 100–4. doi:
45 10.1002/bdra.23331.
46
47
48
49
50
51
52
53
54 28. Mak CM, Lee HC, Chan AY, *et al.* Inborn errors of
55 metabolism and expanded newborn screening: review and
56
57
58
59
60

update. *Crit Rev Clin Lab Sci* 2013; 50(6): 142–62. doi:
10.3109/10408363.2013.847896.

29. Moammar H, Cheriyan G, Mathew R, *et al*. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. *Ann Saudi Med* 2010; 30(4): 271–7. doi: 10.4103/0256-4947.65254.
30. Majeed-Saidan MA, Kashlan FT, Al-Zahrani AA, *et al*. Pattern of neonatal and postneonatal deaths over a decade (1995--2004) at a Military Hospital in Saudi Arabia. *Saudi Med J* 2008; 29(6):879-83.

Tables

Legend: Table 1 Distribution and rates of birth defects among the cohort's pregnancy outcomes, and associated mortality.

Total	With birth defects	Mortality among babies with birth defects		
		Overall (0-2 years)	1st week	Total 1st year

Birth outcome	No	%	No.	%	Rate /100	No.	%	No.	%	No.	%	No.	%
Live births	28376	99	1123	95.3	4.0	505	45.0	177	15.8	64	5.7	158	14.1
Stillbirths	252	0.9	38	3.2	15.1	38	100						
ETOPFA [†]	18	0.1	18	1.5	100	18	100						
Total	28646	100	1179	100	4.1	561	47.6						

Footnote:

[†]ETOPFA, Terminations of Pregnancy for Fetal Anomalies.

Stillbirth (fetal death at 20 weeks of gestation or greater).

Legend: Table 2 Prevalence and distribution of BDs, overall and by pregnancy outcome.

Birth defects	Number†	%	Prevalence		Live birth		Stillbirth		ETOPFA	
			per 1000 births (total births = 28646)	No.	(%)	No.	(%)	No.	(%)	
Any	1179	100	41.2	1123	95.3	38	3.2	18	1.5	
Nervous system	160	13.6	5.6	129	80.6	18	11.3	13	8.1	
Neural Tube Defects	54	4.6	1.9	30	55.5	11	20.4	13	24.1	
Anencephalus	26	2.2	0.9	7	26.9	8	30.8	11	42.3	
Encephalocele	11	0.9	0.4	9	81.8	1	9.1	1	9.1	
Spina Bifida	17	1.4	0.6	14	82.4	2	11.8	1	5.9	
Hydrocephaly	25	2.1	0.9	23	92.0	2	8.0			
Microcephaly	28	2.4	1.0	24	85.7	4	14.3			
Eye	33	2.8	1.2	33	100					
Anophthalmus/microphthalmus	11	0.9	0.4	11	100					
Congenital cataract	5	0.4	0.2	5	100					
Congenital glaucoma	9	0.8	0.3	9	100					
Ear, face and neck	7	0.6	0.2	7	100					
Anotia/microtia	7	0.6	0.2	7	100					
Cardiac	425	36.0	14.8	420	90.9	4	0.9			
Severe congenital heart defects ‡	91	7.7	3.2	89	97.8	2	2.2			
Common arterial truncus	3	0.3	0.1	3	100					

1									
2									
3	Transposition of great vessels	13	1.1	0.5	13	100			
4									
5	Single ventricle	6	0.5	0.2	6	100			
6									
7									
8	Atrioventricular septal defect	17	1.4	0.6	15	88.2	2	11.8	
9									
10	Tetralogy of Fallot	15	1.3	0.5	15	100			
11									
12	Tricuspid atresia and stenosis	4	0.3	0.1	4	100			
13									
14									
15	Pulmonary valve stenosis	22	1.9	0.8	21	95.5	1	4.5	
16									
17	Pulmonary valve atresia	9	0.8	0.3	9	100			
18									
19	Aortic valve atresia/stenosis	5	0.4	0.2	5	100			
20									
21									
22	Hypoplastic left heart	15	1.3	0.5	15	100			
23									
24	Hypoplastic right heart	5	0.4	0.2	5	100			
25									
26	Coarctation of aorta	14	1.2	0.5	14	100			
27									
28									
29	Total anomalous pulmonary venous		0.2						
30	return	2		0.1	2	100			
31									
32									
33	Ventricular septal defect	171	14.5	6.0	171	100			
34									
35	Atrial septal defect	214	18.2	7.5	214	100			
36									
37	Oro-facial clefts								
38									
39									
40	Cleft lip with or without palate	42	3.6	1.5	35	83.3	5	11.9	2 4.8
41									
42	Cleft palate only	11	0.9	0.4	11	100			
43									
44	Respiratory	33	2.8	1.2	33	100			
45									
46	Choanal atresia	5	0.4	0.2	5	100			
47									
48									
49	Digestive system	74	6.3	2.6	71	95.9	3	4.1	
50									
51	Esophageal atresia with/without fistula	12	1.0	0.4	12	100			
52									
53									
54	Ano-rectal atresia and stenosis	26	2.2	0.9	25	96.2	1	3.8	
55									
56									
57									
58									
59									
60									

1										
2										
3	Diaphragmatic hernia	18	1.5	0.6	16	88.9	2	11.1		
4										
5	Abdominal wall defects	7	0.6	0.2	6	85.7	1	14.3		
6										
7										
8	Gastroschisis	2	0.2	0.1	1	50.0	1	50.0		
9										
10	Omphalocele	5	0.4	0.2	5	100				
11										
12	Urinary	323	27.4	11.3	318	98.5	4	1.2	1	0.3
13										
14										
15	Bilateral renal agenesis	18	1.5	0.6	15	83.3	2	11.1	1	5.6
16										
17	Renal dysplasia	60	5.1	2.1	58	96.7	2	3.3		
18										
19	Congenital hydronephrosis	194	16.5	6.8	194	100				
20										
21										
22	Genital	127	10.8	4.4	126	99.2	1	0.8		
23										
24	Hypospadias	108	9.2	3.8	108	100				
25										
26										
27	Indeterminate sex	3	0.3	0.1	2	66.7	1	33.3		
28										
29	Limb	99	8.4	3.5	92	92.9	4	4.0	3	3.0
30										
31	Limb deficiencies, all	17	1.4	0.6	17	100				
32										
33										
34	Upper limb deficiency	12	1.0	0.4	12	100				
35										
36	Lower limb deficiency	7	0.6	0.2	7	100				
37										
38	Club foot - talipes equinovarus	19	1.6	0.7	15	78.9	2	10.5	2	10.5
39										
40	Hip dislocation and/or dysplasia	24	2.0	0.8	23	95.8			1	4.2
41										
42										
43	Polydactyly	23	2.0	0.8	23	100				
44										
45	Syndactyly	9	0.8	0.3	9	100				
46										
47										
48	Musculo-skeletal	40	3.4	1.4	33	82.5	7	17.5		
49										
50	Craniosynostosis	6	0.5	0.2	6	100				
51										
52	Achondroplasia	3	0.3	0.1	2	66.7	1	33.3		
53										
54										
55	Thanatophoric dysplasia	2	0.2	0.1	2	100				
56										
57										
58										
59										
60										

1										
2										
3	Jeune syndrome	2	0.2	0.1	1	50.0	1	50.5		
4										
5	Other malformations	42	3.6	1.5	40	95.2	1	2.4	1	2.4
6										
7										
8	Situs inversus	10	0.8	0.3	10	100				
9										
10	By underlying cause									
11										
12	Chromosomal	82	7.0	2.9	79	96.3	3	3.7		
13										
14										
15	Down Syndrome/trisomy 21	63	5.3	2.2	62	98.4	1	1.6		
16										
17	Edward syndrome/trisomy 18	8	0.7	0.3	7	87.5	1	12.5		
18										
19	Patau syndrome/trisomy 13	2	0.2	0.1	2	100				
20										
21										
22	Turner syndrome	3	0.3	0.1	2	66.7	1	33.3		
23										
24	Wolff-Hirschhorn syndrome	1	0.1	0.03	1	100				
25										
26										
27	Genetic syndromes (including									
28	microdeletions)	38	3.2	1.3	36	94.7	1	2.6	1	2.6
29										
30	Teratogenic (Carbamazepine									
31	embryopathy)	1	0.1	0.1	1	100				
32										
33										
34	Conditions outside Q chapter of ICD-10									
35										
36										
37	Inborn error of metabolism	37	3.1	1.3	37	100				
38										
39	Endocrine disorders	7	0.6	0.2	7	100				
40										
41	Other	11	0.9	0.4	11	100				
42										
43										
44										
45										
46										
47	Footnote:									
48										
49	† The total number of birth defects is greater than the total number of affected									
50	births because some had more than one major BD.									
51										
52										
53										
54										
55										
56										
57										
58										
59										
60										

Footnote:

† The total number of birth defects is greater than the total number of affected births because some had more than one major BD.

1
2
3 ‡ Severe congenital heart disease (EUROCAT definition): common arterial trunk
4 (Q200), double outlet right ventricle (Q201), transposition of great arteries
5 (Q203), single ventricle (Q204), atrioventricular septal defect (AVSD) (Q212),
6 tetralogy of Fallot (Q213), pulmonary valve atresia (Q220), Ebstein anomaly
7 (Q225), hypoplastic right heart (Q226), aortic valve atresia and stenosis (Q230),
8 mitral valve anomalies (Q232, Q233), hypoplastic left heart (Q234), coarctation of
9 the aorta (Q251), aortic atresia / interrupted aortic arch (Q252), total anomalous
10 pulmonary venous return (Q262).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legend: Table 3 Distribution of parental socio-demographic characteristics and association with birth defect risk.

Variable	Cases (total n=1179)		Controls (total n=1262)		Odds Ratio [†]	95% CI	
	No.	%	No.	%		Lower	Upper
	Consanguinity						
Non-consanguineous	537	45.5	693	54.9	Ref	-	-
Consanguineous	642	54.5	569	45.1	1.5	1.30	1.8
Maternal age (years)							
<20	24	2.0	48	3.8	0.58	0.35	0.96
20-30	599	50.8	694	55.0	Ref	-	-
31-40	473	40.1	474	37.6	1.16	0.98	1.37
>40	83	7.0	46	3.6	2.09	1.43	3.05
Paternal age (years)							
20-30	341	28.9	403	31.9	0.92	0.76	1.10
31-40	548	46.5	593	47.0	Ref	-	-
41-50	240	20.4	225	17.8	1.15	0.93	1.43
> 50	50	4.2	41	3.2	1.32	0.86	2.03

1								
2								
3	Maternal body mass index [†]							
4								
5	<18.5	24	2.1	35	2.8	0.75	0.44	1.29
6								
7	18.5-24.99	324	27.8	388	30.8	0.91	0.74	1.12
8								
9	25.0-29.99	352	30.2	385	30.5	Ref	-	-
10								
11	≥30	464	39.9	453	35.9	1.12	0.92	1.36
12								
13								
14	Previous deliveries (parity)							
15								
16	Nulliparous	216	18.3	273	21.6	0.92	0.74	1.16
17								
18	Para 1-2	374	31.7	436	34.5	Ref	-	-
19								
20	Para 3-4	283	24.0	273	21.6	1.21	0.97	1.50
21								
22	Para ≥5	306	26.0	280	22.2	1.27	1.03	1.58
23								
24								
25	Family monthly income Saudi riyals (US \$)							
26								
27	<3,000 SR (<800\$)	19	1.9	12	1.0	1.87	0.89	3.92
28								
29	10,000-14,000 SR (2667-3999\$)	235	23.2	277	22.3	Ref	-	-
30								
31	3,000-6,999 SR (800-1866\$)	232	22.9	291	23.4	0.94	0.74	1.20
32								
33	7,000-9,999 SR (1867-2666\$)	367	36.3	496	39.9	0.87	0.70	1.09
34								
35	≥15, 000 (≥4000\$)	158	15.6	167	13.4	1.12	0.84	1.47
36								
37	Maternal education							
38								
39	Illiterate	391	33.2	333	26.4	1.50	1.26	1.80
40								
41	Schooling up to high school	671	56.9	859	68.1	Ref	-	-
42								
43	University	117	9.9	70	5.5	2.05	1.49	2.81
44								
45	Folic acid intake							
46								
47	Periconceptual	109	9.2	128	10.1	Ref	-	-
48								
49	Improper use [§]	1070	90.8	1134	89.9	1.04	0.79	1.36
50								
51								
52								
53								
54								
55								
56								
57								
58								
59								
60								

Parental Smoking

Neither parent smoked	837	71.0	888	70.4	Ref	-	-
One or both parents smoked	342	29.0	374	29.6	0.97	0.82	1.16

Radiation exposure in pregnancy

None	1161	98.5	1254	99.4	Ref	-	-
Radiation exposure in pregnancy	18	1.5	8	0.6	2.43	1.05	5.61

Diabetes mellitus (DM)

No DM	956	81.1	1062	84.2	Ref	-	-
DM on insulin (all, overt & gestational	86	7.3	41	3.2	2.34	1.60	3.43
Gestational DM on diet only	137	11.6	157	12.6	0.91	0.62	1.16

Sibs of cases and controls (primiparous mothers excluded)

No affected sibling	757	78.6	932	94.2	Ref-	-	-
Sibling with birth defects	85	8.8	58	5.7	1.61	1.14	2.27

Medication use in pregnancy

None	792	67.2	951	75.3	-	-	-
Thyroxin	102	8.7	106	8.4	1.03	0.78	1.37
Insulin	86	7.3	40	3.2	2.34	1.59	3.45
Methyldopa	14	1.2	14	1.1	1.07	0.51	2.26

1								
2								
3	Maternal systemic illnesses							
4								
5	None	808	68.5	971	76.9	Ref-	-	-
6								
7	Mothers with Hypothyroidism	123	10.4	128	10.1	1.03	0.80	1.34
8								
9	Mothers with Bronchial asthma	106	9.0	97	7.7	1.19	0.89	1.58
10								
11	Mothers with depression	12	1.0	6	0.5	2.15	0.81	5.75
12								
13	Mothers with essential	23	2.0	15	1.2	1.65	0.86	3.19
14	hypertension							
15								
16								
17								
18								
19								
20								
21								
22								
23								
24	Footnote:							
25								
26								
27	[†] Odds ratio adjusted for multiple potential confounders in multiple logistic							
28	regression model.							
29								
30								
31	[*] BMI not available for 15 mothers							
32								
33	Some families declined reporting their income.							
34								
35								
36	[§] Improper-use includes FA taken post conception and 49 mothers (43 case							
37	mothers and 6 control mothers) who were not sure about their intake.							
38								
39								
40								
41								
42								
43								
44								
45	Figures legend:							
46								
47								
48								
49	Legend: Figure _1 Catchment site and the study flow chart.							
50								
51								
52	Legend: Figure _2 Study population and distribution of pregnancies and their							
53	outcomes.							
54								
55								
56								
57								
58								
59								
60								

Footnote:

[†]Odds ratio adjusted for multiple potential confounders in multiple logistic regression model.

^{*}BMI not available for 15 mothers

Some families declined reporting their income.

[§]Improper-use includes FA taken post conception and 49 mothers (43 case mothers and 6 control mothers) who were not sure about their intake.

Figures legend:


Legend: Figure _1 Catchment site and the study flow chart.

Legend: Figure _2 Study population and distribution of pregnancies and their outcomes.

1
2
3 Legend: Figure _ 3 Frequency among control subjects of selected risk factors for
4 birth defects.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1- Catchment site and the study flow chart.




Legend: Case catchment areas (A to E). A: antenatal clinic, B: at birth, C: the "one-month clinic", D: geneticist "one-month clinic", and E: other areas. 1,2,3 are postnatal, stillbirth and antenatal respectively. BD, Birth defect

Legend: Figure _1 Catchment site and the study flow chart.

150x120mm (300 x 300 DPI)

Figure 2. Study population and distribution of pregnancies and their outcomes.



Legend:


PSMMC, Prince Sultan Military Medical City; Sp Ab, Spontaneous abortions; ETOPFA, Elective termination of pregnancy for fetal anomaly.

*One control fetus was a Stillbirth.

Legend: Figure _2 Study population and distribution of pregnancies and their outcomes.

150x112mm (300 x 300 DPI)

Figure 3. Frequency among control subjects of selected risk factors for birth defects.



Legend:

BMI, pre-pregnancy maternal body mass index

BD, birth defect

*Frequency of prior child with BD computed among non-primiparous women

Legend: Figure _ 3 Frequency among control subjects of selected risk factors for birth defects.

99x79mm (300 x 300 DPI)

Supplement file

Appendix

Confidential



PSMMC

Booklet of

“Pattern of Fetal Malformations in a Saudi Population”

Study

Control

Local ID No.: _____ / Year 201

Mother’s Name:

Mother’s MRN:

Baby’s Name:

Baby’s MRN:

Date of Birth:

Contact No: Mobile (husband)

Mobile (wife)

Home

Confidential

Keep in a safe place

Pattern of Malformations Study – PSMMC

(Baby and mother)

Local ID No _____

D.O.B. (dd/mm/yy): ____/____/____ Year: 201__

D. O. B./ Year Unknown Sex: Male Female indeterminate Not known

No. of babies delivered: Singleton 1 Twin 2 Triplet 3 Quadruplet 4
 Quintuplet 5 Sextuplet 6
 Not known 9

Specify twin type of birth, like or unlike sex, zygosity: _____

No. of malformed (in multiple set): No. ____ Not known

Type of birth: Live Birth (LB). Still Birth (SB) Spontaneous Abortion
 TOP Not known

Civil registration status LB SB No CR Not known Birth weight (g): _____ Confirmed Length of gestation (weeks): _____ Confirmed

Survival beyond one week of age:

Yes No Alive at discharge <1 Week Not known

Date of death (dd/mm/yy): ____/____/____ Year: _____

D. O. B. Mother (dd/mm/yy): ____/____/____ Year: _____ Confirmed

Age of mother at delivery: _____

Pattern of Malformations Study – RMH

(Baby and mother)

Local ID No _____

Mother's residence code at conception: Province _____ District _____

Mother's residence code at delivery: Province _____ District _____

Total No. of previous pregnancies: None Number (___) Not known

When discovered:

At birth Less than 1 wk 1-4 wk 1-12 m >12 m Prenatal diagnosis

At abortion (sp) or termination Not known Postnatal diagnosis, age not known

Condition at discovery: Alive Dead Not known

Gestational age at discovery (wk): _____

First positive prenatal test:

US at <14 wks US at 14-21 wks US at ≥ 22 wk US GA unknown
Serum/combined screening CVS Amniocentesis Other tests positive

No positive test, all results negative

Specify 'other' prenatal test: _____

Karyotype of infant/ fetus:

Performed, result known Performed, result unknown

Not performed Probe test performed Failed Not known

Specify karyotype: _____

Post mortem exam:

Performed, result known Performed, result unknown

Macerated fetus Not known Not performed

First surgical procedure:

Performed (or expected) in the first year of life

Performed (or expected) after the first year of life

Prenatal surgery No surgery required

Too sever for surgery Not known

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – PSMMC
(Prenatal Malformations)

Local ID No _____

	Code	Text
Syndrome:		
Malformation 1:		
Malformation 2:		
Malformation 3:		
Malformation 4:		
Malformation 5:		
Malformation 6:		
Malformation 7:		
Malformation 8:		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – RMH

(All Malformations)

Local ID No _____

	Code	Text
Syndrome:		
Malformation 1:		
Malformation 2:		
Malformation 3:		
Malformation 4:		
Malformation 5:		
Malformation 6:		
Malformation 7:		
Malformation 8:		

McKusick code: _____

Aetiology:

Chromosome **C** Familial **F** Isolated **I** Multiple **M**

New Dominant **ND** Other Genomic **OG** Syndrome **S** Teratogens **T** Inborn

Error of Metabolism **IEM** Control **Co**

View anomaly subgroup(s):

Pattern of Malformations Study – RMH

Local ID No _____

Assisted conception: No Induced ovulation only Artificial insemination
 In vitro fertilization Gamete intrafollopian transfer
 Intracytoplasmic sperm injection Egg donation Other
 Not known

Mother's occupation: House wife Teacher Student Other

Maternal Systemic illnesses;

None EHT Hypothyroidism CHD
 RHD CRF Asthma SCA SLE
 IDA Anxiety Depression Epilepsy
 Other (specify) _____

Weight before pregnancy (Kg) _____

Current weight (Kg) _____

Mother's height (m) _____

Body Mass Index: <18.5 18.5 – 24.9 25 – 29.9
 30.0 – 34.9 35.0 – 39.9 ≥ 40.0

True DM: Yes No

Gestational DM on Diet (GDOD)

Gestational DM on Insulin (GDOI)

Diabetes screening: GTT (result) 0 time: _____ 1 hour: _____ 2 hours: _____

Booking RBS: _____

HbA1c _____

Infectious disease:

Tuberculosis: Before pregnancy During pregnancy 1st T 2nd T 3rd T

Rubella Before pregnancy During pregnancy 1st T 2nd T 3rd T

CMV Before pregnancy During pregnancy 1st T 2nd T 3rd T

Toxoplasmosis Before pregnancy During pregnancy 1st T 2nd T 3rd T

Syphilis Before pregnancy During pregnancy 1st T 2nd T 3rd T

UTI Before pregnancy During pregnancy 1st T 2nd T 3rd T

Fever Before pregnancy During pregnancy 1st T 2nd T 3rd T

FLU Before pregnancy During pregnancy 1st T 2nd T 3rd T

Others Before pregnancy During pregnancy 1st T 2nd T 3rd T

(Specify others) _____

Previous surgical history: Obstetrical/Gynaecological

Specify; _____

Non Obstetrical

Specify; _____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – PSMMC

Family history & sociodemographic

Local ID No _____

Folic acid supplementation:

At least 0.4 mg folic acid supplement taken regularly, starting periconceptionally

Folic acid supplement taken irregularly or starting post-conceptionally

No folic acid supplement taken or not recorded

ATC code

Text (**only** drugs taken in the 1st trimester of pregnancy)

Drugs 1:		
Drugs 2:		
Drugs 3:		
Drugs 4:		
Drugs 5:		

Consanguinity: Not related or relationship more distant than second cousin

Relationship of second cousin or closer Not known

Specific information on consanguinity:

Sibs with anomalies: Same Other Same and other No Not known

Previous sibs notified to the Saudi Malformations Registry: Yes No Not known

Local ID of previous sibs notified to the SMR (1): _____

Local ID of previous sibs notified to the SMR (2): _____

Local ID of previous sibs notified to the SMR (3): _____

Mother's family with anomalies: Same Other Same and other No

Not known Specify _____

1
2
3 **Father's family with anomalies:** Same Other Same and other No

4
5 Not known Specify _____

6
7 **Maternal education:** Illiterate Elementary and lower secondary

8
9 Upper secondary Tertiary Not known

10
11 **Family monthly income (SR):** _____

12
13 **(husband or combined husband and wife income)**

14
15 **Nationality:** Saudi None Saudi Only father Saudi Only mother Saudi

16
17 **General additional comments:**

18
19
20 _____

21
22 _____

1
2
3
4
5
6
7
8 **Pattern of Malformations Study – PSMMC**

9
10 Local Vars. (1)

11
12 Local ID No _____

13
14 **Place of birth:** _____

15
16 **Birth order (in multiple set),** (please write as 1st, 2nd, 3rd and so on): _____

17
18 **Date of discovery (dd/mm/yy):** ____/____/____ **Year:** _____

19
20 **Amniocentesis:** Performed result positive Performed result not known

21
22 Not performed Performed result negative Failed Not known

23
24 **Ultrasound:** Performed result positive Performed result not known

25
26 Not performed Performed result negative Failed Not known

27
28 **Chorionic villous sampling:** _____

29
30 **Other techniques:**

31
32 Performed result positive Performed result not known Not performed

33
34 Performed result negative Failed Not known

35
36
37
38 **Specify other technique for prenatal diagnosis:** _____

39
40 (Cordocentesis,..etc)

41
42 **No. of previous spontaneous abortions:** None 1 2 3 4

43
44 5 6 7 8+ Not known

45
46 **No. of previous TOP:** None 1 2 3 4 5

47
48 6 7 8+ Not known

49
50 **No. of previous live births:** please write the exact No (1-20) _____ Unknown

51
52 **No. of previous stillbirths:** None 1 2 3 4

53
54 5 6 7 8+ Not known

55
56 **Mode of transmission:** Familial De novo Not known

Habitual exposures: Smoking F179 Oude F159
 Other (specify) _____

Unusual exposures: X-ray during pregnancy (any) Nuclear medicine during pregnancy
 (Radiation & chemical)

Date of birth of father: ____/____/____ **Year:** _____ **Age of father:** _____

Occupation of father: Soldier Officer Civilian

Pattern of Malformations Study – RMH

Local Vars. (2)

Local ID No _____

Date of last LMP: ____/____/____

Certainty of LMP: Certain Uncertain No LMP Not known

Labor: Spontaneous Induced No labor

Delivery: Spontaneous EMLSCS ELSCS ABD
 Instrumental

Sources of information 1:

Notes in routine scan Birth notification or notification of malformation at birth

Hospital case notes Death or stillbirth certificate Prenatal diagnosis

Lab. report (cytogenetic ... etc) Postmortem exam Other Not known

Sources of information 2: please insert as in one _____

Sources of information 3: please insert as in one _____

Sources of information 4: please insert as in one _____

Sources of information 5: please insert as in one _____

Racial information Mother, Tribe code _____ Father, Tribe code _____

Same tribe Different tribe

Otaibi 1, Mutairi 2, Shuhri 3, Asiri 4, Shamrani 5, Onazi 6, Shahrani 7, Zaharani 8, Harbi 9, Qahatni 10, Ghamdi 11, Shamari 12, Asmari 13, Ahmari 14, Amri 15, Dawsari 16, Harthi 17, Subaie 18, Ajman 19, Not known (99)

Other 20, specify: _____

Chronic illness of father (including drug abuse): _____

Confirmation of diagnosis:

Follow up needed for further confirmation Confirmed at <6 months
Confirmed at 6-12 m Confirmed at 12-18 m Confirmed at 18-24 m
Not confirmed, lost for follow up

Source: Booked Un booked Referred

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	Observational, prospective cohort design with a nested case-control study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Abstract Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a BD, for an overall prevalence of 412/10000 total births, or 1 in 24 births.
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	Birth defects (BD) are increasingly recognized as a global health priority because of their lifelong impact on health and survival. ^{1,2} BD affect approximately an estimated 1 in 33 newborns, contribute each year to 300,000 deaths in the first month of life, and are associated with 3.2 million birth-related disabilities. ³ Accordingly, the World Health Assembly has emphasized the urgent need for action to help prevent, diagnose, and provide timely intervention. ¹
Objectives	3	State specific objectives, including any prespecified hypotheses	4	In this study, we implemented an integrated approach to generate these data in well-defined cohort of women, tracked from mid-gestation through the second year of life of their children, to assess concurrently the burden of potentially modifiable risk factors, the occurrence of BD, and survival of affected children, as a basis for better prevention and care. ⁴
Methods				
Study design	4	Present key elements of study design early in the paper	5	Observational, prospective cohort design with a nested case-control study.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	The Prince Sultan Military Medical City (PSMMC) is a tertiary teaching institution with 1250 beds and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

					approximately 10,000 annual deliveries. PSMMC primarily serves Saudi army personnel and their families and is a referral center for the other 16 military hospitals in the Kingdom of Saudi Arabia.
				*15 -24	Study period 1 July 2010 through 30 June 2013. *Figures and tables
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5		All pregnant Saudi women who are eligible for their antenatal care at PSMMC were included and their pregnancy outcome.
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	7		Mothers who delivered elsewhere were not included even if they have their antenatal care at PSMMC. All mothers who care pregnant with an affected foetus (birth defect) are include. For controls a random sample of women in the cohort with a normal USS. The random sample was generated daily by taking the morning list of scheduled USS and using a random number generator (http://www.random.org) to select potential controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants			
					n/a
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed			
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case			
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8		Evaluations for specific BD, Nested Case-Control Study, Follow up, Case review, coding, classification.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group			n/a
Bias	9	Describe any efforts to address potential sources of bias	5		Pregnancies referred from other hospitals because of a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

				diagnosis of a fetal anomaly, and babies with BD delivered elsewhere and referred to PSMMC for evaluation and management
A	10	Explain how the study size was arrived at	5	All mother delivered at PSMMC during the study period were included

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9	Chi-square or Fisher's exact tests.
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9	Odd ratios for BD were computed first via univariate logistic regression, then with a multiple logistic model. The latter was developed by first including uncorrelated significant factors ($p < 0.05$) from the univariate analysis, then reducing the number of variables by stepwise backward elimination for a more parsimonious model.
		(b) Describe any methods used to examine subgroups and interactions		n/a
		(c) Explain how missing data were addressed		
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	n/a randomization
		(e) Describe any sensitivity analyses		n/a
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9-12	Figure 2
		(b) Give reasons for non-participation at each stage		n/a
		(c) Consider use of a flow diagram		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	23	Tables 3
		(b) Indicate number of participants with missing data for each variable of interest		
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8	2 – 5 years. Follow up. Case-infants (with BD) and control-infants were examined in the dedicated study clinic at 1, 6, 12, 18 and 24 months of age
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time		
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	9	1179 as cases and 1262 as controls

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Cross-sectional study—Report numbers of outcome events or summary measures

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5,15-21	Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a BD, for an overall prevalence of 412/10000 total births, or 1 in 24 births. Of these 1179 cases, 38 (3.2%) were stillbirths and 18 (1.5%) were electively terminated because of lethal malformations (13 with anencephaly, 3 with severe hydrops fetalis and cystic hygroma, 1 with Meckel-Gruber syndrome and 1 with bilateral renal agenesis). The antenatal detection rate among women who has had antenatal ultrasound screening examination was 70.6%(561/795), tables b 1,2,3
		(b) Report category boundaries when continuous variables were categorized		
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		n/a
Discussion				
Key results	18	Summarise key results with reference to study objectives	1	In this cohort of women, the burden of potentially modifiable risk factors included high rates of diabetes (7.3%), maternal age >40 years (7.0%), consanguinity (54.5%), and lack of periconceptional folic acid use (90.8%). The birth prevalence of BD was 41.2/1,000 births (1179 cases / 28646 live births and stillbirths), driven mainly by congenital heart disease (14.8 per 1000), renal malformations (11.3), neural tube defects (1.9), and chromosomal anomalies (2.7). Mortality for live births with BD at 1 and 2 years of age was 14% and 15.8%, respectively.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13	Single centre study, Army personnel household only
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		High prevalence of birth defects, multiple modifiable risk factors.
Generalisability	21	Discuss the generalisability (external validity) of the study results		
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3	This project was supported by King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21. The funder has no role in this study.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Congenital anomalies and associated risk factors in a Saudi population: a cohort study from pregnancy to age 2 years

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026351.R1
Article Type:	Research
Date Submitted by the Author:	02-Apr-2019
Complete List of Authors:	Kurdi, Ahmed; Prince Sultan Military Medical City, Majeed-Saidan, Muhammad Ali; Prince Sultan Military Medical City, Paediatrics Al Rakaf, Maha; Prince Sultan Military Medical City, Obstetrics & Gynecology AlHashem, Amal; Prince Sultan Military Medical City Botto, Lorenzo; University of Utah, Pediatrics Baaqeel, Hassan; King Saud bin Abdulaziz University for Health Sciences, College of Medicine Ammari, Amer; Pediatrics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Obstetrics and gynaecology, Paediatrics
Keywords:	Prevalence, Risk factors, Prevention, Outcome, Congenital anomaly

SCHOLARONE™
Manuscripts

1
2
3
4 **Congenital anomalies and associated risk factors in a Saudi population:**
5
6 **a cohort study from pregnancy to age 2 years**
7
8
9

10 Ahmed M Kurdi¹, Muhammad A Majeed-Saidan², Maha S Al Rakaf¹,
11 Amal M AlHashem², Lorenzo D Botto³, Hassan S Baaqeel⁴, Amer N
12 Ammari².
13
14
15
16

17
18
19
20 ¹ Division of Maternal and Foetal Medicine, Department of Obstetrics
21 and Gynaecology, Prince Sultan Military Medical City (PSMMC), P.O.
22 Box 7897, Riyadh, 11159, Saudi Arabia.
23
24
25

26
27
28
29 ² Department of Paediatric, Division of neonatal medicine, PSMMC.
30
31

32
33
34 ² Department of Paediatric, Division of medical genetics, PSMMC
35
36
37

38
39 ³ Department of Paediatric, Division of medical genetics, 295 Chipeta
40 way, Suite 25010, University of Utah school of medicine, Salt Lake City,
41 UT, USA,
42
43
44

45
46
47
48 ⁴ Department of Obstetrics and Gynaecology, King Saud Bin AbdulAziz
49 university for health sciences, Jeddah, Saudi Arabia,
50
51
52

53
54
55 **Running title:** Congenital anomalies and Risk Factors in a Saudi
56 population
57
58
59
60

1
2
3
4 **Corresponding author:**
5

6 **Dr. Ahmed M. Kurdi, MD, German Board, DFM**
7

8 Consultant Maternal and Foetal Medicine
9

10 Avenue Medical Center
11

12 Kingdom of Saudi Arabia
13

14 Telephone: work +966-112000099 Ext. 158
15

16 Mobile: +966505451701
17

18 Fax: 0096611-4500185
19

20 Email: ahmedkurdi1950@gmail.com
21
22
23
24
25
26
27
28
29
30

31 **Abstract**
32
33
34
35

36 **Objective:** To assess the three key issues for CAs prevention and care,
37 namely, CA prevalence, risk factor prevalence, and survival, in a
38 longitudinal cohort in Riyadh, Saudi Arabia.
39
40

41 **Setting:** Tertiary care centre, Riyadh, Saudi Arabia.
42

43 **Participants:** Saudi women enrolled during pregnancy over three years
44 and their 28,646 eligible pregnancy outcomes (births, stillbirths and
45 elective terminations of pregnancy for foetal anomalies [ETOPFAs]). The
46 nested case-control study evaluated the CA risk factor profile of the
47 underlying cohort. All CA cases (1,179) and unaffected controls (1,262)
48 were followed through age 2 years. Referred mothers because of foetal
49 anomaly and mothers who delivered outside the study centre and their
50 pregnancy outcome were excluded.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Primary outcome measures:** Prevalence and pattern of major CAs,
5
6 Frequency of CA-related risk factors, and survival through age 2 years.

7 **Results:** The birth prevalence of CAs was 412/10,000 births (95% CI
8 388.6 to 434.9), driven mainly by congenital heart disease (148 per
9 10,000) (95% CI 134 to 162), renal malformations (113, 95% CI 110 to
10 125), neural tube defects (19, 95% CI 25.3 to 38.3), and chromosomal
11 anomalies (27, 95% CI 21 to 33). In this study, the burden of potentially
12 modifiable risk factors included high rates of diabetes (7.3%, OR 1.98,
13 95% CI 1.04 to 2.12), maternal age >40 years (7.0%, OR 2.1, 95% CI
14 1.35 to 3.3), consanguinity (54.5%, OR 1.5, 95% CI 1.28 to 1.81). The
15 mortality for live births with CAs at 2 years of age was 15.8%.

16 **Conclusions:** This study documented specific opportunities to improve
17 primary prevention and care. Specifically, folic acid fortification (the
18 neural tube defect prevalence was >3 times that theoretically achievable
19 by optimal fortification), preconception diabetes screening and
20 consanguinity-related counselling could have significant and broad
21 health benefits in this cohort and arguably in the larger Saudi population.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Strengths and limitations of this study:**

- 45 • Babies with CAs are diagnosed prospectively, prenatally, and
46 postnatally and followed up to 2 years of age.
 - 47 • Involvement of multidisciplinary teams in establishing the final
48 diagnosis.
 - 49 • Inclusion of elective termination of pregnancies with lethal CAs and
50 stillbirths.
- 51
52
53
54
55
56
57
58
59
60

- Single-centre study. The pregnancy cohort was mainly from families of Saudi army personnel dependents, which could be a limiting factor.

The original protocol of the study: Supplementary file.

Funding statement: This project was supported by a generous grant from King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21.

Disclaimer: The funding institution had no role in the study design, data collection, analysis, interpretation of data, the writing of the various reports or the decision for submission for publication. All authors have full independence from the funder, have full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the analysis.

Competing interests statement:

All authors have completed the ICMJE uniform disclosure from www.icmje.org-coi_disclosure.pdf and declare no support from any organization for the submitted research article; no financial relationship with any organization that might have an interest in the submitted work

1
2
3
4 in the previous three years; and no other relationships or activities that
5
6 could appear to have influenced the submitted work.
7
8
9

10 **Key words:** Congenital anomalies, Prevalence, Risk factors, Prevention,
11
12 and Outcome
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Congenital anomalies and associated risk factors in a Saudi population:**
28
29 **a cohort study from pregnancy to age 2 years**
30
31
32
33

34 **Introduction**

35
36 Because of their lifelong impact on health and survival, congenital
37 anomalies (CAs) are increasingly recognized as a global health priority.¹
38
39 ²With better control of infections and other causes of early mortality,
40
41 CAs are becoming increasingly important drivers of child survival and
42
43 health in low- and middle-income countries.^{1 3} CAs affect approximately
44
45 an estimated 1 in 33 newborns, contribute each year to 300,000 deaths
46
47 in the first month of life, and are associated with 3·2 million birth-related
48
49 disabilities.³ Accordingly, the World Health Assembly has emphasized
50
51 the urgent need for action to help prevent, diagnose, and provide timely
52
53 interventions.¹ Data on the prevalence and mortality associated with CAs
54
55 are scarce in many low- and middle-income countries, with most reports
56
57
58
59
60

1
2
3
4 originating in high-income areas. For example, in a population-based
5
6 study of livebirths with CAs in the United Kingdom, the 20-year survival
7
8 rate was 85.5%.⁴ Similarly, the 25-year survival rate among livebirths
9
10 with CAs in New York state was 82.5%,⁵ with a documented
11
12 improvement from the 1980s (78.1% from 1983 –1988) to the early
13
14 2000s (89.3% from 2001- 2006). Among CAs, the major drivers of
15
16 mortality were cardiovascular anomalies (51.1%) and chromosomal
17
18 anomalies (33.1%). In Korea, infant mortality among babies with CAs
19
20 was 6.8/10,000 live births, and foetal mortality was 13.5/10,000 total
21
22 births.⁶
23
24
25
26
27
28
29
30

31 However, local action, whether focused on primary prevention or on
32
33 improving care, is most effective when based on reliable information
34
35 about the key indicators of the causes and outcomes of CAs in the
36
37 underlying population. In this study, we implemented an integrated
38
39 approach to generate these data in a systematic cohort of women,
40
41 tracked from mid-gestation through the second year of life of their
42
43 children, to assess the prevalence of CAs, the burden of potentially
44
45 modifiable risk factors, and the survival of affected children, as a basis
46
47 for better prevention and care.⁷
48
49
50
51
52
53
54
55

56 **Methods**

57
58
59
60

1
2
3
4 **Setting.** The Prince Sultan Military Medical City (PSMMC) is a tertiary
5
6 teaching institution with 1,250 beds and approximately 10,000 annual
7
8 deliveries. PSMMC primarily serves Saudi army personnel and their
9
10 families and is a referral centre for the other 16 military hospitals in the
11
12 Kingdom of Saudi Arabia. The foetal medicine unit includes advanced
13
14 imaging facilities, including 3D and 4D scanning. The paediatric
15
16 department includes all major subspecialties, including medical genetics,
17
18 paediatric surgery, and paediatric cardiology.
19
20
21
22
23
24
25

26 **Study design** This is an observational, prospective cohort study with a
27
28 nested case-control study. The eligible cohort includes pregnancies of
29
30 women who had their antenatal care and their routine antenatal anomaly
31
32 ultrasound scan examination (USS) between 18 weeks and 22 weeks of
33
34 gestation at PSMMC from 1 July 2010 through 30 June 2013 (figure 1).
35
36
37
38

39 In addition, Saudi women who are eligible for their antenatal care at
40
41 PSMMC, but who did not have an antenatal screening ultrasound
42
43 examination and later delivered at PSMMC, are also included in the
44
45 study.
46
47
48
49
50
51

52 **Inclusions and exclusions.** Pregnancy outcomes included in the study
53
54 were live births, stillbirths (foetal deaths at 20 weeks' gestation or later),
55
56 and pregnancies electively terminated because of foetal anomalies
57
58 (ETOPFAs). The study excluded spontaneous abortions, pregnancies
59
60

1
2
3
4 referred from other hospitals because of a diagnosis of a foetal anomaly,
5
6 and babies with CAs delivered elsewhere and referred to PSMMC for
7
8 evaluation and management.
9

10
11
12
13
14 **Evaluations.** Initial antenatal screening tests included a complete blood
15
16 count, liver and kidney function tests, blood group and antibody
17
18 screening, rubella and Toxoplasma status, hepatitis B screen, random
19
20 blood sugar and HbA1c levels, VDRL, sickle cell screen and urine
21
22 analysis. A glucose tolerance test was performed at 24-28 weeks of
23
24 gestation.
25
26
27
28
29
30
31
32

33 When a structural birth defect was diagnosed or suspected antenatally,
34
35 mothers were counselled by one of the investigators (MSR, AMK),
36
37 demographic and exposure information was gathered, and both parents
38
39 were scheduled within 2-4 weeks to attend a dedicated clinic developed
40
41 for the study. At that time, a detailed diagnostic and care plan was
42
43 developed, which may have included further blood tests and foetal
44
45 imaging, or amniocentesis, chorionic villous and/or foetal blood sampling
46
47 for genetic studies. Consent was requested for cord blood collection for
48
49 future molecular testing.
50
51
52
53
54
55

56 On the first day of life, all newborns in the cohort (with and without CAs)
57
58 were examined by a paediatrician as part of the first clinical screening
59
60

1
2
3
4 examination. Babies with CA, whether identified antenatally or
5
6 postnatally, underwent diagnostic investigations as clinically indicated
7
8 (e.g., echocardiogram, cardiac catheterization, or other imaging studies;
9
10 metabolic and molecular testing) and were referred to the appropriate
11
12 subspecialists. A clinical geneticist evaluated all babies with suspected
13
14 syndromes or multiple CAs. A letter was distributed to all clinical
15
16 departments describing the study and requesting that they inform the
17
18 study team about all infants and children with CAs born at PSMHC.
19
20
21
22
23
24
25

26 **Evaluations for specific congenital anomalies.** If congenital heart disease
27
28 (CHD) was detected or suspected antenatally on USS examination, the
29
30 mother was referred to the paediatric cardiologist for a foetal
31
32 echocardiogram. All these infants were also re-evaluated after birth by a
33
34 paediatric cardiologist. Isolated atrial septal defects (ASDs II) were re-
35
36 evaluated at 6 to 12 months of age, and if the echocardiogram showed
37
38 no evidence of ASD II at the time, the infant was not considered a case.
39
40
41
42 Congenital hydronephrosis (HN) was graded using the Society of Foetal
43
44 Urology grading system.⁸ Babies with grade one HN were given a repeat
45
46 US examination within the first year of life; if HN had resolved, the baby
47
48 was not considered a case. Chromosomal analysis was performed
49
50 was not considered a case. Chromosomal analysis was performed
51
52 according to standard procedures, and a minimum of 20 metaphases
53
54 were analysed (Applied Imaging CytoVision Karyotyping System).
55
56 Reports followed the International System of Human Cytogenetic
57
58 Nomenclature (ISCN 2013). Molecular studies were performed at the
59
60

1
2
3
4 Biocenthia Health Group in Germany (<http://www.bioscientia.de/en/>), the
5
6 Mayo Medical Laboratories in the United States, and at the
7
8 Developmental Genetic Laboratory at King Faisal specialist hospital and
9
10 research centre in Saudi Arabia.
11
12
13
14
15
16

17 **Nested case-control study.** The nested case-control study included as
18 cases all women in the cohort with a pregnancy diagnosed with a CA
19 and as controls a random sample of women in the cohort with a normal
20 USS. The random sample was generated daily by taking the morning list
21 of scheduled USS and using a random number generator
22 (<http://www.random.org>) to select potential controls so that the control
23 sample would eventually be at least as large as the estimated total
24 number of cases. If a woman initially selected as a control had a
25 pregnancy diagnosed with a birth defect at the initial date or later, she
26 was then included in the case group. Investigators administered an in-
27 person structured interview to case and control mothers. The interview
28 included information about age (for both parents); weight before
29 pregnancy; height; parity; family income (father's income or combined
30 parental income if the mother worked); maternal education level
31 (illiterate, primary school graduate, secondary school graduate, or
32 university graduate); parental occupation (mother; housewife, teacher,
33 student and others, father; soldier, officer or civilian employee); folic acid
34 (FA) supplement use (regular use before and during the 1st trimester of
35 pregnancy; irregular or only postconception use; no use or uncertain use
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 as per the mother's report); parental smoking (one or both parents
5 smoking during the current pregnancy); maternal radiation exposure
6 during the first trimester; maternal diabetes (overt or gestational) as
7 defined by the International Association of Diabetes and Pregnancy
8 study groups ⁹ and HbA1c level; family history of CAs (in previous
9 pregnancies and in maternal or paternal lineages); drug and medication
10 use during the first trimester; and chronic maternal systemic illnesses
11 (hypothyroidism, epilepsy, depression, essential hypertension, and
12 bronchial asthma). Consanguinity was defined as women being first or
13 second cousins to their husbands (supplementary file).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Follow-up.** Case infants and control infants were examined in the
32 dedicated study clinic at 1, 6, 12, 18 and 24 months of age. Two
33 neonatologists and a clinical geneticist supervised the clinic. Babies with
34 CAs also continued to be followed by the relevant subspecialty clinics.
35 The remaining cohort (babies without CAs not selected as controls) was
36 re-examined at 4-8 weeks by the paediatrician for a second screening
37 examination. A head ultrasound and a postductal pulse oximetry reading
38 were completed in all babies attending the clinics. If the O₂ saturation
39 was below 95%, the baby was referred to the paediatric cardiologist for
40 evaluation. If any CAs were detected at the second screening
41 examination, the babies were referred to the genetics clinic for further
42 evaluation and diagnosis. If the second screening examination proved to
43 be normal, then no further follow-up was arranged. However, if CAs
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 were discovered later in babies up to 2 years of age, they were included
5
6 in the study.
7
8
9
10

11
12 **Case review, coding, classification.** Congenital anomalies were coded
13 following the International Statistical Classification of Diseases and
14 Related Health Problems, 10th revision, (ICD10, WHO-2010) according
15 to the European Concerted Action on Congenital Anomalies and Twins
16 (EUROCAT) recommended procedures.¹⁰ We did not include isolated
17 minor anomalies or prematurity-related conditions such as patent ductus
18 arteriosus or hydrocephalus complicating intraventricular haemorrhage
19 diagnosed in preterm babies (<37 completed weeks of gestation). Data
20 were entered in a version of EUROCAT Data Management Program
21 (EDMP) modified to include control records and the additional variables
22 generated by the case-control study and the follow up.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Patient and public involvement:** Our long-term experience with the
43 families and their offspring has helped us to shape the research question
44 and the study design. All families recruited were informed about the
45 study objectives. None of the parents were involved in the study design.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4 provider through social media, newspapers, presentation at various
5
6 conferences, and scientific publications.
7
8
9

10
11
12 **Institutional ethics review.** The study was approved by the Ethical
13
14 Committee of the PSMC (Project No. 366, series of 2009).
15
16

17 18 19 **Statistical analysis.**

20
21
22 Odds ratios for the association between risk factors and CAs were
23
24 estimated using multiple logistic regression in a two-step process. An
25
26 initial set of variables was selected by univariate logistic regression as
27
28 being associated with CA risk ($p < 0.05$). Variables highly correlated with
29
30 other variables (e.g., insulin use) were not entered into the model. This
31
32 initial variable set was then reduced by stepwise backward elimination to
33
34 produce a more parsimonious model. The final model retained the
35
36 following covariates: consanguinity, maternal age group, education level,
37
38 diabetes and history of siblings with a congenital anomaly. The model fit
39
40 was assessed with the Hosmer and Lemeshow's goodness of fit test and
41
42 by calculating Nagelkerke R². Statistical analysis was performed with
43
44 SPSS for Windows, version 15 (SPSS Inc., Chicago, Illinois).
45
46
47
48
49
50
51

52 53 **Results**

54
55
56 Of the 31,032 birth outcomes of the 30,351 women followed since
57
58 pregnancy, 30,753 (99.1%) occurred at PSMC (figure 2). Of these,
59
60

1
2
3
4 2,107 were spontaneous abortions (6.9%) and were not included in the
5
6 study, leaving 28,646 eligible births (27,726 singleton births and 920
7
8 multiple births). The overall stillbirth rate was slightly less than 1% (figure
9
10 2).

11
12
13
14
15 **Birth defect occurrence, detection, and mortality.** Of the 28,646 eligible
16 pregnancy outcomes, 1,179 were diagnosed with a CA, for an overall
17 prevalence of 412/10,000 (95% CI 388.6 to 434.9) total births, or 1 in 24
18 births. Of these 1,179 cases, 38 (3.2%) were stillbirths, and 18 (1.5%)
19 were electively terminated because of lethal malformations (13 with
20 anencephaly, 3 with severe hydrops foetalis and cystic hygroma, 1 with
21 Meckel-Gruber syndrome and 1 with bilateral renal agenesis) (table 1).
22 The antenatal detection rate among women who has had an antenatal
23 ultrasound screening examination was 70.6% (561/795). In 90% of these
24 cases (505/561), the diagnosis was made by ultrasound scan at 22
25 weeks of gestation or later. Of the 618 babies diagnosed postnatally,
26 296 (47.9%) were diagnosed at birth, 239 (38.7%) between 1 and 7
27 days, 29 (4.7%) between 1 and 4 weeks, 52 (8.4%) between 1 and 12
28 months, and 2 (0.3%) after one year of age. Mortality among livebirths
29 with CAs (table 1) was 14.1% in the first year, nearly half of which
30 occurred in the first week of life, with a total mortality of 15.8% by the
31 end of the second year of life. Mortality at two years was 0.9% in the
32 unaffected cohort (0.24% for live births). Among the controls, there were
33 8 stillbirths, two deaths because of prematurity and its complications and
34 one death at 2 years of age because of acute fulminating leukaemia.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contribution of specific congenital anomalies.

Approximately half of the overall birth prevalence was due to congenital heart disease and central nervous system anomalies. Neural tube defects occurred at a rate of 19 per 10,000 (95% CI, 13.8 to 23.9) (1 in 526 births). Severe CHD occurred at a rate of 32 per 10,000 (95% CI, 25.3 to 38.3) (1 in 313 births) and accounted for 21.4% of all CHD cases. Chromosomal anomalies whose risk is associated with increased maternal age (trisomies 21, 18, and 13) occurred with a combined prevalence of 25 per 10,000 (95% CI, 19.6 to 31.3) (1 in 392 births). Trisomy 21 accounted for most cases of chromosomal anomalies, with a prevalence of 22 per 10,000 (95% CI, 16.7 to 27.4) or 1 in 456 births (table 2).

Two-thirds of all cases of CAs (773/1179, 65.6%) were isolated (e.g., they involved a single body system) (table 3).

Risk factors. As a proxy of risk factor prevalence in the underlying population, we used the frequency of selected maternal or parental risk factors for CAs among controls in the nested case-control study (figure 3). The most frequent potentially modifiable factors included lack of periconception folic acid supplement use, consanguinity, high body mass index, advanced maternal age, smoking (first or second-hand) and maternal diabetes. Nearly 6% of non-primiparous women had one prior child with a major CA. In the univariate analysis, the nested case-control

1
2
3
4 study (table 4) detected overall increased odds ratios for all CAs
5
6 combined for consanguinity, advanced maternal age, high parity,
7
8 maternal illiteracy, maternal university education, X-ray exposure during
9
10 pregnancy, maternal diabetes, and positive family history of CA in a
11
12 sibling. Increased odds ratios with confidence intervals, including unity,
13
14 were also found for maternal depression and hypertension (table 4). In
15
16 the multiple logistic regression model, only first-degree consanguinity
17
18 (OR 1.5, 95% CI 1.28 to 1.81), maternal age of more than forty years
19
20 (OR 2.1, 95% CI 1.35 to 3.3), maternal illiteracy (OR 1.4, 95% CI 1.17 to
21
22 1.7), maternal university level education, (OR 1.74, 95% CI 1.24 to
23
24 2.44), maternal diabetes mellitus (OR 1.98, 95% CI 1.33 to 2.95) and
25
26 history of a sibling with an anomaly (OR 1.49, 95% CI 1.04 to 2.12) were
27
28 retained in the model (table 5). The Hosmer and Lemeshow goodness of
29
30 fit p value was 0.08, and Nagelkerke R² was 0.055, explaining 6% of the
31
32 effect on CAs.
33
34
35
36
37
38
39
40
41

42 Of the 223 mothers with DM who had CA-affected fetuses (223/1,179,
43
44 18.9%), 36 (3%) had overt DM (ODM), and 187 (15.7%) had gestational
45
46 DM (GDM). Of the mothers with GDM, 50 (26.7%) required insulin.
47
48 Among the controls, 200 mothers had diabetes (200/1,179, 15.8%), of
49
50 whom 12 (0.9%) had ODM, and 188 (15.9%) had GDM. Of the latter, 29
51
52 (14.5%) required insulin.
53
54
55
56
57
58

59 Discussion

60

1
2
3
4
5
6 This longitudinal study of CAs in a pregnancy cohort in Saudi Arabia,
7 followed from mid-gestation through age 2 years, had three integrated
8 aims: to describe the population's risk factor profile, document the
9 associated birth prevalence of CAs, and assess survival as a critical
10 health outcome.⁷ Gathering information about these three critical areas
11 is crucial when planning and evaluating policies and interventions, be
12 they aimed at primary prevention (e.g., folic acid fortification to prevent
13 neural tube defects) or at improving care.
14
15
16
17
18
19
20
21
22
23
24
25
26

27 The burden of CAs was high in this population. The study documented a
28 remarkably high birth prevalence of CAs of 412 per 10,000 or 1 in 24
29 total births. This rate is higher than that reported in studies from many
30 high-income countries, as those reported by EUROCAT (261/10,000
31 births),¹¹ BINOCAR (206/10,000 births),¹² and the Bradford (BIB) study
32 (305/10,000).¹³ This prevalence of CAs is also higher than that
33 previously reported from Saudi Arabia (115 to 257 per 10,000 live
34 births).¹⁴⁻¹⁶ Although some studies report an even higher prevalence,
35 e.g., such as an antenatal CA prevalence of 521/10,000 pregnancies
36 screened, and a prevalence among livebirths of 465/10,000,¹⁷ these
37 figures may be overestimates of the true prevalence because of the
38 inclusion of mothers referred from other institutions. In the current study,
39 we strove to obtain as complete an ascertainment as possible by
40 initiating follow-up in pregnancy and extending it through the second
41 year of life, by including stillbirths and elective termination of
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 pregnancies for foetal anomalies (ETOPFAs), and by successfully
5
6 including some genetic conditions that tend to be diagnosed after the
7
8 newborn period.
9

10
11 However, the high prevalence of CAs is likely to be due not only to the
12
13 completeness of the ascertainment but also to the high frequency of
14
15 adverse risk factors in the underlying population, as documented in the
16
17 controls of the nested case-control study. When focusing on factors that
18
19 are potentially modifiable, three such factors seem to stand out. The first
20
21 is insufficient folic acid use in this cohort (<10% in the periconception
22
23 period). The rate of neural tube defects was 19 per 10,000/births (table
24
25 2), at least three times higher than the rate of 6 per 10,000/births, which
26
27 seems achievable by providing sufficient folic acid to women of
28
29 childbearing age.^{18 19} Although legislation requiring the mandatory
30
31 fortification of flour had been in place in Saudi Arabia for years prior to
32
33 this study (Kingdom of Saudi Arabia, 2000; Food fortification initiative,
34
35 2013),^{20 21} our findings suggest that there are gaps in coverage or
36
37 effectiveness, which could be evaluated with nutrition or blood folate
38
39 surveys. Such information would provide important evidence to improve
40
41 folate sufficiency in the population, with its attendant health benefits,
42
43 including a substantial reduction in the burden of neural tube defects.
44
45 Because of the inclusion of stillbirths and pregnancy terminations, this
46
47 study also provides a fuller estimate of the potential benefits of primary
48
49 prevention than if only livebirths had been identified (representing just
50
51 over half of all cases, 30/54).
52
53
54
55
56
57
58
59
60

1
2
3
4 The second factor is maternal diabetes (tables 4 and 5). Diabetes is an
5
6 established risk factor for many CAs, and diabetes control before
7
8 conception has been shown to reduce and nearly normalize CA risk.^{9 22}
9
10 ²³ Several avenues for preventing diabetes and its health effects are
11
12 available, including population screening (many diabetic women are
13
14 undiagnosed), health care and counselling, and education on healthy
15
16 lifestyle and dietary choices starting from childhood. The current
17
18 reported prevalence in Saudi Arabia of overt diabetes in women above
19
20 age 40 years ranges from 7.7% – 21.7%.^{24 - 26} In the study cohort, overt
21
22 diabetes was observed in 2% of women and increased in women 30
23
24 years old or older. Al-Nozha and colleagues²⁷ reported a prevalence of
25
26 overt diabetes of 11.6% in women aged 30-39 years and >22% in
27
28 women aged ≥40 years compared to 2.7% and 7.1% in our study,
29
30 respectively. Though lower than these estimates, the prevalence of overt
31
32 diabetes in the study cohort is alarmingly high.
33
34
35
36
37
38
39
40

41 Third, we observed a high rate of parental consanguinity (54.5%),
42
43 especially first-cousin marriages (48.0%). These marriages are common
44
45 in many parts of the Middle East, Africa, and the Indian subcontinent,²⁸⁻³⁰
46
47 with one estimate suggesting that “one billion people live in communities
48
49 with a preference for consanguineous marriage” (Hamamy, 2012).²⁹ This
50
51 preference has deep social roots. Nevertheless, education combined
52
53 with preconception and premarital counselling can be important
54
55 prevention strategies by focusing on increasing awareness to allow
56
57 couples to make more informed choices. Close consanguinity is a known
58
59
60

1
2
3
4 risk factor for CAs,³⁰ as well as Mendelian conditions such as inborn
5 errors of metabolism (occurring in 1 in 770 births in this study), as
6 confirmed in prior reports from Saudi Arabia and from the world
7 literature.^{31 32}
8
9
10
11
12
13
14

15 We did not diagnose cases of congenital rubella syndrome. This is likely
16 due to the active immunization programme in Saudi Arabia, with a
17 measles, mumps and rubella vaccine uptake of 97%. In addition,
18 preschool age girls are given a booster vaccine against rubella.
19
20
21
22
23
24
25
26
27

28 In a prior publication, we reported a low regular (periconception) folic
29 acid (FA) intake (9.7%) in this study population³³ and suggested
30 fortification of rice in addition to wheat, complemented by education
31 programmes supporting FA supplementation, as an efficient strategy to
32 achieve folate sufficiency in the population.
33
34
35
36
37
38
39

40 Finally, our findings emphasize the impact of CAs in this
41 population by documenting not only birth prevalence but also the
42 associated early mortality (table 1), which was 15.8% by the
43 second year of life (nearly all in the first year). Further supporting
44 the high impact of CAs are the findings by Majeed-Saidan and
45 colleagues,³⁴ who reported that 36% of deaths in a large neonatal
46 intensive care unit in Riyadh were due to lethal CAs. These
47 findings highlight the crucial importance and urgency to improve
48 care in addition to primary prevention.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 This study demonstrated the importance of the “triple
8
9 surveillance” programme, suggested by Botto and Masteroiacova,⁴
10
11 for identifying the risk factors for CAs (causes), estimating the
12
13 burden of the disease (prevalence), and assessing disease
14
15 outcome (mortality). This will ultimately lead to disease burden
16
17 reduction or prevention by instituting appropriate interventions.
18
19
20
21
22
23
24

25 The study has limitations. Because of the cohort design, the
26
27 resulting sample size did not allow a more detailed analysis of
28
29 specific CA groups. Estimates of some key risk factors, such as
30
31 folic acid insufficiency, were based on maternal reports (e.g.,
32
33 reported supplement use) rather than biomarkers. Furthermore,
34
35 the pregnancy cohort was mainly from families of Saudi army
36
37 personnel dependents. Although the Saudi Army recruits from all
38
39 sectors of Saudi society, a broader survey of the Saudi population
40
41 would provide additional information to better assess gaps and
42
43 opportunities for prevention and care nationwide.
44
45
46
47
48
49
50

51 **Conclusion.** This longitudinal surveillance programme that encompassed
52
53 the causal chain from risk factors to health outcomes documented
54
55 several opportunities to reduce the burden of CAs through primary
56
57 prevention and better care. Folic acid fortification, preconception
58
59
60

1
2
3
4 diabetes screening, and consanguinity-related counselling could have
5 significant health benefits in this cohort and arguably in the larger Saudi
6 population, particularly if associated with a national CA monitoring
7 programme to support and track the impact of interventions.
8
9
10
11
12
13
14

15 **Acknowledgments**

16
17 We thank the Medical Services Directorate of the Saudi Armed Forces
18 and the PSMCMC directorate for their support during the initiation and
19 execution of the study; the study's advisory board (Eduardo Castilla,
20 Pierpaolo Mastroiacovo, Ester Garne, Fowzan Alkuraya, and Wesam
21 Kurdi) for advice and guidance throughout the study; and the study
22 secretaries for their commitment and enthusiasm.
23
24
25
26
27
28
29
30
31

32 **Author's statement:**

33
34
35 **AMK** study conception and design, revised the manuscript. **MAMS**,
36 study conception and design, drafting and revising the manuscript.,
37
38 **MSR**, study design, data collection. **AMH**, data collection, revised the
39 manuscript. **LDB**, study design, critically revised the manuscript for
40 intellectual content. **HSB**, statistical analysis and revised the manuscript.
41
42 **ANA**, study design, data collection, revised the manuscript. All authors
43 approved the submission of the manuscript.
44
45
46
47
48
49
50
51
52
53
54

55 **Patient consent form:** n/a
56
57
58
59

60 **Data sharing statement:**

1
2
3
4 Dataset can be obtained on request through a third party “King
5
6 AbdulAziz city for science and technology.
7
8
9

10 Word count: 4,210
11
12
13
14
15
16
17
18
19

20 References

- 21
22
23
24 1. World Health Organization. Sixty -Third World Health
25 Assembly. CA Report by the Secretariat, A63/10. Geneva,
26 Switzerland: World Health Organization, 2010.
27
28
29
30
31
32
33
- 34 2. World Health Organization. Global Health Observatory (GHO)
35 data. Under-five mortality 2016.
36 [http://www.who.int/gho/child_health/mortality/mortality_under_f](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/)
37 [ive_text/en/](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/) (accessed 12 December 2017).
38
39
40
41
42
43
44
45
- 46 3. Christianson AL, Howson CP, Modell B. Global report on CA:
47 the hidden toll of dying and disabled children. White Plains
48 (NY): March of Dimes Defects Foundation 2006.
49
50
51
52
53
- 54 4. Tennant PWG, Pearce MS, Bythell M, *et al*.
55
56 20-year survival of children born with congenital anomalies:
57
58
59
60

1
2
3
4 a population-based study. *Lancet* 2010; 375: 649–56.
5
6
7

- 8 5. Wang Y, Hu J, Druschel CM, *et al.* Twenty-Five-Year Survival
9 of Children with Birth Defects in New York State: A
10 Population-Based Study. *Birth Defects Research (Part A)*
11 201;1 91:995-1003.
12
13
14
15
16
17
18 6. Ko HS, Kim DJ, Chung Y, *et al.* A national cohort study
19 evaluating infant and fetal mortality caused by birth defects in
20 Korea. *BMJ Open* 2017;7: e017963. doi:10.1136/bmjopen-
21 2017-017963
22
23
24
25
26
27
28
29 7. Botto LD, Mastroiacovo P. Triple surveillance: a proposal for
30 an integrated strategy to support and accelerate birth defect
31 prevention. *Ann. N. Y. Acad. Sci* 2018; (1414):126-36.
32
33
34
35
36
37
38 8. Avni FE, Maugey-Laulom B, Cassart M, *et al.* Foetal
39 genitourinary tract. In: Callen PW, ed. *Ultrasonography in*
40 *Obstetrics and Gynecology*. 5th Ed. New York: W.B. Saunders
41 2007; 640-75.
42
43
44
45
46
47
48
49
50 9. Metzger BE, Gabbe SG, Persson B, *et al.* International
51 association of diabetes and pregnancy study groups
52 recommendations on the diagnosis and classification of
53
54
55
56
57
58
59
60

1
2
3
4 hyperglycemia in pregnancy. *Diabetes Care* 2010; 33(3): 676–
5
6 82. doi: 10.2337/dc09-1848.
7
8
9

10
11 10. EUROCAT. Eurocat Guide 1.3. Instructions for registration
12 and surveillance of congenital anomalies. Belfast, Northern
13 Ireland University of Ulster 2005. [http://www.eurocat-](http://www.eurocat-network.eu/content/Section%202.4-%2027_Oct2016.pdf)
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11. EUROCAT. Prevalence Tables, 2011-2015
[http://www.eurocat-](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx)
[network.eu/newprevdata/showPDF.aspx?winx=1896&winy=9](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx)
[40&file=allsubgroups.aspx](http://www.eurocat-network.eu/newprevdata/showPDF.aspx?winx=1896&winy=940&file=allsubgroups.aspx) 2015. (accessed 12 December
2017).

12. Springett A, Budd J, Draper ES, *et al.* Congenital Anomaly
Statistics 2012 England and Wales, London 2014.
[www.binocar.org/content/Annual%20report%202012_FINAL](http://www.binocar.org/content/Annual%20report%202012_FINAL_nologo.pdf)
[nologo.pdf](http://www.binocar.org/content/Annual%20report%202012_FINAL_nologo.pdf).

13. Sheridan E, Wright J, Small N, *et al.* Risk factors for
congenital anomaly in a multiethnic birth cohort: an analysis of
the Born in Bradford study. *Lancet* 2013; 382(9901): 1350–9.
doi: 10.1016/S0140-6736(13)61132-0.

14. Al Bu Ali WH, Balaha MH, Al Moghannum MS, *et al.* Risk
factors and birth prevalence of CA and inborn errors of

1
2
3
4 metabolism in Al Ahsa, Saudi Arabia. *Pan Afr Med J* 2011; 8:
5
6 14.
7
8
9

10
11 15. Fida NM, Al-Aama J, Nichols W, *et al*. A prospective study of
12 congenital malformations among live born neonates at a
13 University Hospital in Western Saudi Arabia. *Saudi Med J*
14 2007; 28(9): 1367–73.
15
16
17
18

19
20
21
22 16. Refat MY, Al-Moghanem M, McDonald, *et al*. Major CA at
23 King Fahd Hofuf Hospital: Prevalence, risk factors and
24 outcome. *Ann Saudi Med* 1995; 15(4): 339–43.
25
26
27
28

29
30
31
32 17. Sallout B, Obedat N, Shakeel F, *et al*. Prevalence of major
33 congenital anomalies at King Fahad Medical City in Saudi
34 Arabia: a tertiary care centre-based study. *Ann Saudi Med*
35 2015; 35(5): 343–51.
36
37
38
39

40
41
42
43 18. Kancherla V, Oakley GP Jr, Brent RL. Urgent global
44 opportunities to prevent CA. *Semin Foetal Neonatal Med*
45 2014; 19(3): 153–60.
46
47
48
49

50
51
52
53 19. Youngblood ME, Williamson R, Bell KN, *et al*. Update on
54 global prevention of folic acid-preventable spina bifida and
55 anencephaly. *CA Res A Clin Mol Teratol* 2013; 97(10): 658–
56
57
58 63. doi: 10.1002/CAra.23166. Epub 2013.
59
60

- 1
2
3
4
5
6 20. Kingdom of Saudi Arabia, Ministry of health, Nutritional
7
8 department directive. Number 652/1/26, 2000; 13/09/2000.
9
10
11
12
13 21. Food Fortification Initiative. (2013).
14
15 [http://www.ffinetwork.org/country_profiles/country.php?record](http://www.ffinetwork.org/country_profiles/country.php?record=194)
16 [=194](http://www.ffinetwork.org/country_profiles/country.php?record=194) (accessed 12 December 2017).
17
18
19
20
21
22 22. Kitzmiller JL, Wallerstein R, Correa A, *et al*. Preconception
23 care for women with diabetes and prevention of major
24 congenital malformations. *CA Res A Clin Mol Teratol* 2010;
25 88(10): 791–03. doi: 10.1002/CAra.20734.
26
27
28
29
30
31
32
33 23. Simeone RM, Devine OJ, Marcinkevage JA, *et al*/Diabetes
34 and congenital heart defects: a systematic review, meta-
35 analysis, and modeling project. *Am J Prev Med* 2014; 48(2):
36 195–204. doi: 10.1016/j.amepre.2014.09.002.
37
38
39
40
41
42
43
44
45 24. Al-Nuaim AR, Al-Rubean K, Al-Mazrou Y, *et al*. Prevalence of
46 diabetes mellitus, obesity and hypercholesterolemia in Saudi
47 Arabia: national chronic disease survey. Riyadh (KSA):
48 Ministry of Health and King Saud University. ISBN: 1995;
49 9960-603-01-6.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 25. El-Hazmi M, Warsy A, Al-Swailem AR, *et al.* Diabetes
5
6 mellitus as a health problem in Saudi Arabia. East Mediterr
7
8 Health J 1998 (4): 58–67.
9
10
11
12
13 26. Warsy AS, el-Hazmi MA. Diabetes mellitus, hypertension and
14
15 obesity--common multifactorial disorders in Saudis. East
16
17 Mediterr Health J 1999; 5(6): 1236–42.
18
19
20
21
22 27. Al-Nozha MM, Al-Maatouq M, Al-Mazrou YY. *et al.* Diabetes
23
24 mellitus in Saudi Arabia. Saudi Med J 2004; 25(11): 1603–10.
25
26
27
28
29 28. El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, *et al.* Regional
30
31 variations in the prevalence of consanguinity in Saudi Arabia.
32
33 Saudi Med J 2007; 28(12): 1881–4.
34
35
36
37
38
39 29. Hamamy H. Consanguineous marriages: Preconception
40
41 consultation in primary health care settings. J Community
42
43 Genet 2012; 3(3): 185–92.
44
45
46
47
48 30. Majeed-Saidan MA, Ammari AN, AlHashem AM, *et al.* Effect
49
50 of consanguinity on CA in Saudi women: results from a nested
51
52 case-control study. CA Res A Clin Mol Teratol 2015; 103(2):
53
54 100–4. doi: 10.1002/CAra.23331.
55
56
57
58
59
60

- 1
2
3
4 31. Mak CM, Lee HC, Chan AY, *et al.* Inborn errors of
5
6 metabolism and expanded newborn screening: review and
7
8 update. *Crit Rev Clin Lab Sci* 2013; 50(6): 142–62. doi:
9
10 10.3109/10408363.2013.847896.
11
12
13
14
15 32. Moammar H, Cheriyan G, Mathew R, *et al.* Incidence and
16
17 patterns of inborn errors of metabolism in the Eastern
18
19 Province of Saudi Arabia, 1983-2008. *Ann Saudi Med* 2010;
20
21 30(4): 271–7. doi: 10.4103/0256-4947.65254.
22
23
24
25
26
27
28 33. Al Rakaf MS, Kurdi AM, Ammari AN, *et al.* Patterns
29
30 of folic acid use in pregnant Saudi women and prevalence of
31
32 neural tube defects — Results from a nested case–control
33
34 study. *Preventive Medicine Reports* 2 (2015) 572–576.
35
36
37
38 34. Majeed-Saidan MA, Kashlan FT, Al-Zahrani AA, *et al.* Pattern
39
40 of neonatal and postneonatal deaths over a decade (1995--
41
42 2004) at a Military Hospital in Saudi Arabia. *Saudi Med J*
43
44 2008; 29(6):879-83.
45
46
47
48
49
50
51

52 Tables

53
54
55
56
57
58
59
60

Legend: Table 1 Distribution and rates of congenital anomalies (CA) among the cohort's pregnancy outcomes, and associated mortality.

	Total cohort		With CA			Timing of CA detection				Mortality among livebirths with CA					
	No	%	No.	%	Rate /10000	Prenatal		Postnatal		Overall (0-2 years)		1st week		Total 1 st year	
Birth outcome	No	%	No.	%	Rate /10000	No.	%	No.	%	No.	%	No.	%	No.	%
Live births	28 369	99	1 123	95.3	396	505	45.0	618	55	177	15.8	64	5.7	158	14.1
Stillbirths	259	0.9	38	3.2	1467	38	100								
ETOPFA	18	0.1	18	1.5	10000	18	100								
Total	28 646		1 179		412	561	47.6	618	52.4						

Footnote:

†ETOPFA, Terminations of pregnancy for foetal anomalies.

Stillbirth (foetal death at 20 weeks of gestation or greater).

Table 2 Prevalence and distribution of congenital anomalies, overall and by pregnancy outcome.

Birth defects	Number*	%	Prevalence per 1000	Live births	Prevalence per 10000 live birth	Stillbirth	ETOPFA

			births (total births = 28646)			(total live births = 28376)				
				No.	%		No.	%	No	(%)
Any	1179	100	412	1123	95.3	396	38	3.2	18	1.5
Nervous system	160	13.6	56	129	80.6	45.7	18	11.3	13	8.1
Neural Tube Defects	54	4.6	19	30	55.5	10.6	11	20.4	13	24.1
Anencephalus	26	2.2	9	7	26.9	2.5	8	30.8	11	42.3
Encephalocele	11	0.9	4	9	81.8	3.2	1	9.1	1	9.1
Spina Bifida	17	1.4	6	14	82.4	4.9	2	11.8	1	5.9
Hydrocephaly	25	2.1	9	23	92.0	8.1	2	8.0		
Microcephaly	28	2.4	10	24	85.7	8.5	4	14.3		
Eye	33	2.8	12	33	100	11.6				
Anophthalmus/microphthalmus	11	0.9	4	11	100	3.9				
Congenital cataract	5	0.4	2	5	100	1.8				
Congenital glaucoma	9	0.8	3	9	100	3.2				
Ear, face and neck	7	0.6	2	7	100	2.5				
Anotia/microtia	7	0.6	2	7	100	2.5				
Cardiac	425	36.0	148	420	90.9	148	4	0.9		
Severe congenital heart defects *	91	7.7	32	89	97.8	31.4	2	2.2		
Common arterial truncus	3	0.3	1	3	100	1.1				
Transposition of great vessels	13	1.1	5	13	100	4.6				
Single ventricle	6	0.5	2	6	100	2.1				

Atrioventricular septal defect	17	1.4	6	15	88.2	5.3	2	11.8		
Tetralogy of Fallot	15	1.3	5	15	100	5.3				
Tricuspid atresia and stenosis	4	0.3	1	4	100	1.4				
Pulmonary valve stenosis	22	1.9	8	21	95.5	7.4	1	4.5		
Pulmonary valve atresia	9	0.8	3	9	100	3.2				
Aortic valve atresia/stenosis	5	0.4	2	5	100	1.8				
Hypoplastic left heart	15	1.3	5	15	100	5.3				
Hypoplastic right heart	5	0.4	2	5	100	1.8				
Coarctation of aorta	14	1.2	5	14	100	4.9				
Total anomalous pulmonary venous return	2	0.2	0.7	2	100	0.7				
Ventricular septal defect	171	14.5	60	171	100	60.2				
Atrial septal defect	214	18.2	74.7	214	100	75.4				
Oro-facial clefts										
Cleft lip with or without palate	42	3.6	14.7	35	83.3	12.3	5	11.9	2	4.8
Cleft palate only	11	0.9	3.8	11	100	3.9				
Respiratory	33	2.8	11.5	33	100	11.6				
Choanal atresia	5	0.4	1.7	5	100	1.8				
Digestive system	74	6.3	25.8	71	95.9	25.0	3	4.1		
Esophageal atresia with/without fistula	12	1.0	4.2	12	100	4.2				
Ano-rectal atresia and stenosis	26	2.2	9.1	25	96.2	8.8	1	3.8		
Diaphragmatic hernia	18	1.5	6.3	16	88.9	5.6	2	11.1		
Abdominal wall defects	7	0.6	2.4	6	85.7	2.1	1	14.3		
Gastroschisis	2	0.2	0.7	1	50.0	0.4	1	50.0		

Omphalocele	5	0.4	1.7	5	100	1.8				
Urinary	323	27.4	113	318	98.5	112.1	4	1.2	1	0.3
Bilateral renal agenesis	18	1.5	6.3	15	83.3	5.3	2	11.1	1	5.6
Renal dysplasia	60	5.1	21	58	96.7	20.4	2	3.3		
Congenital hydronephrosis	194	16.5	67.7	194	100	68.4				
Genital	127	10.8	44.3	126	99.2	44.4	1	0.8		
Hypospadias	108	9.2	37.7	108	100	38.1				
Indeterminate sex	3	0.3	1.0	2	66.7	0.7	1	33.3		
Limb	99	8.4	34.6	92	92.9	32.4	4	4.0	3	3.0
Limb deficiencies, all	17	1.4	5.9	17	100	6.0				
Upper limb deficiency	12	1.0	4.2	12	100	4.2				
Lower limb deficiency	7	0.6	2.4	7	100	2.5				
Club foot - talipes equinovarus	19	1.6	6.6	15	78.9	5.3	2	10.5	2	10.5
Hip dislocation and/or dysplasia	24	2.0	8.4	23	95.8	8.1			1	4.2
Polydactyly	23	2.0	8.0	23	100	8.1				
Syndactyly	9	0.8	3.1	9	100	3.2				
Musculo-skeletal	40	3.4	14	33	82.5	11.6	7	17.5		
Craniosynostosis	6	0.5	2.1	6	100	2.1				
Achondroplasia	3	0.3	1	2	66.7	0.7	1	33.3		
Thanatophoric dysplasia	2	0.2	0.7	2	100	0.7				
Jeune syndrome	2	0.2	0.7	1	50.0	0.4	1	50.5		
Other malformations	42	3.6	14.7	40	95.2	14.1	1	2.4	1	2.4
Situs inversus	10	0.8	3.5	10	100	3.5				
By underlying cause										

Chromosomal	82	7.0	8.6	79	96.3	27.8	3	3.7		
Down Syndrome/trisomy 21	63	5.3	22	62	98.4	21.8	1	1.6		
Edward syndrome/trisomy 18	8	0.7	2.8	7	87.5	2.5	1	12.5		
Patau syndrome/trisomy 13	2	0.2	0.7	2	100	0.7				
Turner syndrome	3	0.3	1	2	66.7	0.7	1	33.3		
Wolff-Hirschhorn syndrome	1	0.1	0.3	1	100	0.4				
Genetic syndromes (including microdeletions)	38	3.2	13.2	36	94.7	12.7	1	2.6	1	2.6
Teratogenic (Carbamazepine embryopathy)	1	0.1	0.3	1	100	0.4				
Conditions outside Q chapter of ICD-10										
Inborn error of metabolism	37	3.1	12.9	37	100	13.0				
Endocrine disorders	7	0.6	0.2	7	100	2.5				
Other	11	0.9	4	11	100	3.9				

Legend:

* The total number of birth defects is greater than the total number of affected births because some had more than one major CA.

§ Severe congenital heart disease (EUROCAT definition): common arterial trunk (Q200), double outlet right ventricle (Q201), transposition of great arteries (Q203), single ventricle (Q204), atrioventricular septal defect (AVSD) (Q212), tetralogy of Fallot (Q213), pulmonary valve atresia (Q220), Ebstein anomaly (Q225), hypoplastic right heart (Q226), aortic valve atresia and stenosis (Q230), mitral valve anomalies (Q232, Q233), hypoplastic left heart (Q234), coarctation of the aorta (Q251), aortic atresia / interrupted aortic arch (Q252), total anomalous pulmonary venous return (Q262).

Legend: Table 3 Common single congenital anomalies (CA) per body system involved

Body system	Total number Of CA	Isolated CA		Common isolated anomalies
		No.	%	
Cardiovascular	424	265	62.5	ventricular septal defects in 75 (28.3%). Atrial septal defects in 67 (25.3%). Pulmonary valve atresia and stenosis in 18 (6.8%). Sever CHD in 54 (20.4%)
Urinary	323	229	70.8	Congenital hydronephrosis in 147 (64.2%). Bilateral renal agenesis in 3 (1.3%).
Central nervous	161	68	42.8	Neural tube defects in 32 (47.1%). Encephalocele in 4 (5.9%)
Gastrointestinal	74	33	44.6	Ano-rectal atresia and stenosis in 16 (48.5%). Diaphragmatic hernia in 6 (18.2).
Limb	97	31	32	Total limbs reduction in 9 (29%). Upper limb reduction in 7 (22.6%). Lower limb reduction in 3 (9.7%).
Eye	32	14	43.8	Congenital glaucoma in 6 (42.9%). Congenital cataract in 4 (28.6%).

				Anophthalmia + microphthalmia in 3 (21.4%).
--	--	--	--	---

Legend: Table 4 Distribution of parental socio-demographic characteristics and association with congenital anomaly risk (univariate analysis).

Variable	Cases (total n=1179)		Controls (total n=1262)		Odds Ratio [†]	95% CI		
	No.	%	No.	%		Lower	Upper	
Consanguinity								
Non-consanguineous	537	45.5	693	54.9	Ref	-	-	
Consanguineous	642	54.5	569	45.1	1.53	1.30	1.8	
Maternal age (years)								
<20	24	2.0	48	3.8	0.58	0.35	0.96	
20-30	599	50.8	694	55.0	Ref	-	-	
31-40	473	40.1	474	37.6	1.16	0.98	1.37	
>40	83	7.0	46	3.6	2.09	1.43	3.05	
Paternal age (years)								
20-30	341	28.9	403	31.9	0.92	0.76	1.10	
31-40	548	46.5	593	47.0	Ref	-	-	
41-50	240	20.4	225	17.8	1.15	0.93	1.43	
> 50	50	4.2	41	3.2	1.32	0.86	2.03	

Maternal body mass index [‡]							
<18.5	24	2.1	35	2.8	0.75	0.44	1.29
18.5-24.99	324	27.8	388	30.8	0.91	0.74	1.12
25.0-29.99	352	30.2	385	30.5	Ref	-	-
≥30	464	39.9	453	35.9	1.12	0.92	1.36
Previous deliveries (parity)							
Nulliparous	216	18.3	273	21.6	0.92	0.74	1.16
Para 1-2	374	31.7	436	34.5	Ref	-	-
Para 3-4	283	24.0	273	21.6	1.21	0.97	1.50
Para ≥5	306	26.0	280	22.2	1.27	1.03	1.58
Family monthly income Saudi riyals (US \$)							
<3,000 SR (<800\$)	19	1.9	12	1.0	1.87	0.89	3.92
10,000-14,000 SR (2667-3999\$)	235	23.2	277	22.3	Ref	-	-
3,000-6,999 SR (800-1866\$)	232	22.9	291	23.4	0.94	0.74	1.20
7,000-9,999 SR (1867-2666\$)	367	36.3	496	39.9	0.87	0.70	1.09
≥15, 000 (≥4000\$)	158	15.6	167	13.4	1.12	0.84	1.47
Maternal education							
Illiterate	391	33.2	333	26.4	1.50	1.26	1.80
Schooling up to high school	671	56.9	859	68.1	Ref	-	-
University	117	9.9	70	5.5	2.05	1.49	2.81
Folic acid intake							
Periconceptual	109	9.2	128	10.1	Ref	-	-

Improper use [§]	1070	90.8	1134	89.9	1.04	0.79	1.36
Parental Smoking							
Neither parent smoked	837	71.0	888	70.4	Ref	-	-
One or both parents smoked	342	29.0	374	29.6	0.97	0.82	1.16
Radiation exposure in pregnancy							
None	1161	98.5	1254	99.4	Ref	-	-
Radiation exposure in pregnancy	18	1.5	8	0.6	2.43	1.05	5.61
Diabetes mellitus (DM)							
No DM	956	81.1	1062	84.2	Ref	-	-
DM on insulin (all, overt & gestational)	86	7.3	41	3.2	2.34	1.60	3.43
Gestational DM on diet only	137	11.6	157	12.6	0.91	0.62	1.16
Sibs of cases and controls (primiparous mothers excluded)							
No affected sibling	757	78.6	932	94.2	Ref-	-	-
Sibling with CA	85	8.8	58	5.7	1.61	1.14	2.27
Medication use in pregnancy							
None	792	67.2	951	75.3	-	-	-
Thyroxin	102	8.7	106	8.4	1.03	0.78	1.37
Insulin	86	7.3	40	3.2	2.34	1.59	3.45
Methyldopa	14	1.2	14	1.1	1.07	0.51	2.26

Maternal systemic illnesses							
None	808	68.5	971	76.9	Ref-	-	-
Mothers with Hypothyroidism	123	10.4	128	10.1	1.03	0.80	1.34
Mothers with Bronchial asthma	106	9.0	97	7.7	1.19	0.89	1.58
Mothers with depression	12	1.0	6	0.5	2.15	0.81	5.75
Mothers with essential hypertension	23	2.0	15	1.2	1.65	0.86	3.19

Footnote:

‡BMI not available for 15 mothers

Some families declined reporting their income.

§Improper-use includes FA taken post conception and 49 mothers (43 case mothers and 6 control mothers) who were not sure about their intake.

Legend: Table 5 multiple logistic regression model results for the significant risk factors on univariate analysis

Variable	ADJUSTED OR (from multiple logistic regression model) †			CRUDE OR (from univariate analysis)		
	OR	95% C.I.		OR	95% C.I.	
		Lower	Upper		Lower	Upper
Consanguinity, none (reference group)	-	-	-	-	-	-
Consanguinity, first degree	1.5 2	1.28	1.81	1.5 3	1.30	1.81
Maternal age, 20-30 years (reference group)	-	-	-	-	-	-
Maternal age, <20 years	0.5 4	0.32	0.91	0.5 8	0.35	0.96
Maternal age, >40 years	2.1 1	1.35	3.30	2.0 9	1.43	3.05
Maternal education, up to high school (reference group)	-	-	-	-	-	-
Maternal education, illiterate	1.4 1	1.17	1.70	1.5 0	1.26	1.80
Maternal education, university	1.7 4	1.24	2.44	2.0 5	1.49	2.81
Diabetes on insulin, overt or gestational (yes/no)	1.9 8	1.33	2.95	2.3 4	1.60	3.43
Sibling with anomalies (yes/no)	1.4 9	1.04	2.12	1.6 1	1.14	2.27

1
2
3
4
5
6 †: Adjustment for consanguinity, maternal age, maternal education, diabetes
7
8 mellitus, sibling with anomalies.
9
10
11
12
13
14
15
16
17


18 **Figures legend:**

19
20
21
22 Legend: Figure _1 Catchment site and the study flow chart.
23
24

25 Legend: Figure _2 Study population and distribution of pregnancies and their
26
27 outcomes.
28
29

30 Legend: Figure _ 3 Frequency among control subjects of selected risk factors for CA.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1- Catchment site and the study flow chart.




Legend: Case catchment areas (A to E). A: antenatal clinic, B: at birth, C: the "one-month clinic, D: geneticist "one-month clinic", and E: other areas. 1,2,3 are postnatal, stillbirth and antenatal respectively. BD, Birth defect

Legend: Figure _1 Catchment site and the study flow chart.

150x120mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure_2 Study population and distribution of pregnancies and their outcomes.




Legend:

PSMMC, Prince Sultan Military Medical City; ETOPFA, Elective termination of pregnancy for foetal anomaly.

†Eight control foetuses were stillbirth.

Figure 3. Frequency among control subjects of selected risk factors for birth defects.



Legend:

BMI, pre-pregnancy maternal body mass index

BD, birth defect

*Frequency of prior child with BD computed among non-primiparous women

Legend: Figure _ 3 Frequency among control subjects of selected risk factors for birth defects.

99x79mm (300 x 300 DPI)

Supplement file

Appendix

Confidential



PSMMC

Booklet of

“Pattern of Fetal Malformations in a Saudi Population”

Study

Control

Local ID No.: _____ / Year 201

Mother’s Name:

Mother’s MRN:

Baby’s Name:

Baby’s MRN:

Date of Birth:

_____ / _____ / _____

Contact No: Mobile (husband)

Mobile (wife)

Home

Confidential

Keep in a safe place

Pattern of Malformations Study – PSMMC

(Baby and mother)

Local ID No _____

D.O.B. (dd/mm/yy): ____/____/____ Year: 201__

D. O. B./ Year Unknown Sex: Male Female indeterminate Not known

No. of babies delivered: Singleton 1 Twin 2 Triplet 3 Quadruplet 4
 Quintuplet 5 Sextuplet 6
 Not known 9

Specify twin type of birth, like or unlike sex, zygosity: _____

No. of malformed (in multiple set): No. _____ Not known Type of birth: Live Birth (LB). Still Birth (SB) Spontaneous Abortion TOP Not known Civil registration status LB SB No CR Not known Birth weight (g): _____ Confirmed Length of gestation (weeks): _____ Confirmed

Survival beyond one week of age:

Yes No Alive at discharge <1 Week Not known

Date of death (dd/mm/yy): ____/____/____ Year: _____

D. O. B. Mother (dd/mm/yy): ____/____/____ Year: _____ Confirmed

Age of mother at delivery: _____

1
2
3 **Pattern of Malformations Study – RMH**

4
5 (Baby and mother)

6
7 **Local ID No** _____

8
9 **Mother's residence code at conception:** Province _____ District _____

10
11 Mother's residence code at delivery: Province _____ District _____

12
13 **Total No. of previous pregnancies:** None Number (___) Not known

14
15 **When discovered:**

16
17 At birth Less than 1 wk 1-4 wk 1-12 m >12 m Prenatal diagnosis

18
19 At abortion (sp) or termination Not known Postnatal diagnosis, age not known

20
21 **Condition at discovery:** Alive Dead Not known

22
23 **Gestational age at discovery (wk):** _____

24
25 **First positive prenatal test:**

26
27 US at <14 wks US at 14-21 wks US at ≥ 22 wk US GA unknown
28 Serum/combined screening CVS Amniocentesis Other tests positive

29
30 No positive test, all results negative

31
32 **Specify 'other' prenatal test:** _____

33
34 **Karyotype of infant/ fetus:**

35
36 Performed, result known Performed, result unknown

37
38 Not performed Probe test performed Failed Not known

39
40 **Specify karyotype:** _____

41
42 **Post mortem exam:**

43
44 Performed, result known Performed, result unknown

45
46 Macerated fetus Not known Not performed

47
48 **First surgical procedure:**

49
50 Performed (or expected) in the first year of life

51
52 Performed (or expected) after the first year of life

53
54 Prenatal surgery No surgery required

55
56 Too sever for surgery Not known

Pattern of Malformations Study – PSMMC

(Prenatal Malformations)

Local ID No _____

Code Text

Syndrome:		
Malformation 1:		
Malformation 2:		
Malformation 3:		
Malformation 4:		
Malformation 5:		
Malformation 6:		
Malformation 7:		
Malformation 8:		

1
2
3 **Pattern of Malformations Study – RMH**

4
5 (All Malformations)

6
7 Local ID No _____

8
9

	Code	Text
11	Syndrome:	
12		
13	Malformation 1:	
14		
15	Malformation 2:	
16		
17	Malformation 3:	
18		
19	Malformation 4:	
20		
21	Malformation 5:	
22		
23	Malformation 6:	
24		
25	Malformation 7:	
26		
27	Malformation 8:	
28		

29

30
31 **McKusick code:** _____

32
33 **Aetiology:**

34
35 Chromosome **C** Familial **F** Isolated **I** Multiple **M**

36
37 New Dominant **ND** Other Genomic **OG** Syndrome **S** Teratogens **T** Inborn

38
39 Error of Metabolism **IEM** Control **Co**

40
41
42
43

44 **View anomaly subgroup(s):**

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – RMH

Local ID No _____

Assisted conception: No Induced ovulation only Artificial insemination
 In vitro fertilization Gamete intrafollopian transfer
 Intracytoplasmic sperm injection Egg donation Other
 Not known

Mother's occupation: House wife Teacher Student Other

Maternal Systemic illnesses;

None EHT Hypothyroidism CHD
 RHD CRF Asthma SCA SLE
 IDA Anxiety Depression Epilepsy
 Other (specify) _____

Weight before pregnancy (Kg) _____

Current weight (Kg) _____

Mother's height (m) _____

Body Mass Index: <18.5 18.5 – 24.9 25 – 29.9
 30.0 – 34.9 35.0 – 39.9 ≥ 40.0

True DM: Yes No

Gestational DM on Diet (GDOD)

Gestational DM on Insulin (GDOI)

Diabetes screening: GTT (result) 0 time: _____ 1hour: _____ 2 hours: _____

Booking RBS: _____

HbA1c _____

Infectious disease:

Tuberculosis: Before pregnancy During pregnancy 1st T 2nd T 3rd T

Rubella Before pregnancy During pregnancy 1st T 2nd T 3rd T

CMV Before pregnancy During pregnancy 1st T 2nd T 3rd T

Toxoplasmosis Before pregnancy During pregnancy 1st T 2nd T 3rd T

Syphilis Before pregnancy During pregnancy 1st T 2nd T 3rd T

UTI Before pregnancy During pregnancy 1st T 2nd T 3rd T

Fever Before pregnancy During pregnancy 1st T 2nd T 3rd T

FLU Before pregnancy During pregnancy 1st T 2nd T 3rd T

Others Before pregnancy During pregnancy 1st T 2nd T 3rd T

(Specify others) _____

Previous surgical history: Obstetrical/Gynaecological

Specify; _____

Non Obstetrical

Specify; _____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – PSMMC

Family history & sociodemographic

Local ID No _____

Folic acid supplementation:

At least 0.4 mg folic acid supplement taken regularly, starting periconceptionally

Folic acid supplement taken irregularly or starting post-conceptionally

No folic acid supplement taken or not recorded

ATC code

Text (**only** drugs taken in the 1st trimester of pregnancy)

Drugs 1:		
Drugs 2:		
Drugs 3:		
Drugs 4:		
Drugs 5:		

Consanguinity: Not related or relationship more distant than second cousin

Relationship of second cousin or closer Not known

Specific information on consanguinity:

Sibs with anomalies: Same Other Same and other No Not known

Previous sibs notified to the Saudi Malformations Registry: Yes No Not known

Local ID of previous sibs notified to the SMR (1): _____

Local ID of previous sibs notified to the SMR (2): _____

Local ID of previous sibs notified to the SMR (3): _____

Mother's family with anomalies: Same Other Same and other No

Not known Specify _____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Father’s family with anomalies: Same Other Same and other No

Not known Specify _____

Maternal education: Illiterate Elementary and lower secondary

Upper secondary Tertiary Not known

Family monthly income (SR): _____

(husband or combined husband and wife income)

Nationality: Saudi None Saudi Only father Saudi Only mother Saudi

General additional comments:

1
2
3
4
5
6
7
8 **Pattern of Malformations Study – PSMMC**

9 Local Vars. (1)

10
11
12 **Local ID No** _____

13
14 **Place of birth:** _____

15
16 **Birth order (in multiple set),** (please write as 1st, 2nd, 3rd and so on): _____

17
18 **Date of discovery (dd/mm/yy):** ____/____/____ **Year:** _____

19
20 **Amniocentesis:** Performed result positive Performed result not known

21
22 Not performed Performed result negative Failed Not known

23
24 **Ultrasound:** Performed result positive Performed result not known

25
26 Not performed Performed result negative Failed Not known

27
28 **Chorionic villous sampling:** _____

29
30 **Other techniques:**

31
32 Performed result positive Performed result not known Not performed

33
34 Performed result negative Failed Not known

35
36
37
38 **Specify other technique for prenatal diagnosis:** _____

39
40
41 (Cordocentesis,..etc)

42
43 **No. of previous spontaneous abortions:** None 1 2 3 4

44
45 5 6 7 8+ Not known

46
47 **No. of previous TOP:** None 1 2 3 4 5

48
49 6 7 8+ Not known

50
51 **No. of previous live births:** please write the exact No (1-20) _____ Unknown

52
53 **No. of previous stillbirths:** None 1 2 3 4

54
55 5 6 7 8+ Not known

56
57 **Mode of transmission:** Familial De novo Not known

Habitual exposures: Smoking F179 Oude F159
 Other (specify) _____

Unusual exposures: X-ray during pregnancy (any) Nuclear medicine during pregnancy
 (Radiation & chemical)

Date of birth of father: ____/____/____ **Year:** _____ **Age of father:** _____

Occupation of father: Soldier Officer Civilian

Pattern of Malformations Study – RMH

Local Vars. (2)

Local ID No _____

Date of last LMP: ____/____/____

Certainty of LMP: Certain Uncertain No LMP Not known

Labor: Spontaneous Induced No labor

Delivery: Spontaneous EMLSCS ELSCS ABD
 Instrumental

Sources of information 1:

Notes in routine scan Birth notification or notification of malformation at birth

Hospital case notes Death or stillbirth certificate Prenatal diagnosis

Lab. report (cytogenetic ... etc) Postmortem exam Other Not known

Sources of information 2: please insert as in one _____

Sources of information 3: please insert as in one _____

Sources of information 4: please insert as in one _____

Sources of information 5: please insert as in one _____

Racial information Mother, Tribe code _____ Father, Tribe code _____

Same tribe Different tribe

Otaibi 1, Mutairi 2, Shuhri 3, Asiri 4, Shamrani 5, Onazi 6, Shahrani 7, Zaharani 8, Harbi 9, Qahatni 10, Ghamdi 11, Shamari 12, Asmari 13, Ahmari 14, Amri 15, Dawsari 16, Harthi 17, Subaie 18, Ajman 19, Not known (99)

Other 20, specify: _____

Chronic illness of father (including drug abuse): _____

Confirmation of diagnosis:

Follow up needed for further confirmation Confirmed at <6 months
Confirmed at 6-12 m Confirmed at 12-18 m Confirmed at 18-24 m
Not confirmed, lost for follow up

Source: Booked Un booked Referred

Checklist

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	Observational, prospective cohort design with a nested case-control study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Abstract Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a CA, for an overall prevalence of 412/10000 total births, or 1 in 24 births.
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	Congenital anomalies(CA) are increasingly recognized as a global health priority because of their lifelong impact on health and survival. ^{1,2} CA affect approximately an estimated 1 in 33 newborns, contribute each year to 300,000 deaths in the first month of life, and are associated with 3·2 million birth-related disabilities. ³ Accordingly, the World Health Assembly has emphasized the urgent need for action to help prevent, diagnose, and provide timely intervention. ¹
Objectives	3	State specific objectives, including any prespecified hypotheses	4,5	In this study, we implemented an integrated approach to generate these data in well-defined cohort of women, tracked from mid-gestation through the second year of life of their children, to assess concurrently the burden of potentially modifiable risk factors, the occurrence of CA, and survival of affected children, as a basis for better prevention and care. ⁴
Methods				
Study design	4	Present key elements of study design early in the paper	5	Observational, prospective cohort design with a nested case-control study.

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group		n/a
Bias	9	Describe any efforts to address potential sources of bias	5,6	Pregnancies referred from other hospitals because of a diagnosis of a foetal anomaly, and babies with CA delivered elsewhere and referred to PSMHC for evaluation and management
Study size	10	Explain how the study size was arrived at	5	All mother delivered at PSMHC during the study period were included
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9,10	Odd ratios for CA were computed first via univariate logistic regression, then with a multiple logistic model. The latter was developed by first including uncorrelated significant factors ($p < 0.05$) from the univariate analysis, then reducing the number of variables by stepwise backward elimination for a more parsimonious model.
		(b) Describe any methods used to examine subgroups and interactions		n/a
		(c) Explain how missing data were addressed		
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	n/a randomization n/a

		(e) Describe any sensitivity analyses		n/a
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9 -11	All mothers and their offspring were included. For details see Figure 2.
		(b) Give reasons for non-participation at each stage		n/a
		(c) Consider use of a flow diagram		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	29 - 32	All demographic data were shown in Tables 4 and 5
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure		
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8	2 – 5 years. Follow up. Case-infants (with CA) and control-infants were examined in the dedicated study clinic at 1, 6, 12, 18 and 24 months of age
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time		
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	9	1179 as cases and 1262 as controls
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	9-11	Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a CA, for an overall prevalence of 412/10000 total births, or 1 in 24 births. Of these 1179 cases, 38 (3.2%) were stillbirths and 18 (1.5%) were electively terminated because of lethal malformations

		which confounders were adjusted for and why they were included		(13 with anencephaly, 3 with severe hydrops foetalis and cystic hygroma, 1 with Meckel-Gruber syndrome and 1 with bilateral renal agenesis). The antenatal detection rate among women who has had antenatal ultrasound screening examination was 70.6%(561/795), tables b 1,2,3
		(b) Report category boundaries when continuous variables were categorized		
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		n/a
Discussion				
Key results	18	Summarise key results with reference to study objectives	2	In this cohort of women, the burden of potentially modifiable risk factors included high rates of diabetes (7.3%), maternal age >40 years (7.0%), consanguinity (54.5%), and lack of periconceptional folic acid use (90.8%). The birth prevalence of CA was 41.2/1,000 births (1179 cases / 28646 live births and stillbirths), driven mainly by congenital heart disease (14.8 per 1000), renal malformations (11.3), neural tube defects (1.9), and chromosomal anomalies (2.7). Mortality for live births with CA at 1 and 2 years of age was 14% and 15.8%, respectively.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15	Single centre study, Army personnel household only
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15	High prevalence of CA, multiple modifiable risk factors.

Generalizability	21	Discuss the generalizability (external validity) of the study results	15	Since it's a single centre study, it should be generalized with caution as mentioned in the discussion.
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2	This project was supported by King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21. The funder has no role in this study.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Congenital anomalies and associated risk factors in a Saudi population: a cohort study from pregnancy to age 2 years

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026351.R2
Article Type:	Research
Date Submitted by the Author:	19-May-2019
Complete List of Authors:	Kurdi, Ahmed; Prince Sultan Military Medical City, Majeed-Saidan, Muhammad Ali; Prince Sultan Military Medical City, Paediatrics Al Rakaf, Maha; Prince Sultan Military Medical City, Obstetrics & Gynecology AlHashem, Amal; Prince Sultan Military Medical City Botto, Lorenzo; University of Utah, Pediatrics Baaqeel, Hassan; King Saud bin Abdulaziz University for Health Sciences, College of Medicine Ammari, Amer; Pediatrics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Obstetrics and gynaecology, Paediatrics
Keywords:	Prevalence, Risk factors, Prevention, Outcome, Congenital anomaly

SCHOLARONE™
Manuscripts

1
2
3
4 **Congenital anomalies and associated risk factors in a Saudi**
5
6 **population: a cohort study from pregnancy to age 2 years**
7
8
9

10 Ahmed M Kurdi¹, Muhammad A Majeed-Saidan², Maha S Al Rakaf¹,
11
12 Amal M AlHashem², Lorenzo D Botto³, Hassan S Baaqeel⁴, Amer N
13
14 Ammari².
15
16
17
18
19

20 ¹ Division of Maternal and Foetal Medicine, Department of Obstetrics
21 and Gynaecology, Prince Sultan Military Medical City (PSMMC), P.O.
22 Box 7897, Riyadh, 11159, Saudi Arabia.
23
24
25
26
27
28

29 ² Department of Paediatric, Division of neonatal medicine, PSMMC.
30
31
32

33 ² Department of Paediatric, Division of medical genetics, PSMMC
34
35
36
37

38 ³ Department of Paediatric, Division of medical genetics, 295 Chipeta
39 way, Suite 25010, University of Utah school of medicine, Salt Lake
40 City, UT, USA,
41
42
43
44
45
46

47 ⁴ Department of Obstetrics and Gynaecology, King Saud Bin
48 AbdulAziz university for health sciences, Jeddah, Saudi Arabia,
49
50
51
52
53

54 **Running title:** Congenital anomalies and Risk Factors in a Saudi
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4 **Corresponding author:**
5

6 **Dr. Ahmed M. Kurdi, MD, German Board, DFM**
7

8 Consultant Maternal and Foetal Medicine
9

10 Avenue Medical Center
11

12 Kingdom of Saudi Arabia
13

14 Telephone: work +966-112000099 Ext. 158
15

16 Mobile: +966505451701
17

18 Fax: 0096611-4500185
19

20 Email: ahmedkurdi1950@gmail.com
21
22
23
24
25
26
27
28
29
30

31 **Abstract**
32
33
34
35

36 **Objective:** To assess the three key issues for CAs prevention and care,
37 namely, CA prevalence, risk factor prevalence, and survival, in a
38 longitudinal cohort in Riyadh, Saudi Arabia.
39
40

41 **Setting:** Tertiary care centre, Riyadh, Saudi Arabia.
42
43

44 **Participants:** Saudi women enrolled during pregnancy over three
45 years and their 28,646 eligible pregnancy outcomes (births, stillbirths
46 and elective terminations of pregnancy for foetal anomalies
47 [ETOPFAs]). The nested case-control study evaluated the CA risk
48 factor profile of the underlying cohort. All CA cases (1,179) and
49 unaffected controls (1,262) were followed through age 2 years.
50 Referred mothers because of foetal anomaly and mothers who
51
52
53
54
55
56
57
58
59
60

1
2
3
4 delivered outside the study centre and their pregnancy outcome were
5 excluded.
6

7
8 **Primary outcome measures:** Prevalence and pattern of major CAs,
9 Frequency of CA-related risk factors, and survival through age 2 years.
10

11 **Results:** The birth prevalence of CAs was 412/10,000 births (95% CI
12 388.6 to 434.9), driven mainly by congenital heart disease (148 per
13 10,000) (95% CI 134 to 162), renal malformations (113, 95% CI 110 to
14 125), neural tube defects (19, 95% CI 25.3 to 38.3), and chromosomal
15 anomalies (27, 95% CI 21 to 33). In this study, the burden of
16 potentially modifiable risk factors included high rates of diabetes
17 (7.3%, OR 1.98, 95% CI 1.04 to 2.12), maternal age >40 years (7.0%,
18 OR 2.1, 95% CI 1.35 to 3.3), consanguinity (54.5%, OR 1.5, 95% CI 1.28
19 to 1.81). The mortality for live births with CAs at 2 years of age was
20 15.8%.
21

22 **Conclusions:** This study documented specific opportunities to
23 improve primary prevention and care. Specifically, folic acid
24 fortification (the neural tube defect prevalence was >3 times that
25 theoretically achievable by optimal fortification), preconception
26 diabetes screening and consanguinity-related counselling could have
27 significant and broad health benefits in this cohort and arguably in
28 the larger Saudi population.
29
30
31

32 **Strengths and limitations of this study:**

- 33 • Babies with CAs are diagnosed prospectively, prenatally, and
34 postnatally and followed up to 2 years of age.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Involvement of multidisciplinary teams in establishing the final diagnosis.
- Inclusion of elective termination of pregnancies with lethal CAs and stillbirths.
- Single-centre study. The pregnancy cohort was mainly from families of Saudi army personnel dependents, which could be a limiting factor.

Funding statement: This project was supported by a generous grant from King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21.

Disclaimer: The funding institution had no role in the study design, data collection, analysis, interpretation of data, the writing of the various reports or the decision for submission for publication. All authors have full independence from the funder, have full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the analysis.

Competing interests statement: None declared

All authors have completed the ICMJE uniform disclosure from www.icmje.org-coi_disclosure.pdf and declare no support from any organization for the submitted research article; no financial

1
2
3
4 relationship with any organization that might have an interest in the
5 submitted work in the previous three years; and no other
6 relationships or activities that could appear to have influenced the
7 submitted work.
8
9
10
11
12
13
14

15 **Key words:** Congenital anomalies, Prevalence, Risk factors, Prevention,
16 and Outcome
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Congenital anomalies and associated risk factors in a Saudi** 32 **population: a cohort study from pregnancy to age 2 years** 33 34 35 36 37

38 **Introduction** 39

40 Because of their lifelong impact on health and survival, congenital
41 anomalies (CAs) are increasingly recognized as a global health
42 priority.^{1 2} With better control of infections and other causes of early
43 mortality, CAs are becoming increasingly important drivers of child
44 survival and health in low- and middle-income countries.^{1 3} CAs affect
45 approximately an estimated 1 in 33 newborns, contribute each year to
46 300,000 deaths in the first month of life, and are associated with 3·2
47 million birth-related disabilities.³ Accordingly, the World Health
48 Assembly has emphasized the urgent need for action to help prevent,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 diagnose, and provide timely interventions.¹ Data on the prevalence
5 and mortality associated with CAs are scarce in many low- and
6 middle-income countries, with most reports originating in high-
7 income areas. For example, in a population-based study of livebirths
8 with CAs in the United Kingdom, the 20-year survival rate was 85.5%.⁴
9
10 Similarly, the 25-year survival rate among livebirths with CAs in New
11 York state was 82.5%,⁵ with a documented improvement from the
12 1980s (78.1% from 1983 –1988) to the early 2000s (89.3% from 2001-
13 2006). Among CAs, the major drivers of mortality were cardiovascular
14 anomalies (51.1%) and chromosomal anomalies (33.1%). In Korea,
15 infant mortality among babies with CAs was 6.8/10,000 live births,
16 and foetal mortality was 13.5/10,000 total births.⁶
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 However, local action, whether focused on primary prevention or on
37 improving care, is most effective when based on reliable information
38 about the key indicators of the causes and outcomes of CAs in the
39 underlying population. In this study, we implemented an integrated
40 approach to generate these data in a systematic cohort of women,
41 tracked from mid-gestation through the second year of life of their
42 children, to assess the prevalence of CAs, the burden of potentially
43 modifiable risk factors, and the survival of affected children, as a basis
44 for better prevention and care.⁷
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Setting. The Prince Sultan Military Medical City (PSMMC) is a tertiary teaching institution with 1,250 beds and approximately 10,000 annual deliveries. PSMMC primarily serves Saudi army personnel and their families and is a referral centre for the other 16 military hospitals in the Kingdom of Saudi Arabia. The foetal medicine unit includes advanced imaging facilities, including 3D and 4D scanning. The paediatric department includes all major subspecialties, including medical genetics, paediatric surgery, and paediatric cardiology.

Study design This is an observational, prospective cohort study with a nested case-control study. The eligible cohort includes pregnancies of women who had their antenatal care and their routine antenatal anomaly ultrasound scan examination (USS) between 18 weeks and 22 weeks of gestation at PSMMC from 1 July 2010 through 30 June 2013 (figure 1).

In addition, Saudi women who are eligible for their antenatal care at PSMMC, but who did not have an antenatal screening ultrasound examination and later delivered at PSMMC, are also included in the study.

Inclusions and exclusions. Pregnancy outcomes included in the study were live births, stillbirths (foetal deaths at 20 weeks' gestation or

1
2
3
4 later), and pregnancies electively terminated because of foetal
5
6 anomalies (ETOPFAs). The study excluded spontaneous abortions,
7
8 pregnancies referred from other hospitals because of a diagnosis of a
9
10 foetal anomaly, and babies with CAs delivered elsewhere and referred
11
12 to PSMC for evaluation and management.
13
14
15
16
17
18

19 **Evaluations.** Initial antenatal screening tests included a complete
20
21 blood count, liver and kidney function tests, blood group and
22
23 antibody screening, rubella and Toxoplasma status, hepatitis B screen,
24
25 random blood sugar and HbA1c levels, VDRL, sickle cell screen and
26
27 urine analysis. A glucose tolerance test was performed at 24-28 weeks
28
29 of gestation.
30
31
32
33
34
35
36

37 When a structural birth defect was diagnosed or suspected
38
39 antenatally, mothers were counselled by one of the investigators
40
41 (MSR, AMK), demographic and exposure information was gathered,
42
43 and both parents were scheduled within 2-4 weeks to attend a
44
45 dedicated clinic developed for the study. At that time, a detailed
46
47 diagnostic and care plan was developed, which may have included
48
49 further blood tests and foetal imaging, or amniocentesis, chorionic
50
51 villous and/or foetal blood sampling for genetic studies. Consent was
52
53 requested for cord blood collection for future molecular testing.
54
55
56
57
58
59
60

1
2
3
4 On the first day of life, all newborns in the cohort (with and without
5
6 CAs) were examined by a paediatrician as part of the first clinical
7
8 screening examination. Babies with CA, whether identified antenatally
9
10 or postnatally, underwent diagnostic investigations as clinically
11
12 indicated (e.g., echocardiogram, cardiac catheterization, or other
13
14 imaging studies; metabolic and molecular testing) and were referred
15
16 to the appropriate subspecialists. A clinical geneticist evaluated all
17
18 babies with suspected syndromes or multiple CAs. A letter was
19
20 distributed to all clinical departments describing the study and req
21
22 uesting that they inform the study team about all infants and children
23
24 with CAs born at PSMMC.
25
26
27
28
29
30
31
32

33 **Evaluations for specific congenital anomalies.** If congenital heart
34
35 disease (CHD) was detected or suspected antenatally on USS
36
37 examination, the mother was referred to the paediatric cardiologist
38
39 for a foetal echocardiogram. All these infants were also re-evaluated
40
41 after birth by a paediatric cardiologist. Isolated atrial septal defects
42
43 (ASDs II) were re-evaluated at 6 to 12 months of age, and if the
44
45 echocardiogram showed no evidence of ASD II at the time, the infant
46
47 was not considered a case. Congenital hydronephrosis (HN) was
48
49 graded using the Society of Foetal Urology grading system.⁸ Babies
50
51 with grade one HN were given a repeat US examination within the
52
53 first year of life; if HN had resolved, the baby was not considered a
54
55 case. Chromosomal analysis was performed according to standard
56
57
58
59
60

1
2
3
4 procedures, and a minimum of 20 metaphases were analysed
5
6 (Applied Imaging CytoVision Karyotyping System). Reports followed
7
8 the International System of Human Cytogenetic Nomenclature (ISCN
9
10 2013). Molecular studies were performed at the Biocenthia Health
11
12 Group in Germany (<http://www.bioscientia.de/en/>), the Mayo Medical
13
14 Laboratories in the United States, and at the Developmental Genetic
15
16 Laboratory at King Faisal specialist hospital and research centre in
17
18 Saudi Arabia.
19
20
21
22
23
24
25

26 **Nested case-control study.** The nested case-control study included
27
28 as cases all women in the cohort with a pregnancy diagnosed with a
29
30 CA and as controls a random sample of women in the cohort with a
31
32 normal USS. The random sample was generated daily by taking the
33
34 morning list of scheduled USS and using a random number generator
35
36 (<http://www.random.org>) to select potential controls so that the
37
38 control sample would eventually be at least as large as the estimated
39
40 total number of cases. If a woman initially selected as a control had a
41
42 pregnancy diagnosed with a birth defect at the initial date or later,
43
44 she was then included in the case group. Investigators administered
45
46 an in-person structured interview to case and control mothers. The
47
48 interview included information about age (for both parents); weight
49
50 before pregnancy; height; parity; family income (father's income or
51
52 combined parental income if the mother worked); maternal education
53
54 level (illiterate, primary school graduate, secondary school graduate,
55
56
57
58
59
60

1
2
3
4 or university graduate); parental occupation (mother; housewife,
5
6 teacher, student and others, father; soldier, officer or civilian
7
8 employee); folic acid (FA) supplement use (regular use before and
9
10 during the 1st trimester of pregnancy; irregular or only postconception
11
12 use; no use or uncertain use as per the mother's report); parental
13
14 smoking (one or both parents smoking during the current pregnancy);
15
16 maternal radiation exposure during the first trimester; maternal
17
18 diabetes (overt or gestational) as defined by the International
19
20 Association of Diabetes and Pregnancy study groups ⁹ and HbA1c
21
22 level; family history of CAs (in previous pregnancies and in maternal
23
24 or paternal lineages); drug and medication use during the first
25
26 trimester; and chronic maternal systemic illnesses (hypothyroidism,
27
28 epilepsy, depression, essential hypertension, and bronchial asthma).
29
30 Consanguinity was defined as women being first or second cousins to
31
32 their husbands (supplementary file).
33
34
35
36
37
38
39
40
41
42

43 **Follow-up.** Case infants and control infants were examined in the
44
45 dedicated study clinic at 1, 6, 12, 18 and 24 months of age. Two
46
47 neonatologists and a clinical geneticist supervised the clinic. Babies
48
49 with CAs also continued to be followed by the relevant subspecialty
50
51 clinics. The remaining cohort (babies without CAs not selected as
52
53 controls) was re-examined at 4-8 weeks by the paediatrician for a
54
55 second screening examination. A head ultrasound and a postductal
56
57 pulse oximetry reading were completed in all babies attending the
58
59
60

1
2
3
4 clinics. If the O₂ saturation was below 95%, the baby was referred to
5
6 the paediatric cardiologist for evaluation. If any CAs were detected at
7
8 the second screening examination, the babies were referred to the
9
10 genetics clinic for further evaluation and diagnosis. If the second
11
12 screening examination proved to be normal, then no further follow-
13
14 up was arranged. However, if CAs were discovered later in babies up
15
16 to 2 years of age, they were included in the study.
17
18
19
20
21
22
23

24 **Case review, coding, classification.** Congenital anomalies were
25
26 coded following the International Statistical Classification of Diseases
27
28 and Related Health Problems, 10th revision, (ICD10, WHO-2010)
29
30 according to the European Concerted Action on Congenital
31
32 Anomalies and Twins (EUROCAT) recommended procedures.¹⁰ We did
33
34 not include isolated minor anomalies or prematurity-related
35
36 conditions such as patent ductus arteriosus or hydrocephalus
37
38 complicating intraventricular haemorrhage diagnosed in preterm
39
40 babies (<37 completed weeks of gestation). Data were entered in a
41
42 version of EUROCAT Data Management Program (EDMP) modified to
43
44 include control records and the additional variables generated by the
45
46 case-control study and the follow up.
47
48
49
50
51

52 **Institutional ethics review.** The study and the consent procedure
53
54 were approved by the Ethical Committee of the PSMC (Project No.
55
56 366, series of 2009).
57
58
59
60

Statistical analysis.

The data collected and used in this study was part of our routine care and was anonymised.

Odds ratios for the association between risk factors and CAs were estimated using multiple logistic regression in a two-step process. An initial set of variables was selected by univariate logistic regression as being associated with CA risk ($p < 0.05$). Variables highly correlated with other variables (e.g., insulin use) were not entered into the model. This initial variable set was then reduced by stepwise backward elimination to produce a more parsimonious model. The final model retained the following covariates: consanguinity, maternal age group, education level, diabetes and history of siblings with a congenital anomaly. The model fit was assessed with the Hosmer and Lemeshow's goodness of fit test and by calculating Nagelkerke R². Statistical analysis was performed with SPSS for Windows, version 15 (SPSS Inc., Chicago, Illinois).

Patient and public involvement: Our long-term experience with the families and their offspring has helped us to shape the research question and the study design. All families recruited were informed about the study objectives. None of the parents were involved in the study design, recruitment to and conduct of the study. The study results were disseminated to the community and to the professional

1
2
3
4 health care provider through social media, newspapers, presentation
5
6 at various conferences, and scientific publications.
7
8
9
10

11 12 13 14 **Results**

15
16
17 Of the 31,032 birth outcomes of the 30,351 women followed since
18 pregnancy, 30,753 (99.1%) occurred at PSMC (figure 2). Of these,
19 2,107 were spontaneous abortions (6.9%) and were not included in
20 the study, leaving 28,646 eligible births (27,726 singleton births and
21 920 multiple births). The overall stillbirth rate was slightly less than
22 1% (figure 2).
23
24
25
26
27
28
29
30
31
32

33 **Birth defect occurrence, detection, and mortality.** Of the 28,646
34 eligible pregnancy outcomes, 1,179 were diagnosed with a CA, for an
35 overall prevalence of 412/10,000 (95% CI 388.6 to 434.9) total births,
36 or 1 in 24 births. Of these 1,179 cases, 38 (3.2%) were stillbirths, and
37 18 (1.5%) were electively terminated because of lethal malformations
38 (13 with anencephaly, 3 with severe hydrops foetalis and cystic
39 hygroma, 1 with Meckel-Gruber syndrome and 1 with bilateral renal
40 agenesis) (table 1). The antenatal detection rate among women who
41 has had an antenatal ultrasound screening examination was 70.6%
42 (561/795). In 90% of these cases (505/561), the diagnosis was made
43 by ultrasound scan at 22 weeks of gestation or later. Of the 618
44 babies diagnosed postnatally, 296 (47.9%) were diagnosed at birth,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 239 (38.7%) between 1 and 7 days, 29 (4.7%) between 1 and 4 weeks,
5
6 52 (8.4%) between 1 and 12 months, and 2 (0.3%) after one year of
7
8 age. Mortality among livebirths with CAs (table 1) was 14.1% in the
9
10 first year, nearly half of which occurred in the first week of life, with a
11
12 total mortality of 15.8% by the end of the second year of life.

13
14
15 Mortality at two years was 0.9% in the unaffected cohort (0.24% for
16
17 live births). Among the controls, there were 8 stillbirths, two deaths
18
19 because of prematurity and its complications and one death at 2
20
21 years of age because of acute fulminating leukaemia.
22
23
24
25
26

27 **Contribution of specific congenital anomalies.**

28
29 Approximately half of the overall birth prevalence was due to
30
31 congenital heart disease and central nervous system anomalies.
32
33 Neural tube defects occurred at a rate of 19 per 10,000 (95% CI, 13.8
34
35 to 23.9) (1 in 526 births). Severe CHD occurred at a rate of 32 per
36
37 10,000 (95% CI, 25.3 to 38.3) (1 in 313 births) and accounted for
38
39 21.4% of all CHD cases. Chromosomal anomalies whose risk is
40
41 associated with increased maternal age (trisomies 21, 18, and 13)
42
43 occurred with a combined prevalence of 25 per 10,000 (95% CI, 19.6
44
45 to 31.3) (1 in 392 births). Trisomy 21 accounted for most cases of
46
47 chromosomal anomalies, with a prevalence of 22 per 10,000 (95% CI,
48
49 16.7 to 27.4) or 1 in 456 births (table 2).
50
51
52
53
54
55
56

57 Two-thirds of all cases of CAs (773/1179, 65.6%) were isolated (e.g.,
58
59 they involved a single body system) (table 3).
60

1
2
3
4
5
6 **Risk factors.** As a proxy of risk factor prevalence in the underlying
7 population, we used the frequency of selected maternal or parental
8 risk factors for CAs among controls in the nested case-control study
9 (figure 3). The most frequent potentially modifiable factors included
10 lack of periconception folic acid supplement use, consanguinity, high
11 body mass index, advanced maternal age, smoking (first or second-
12 hand) and maternal diabetes. Nearly 6% of non-primiparous women
13 had one prior child with a major CA. In the univariate analysis, the
14 nested case-control study (table 4) detected overall increased odds
15 ratios for all CAs combined for consanguinity, advanced maternal age,
16 high parity, maternal illiteracy, maternal university education, X-ray
17 exposure during pregnancy, maternal diabetes, and positive family
18 history of CA in a sibling. Increased odds ratios with confidence
19 intervals, including unity, were also found for maternal depression
20 and hypertension (table 4). In the multiple logistic regression model,
21 only first-degree consanguinity (OR 1.5, 95% CI 1.28 to 1.81),
22 maternal age of more than forty years (OR 2.1, 95% CI 1.35 to 3.3),
23 maternal illiteracy (OR 1.4, 95% CI 1.17 to 1.7), maternal university
24 level education, (OR 1.74, 95% CI 1.24 to 2.44), maternal diabetes
25 mellitus (OR 1.98, 95% CI 1.33 to 2.95) and history of a sibling with an
26 anomaly (OR 1.49, 95% CI 1.04 to 2.12) were retained in the model
27 (table 5). The Hosmer and Lemeshow goodness of fit p value was
28 0.08, and Nagelkerke R² was 0.055, explaining 6% of the effect on
29 CAs.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Of the 223 mothers with DM who had CA-affected foetuses
8 (223/1,179, 18.9%), 36 (3%) had overt DM (ODM), and 187 (15.7%)
9 had gestational DM (GDM). Of the mothers with GDM, 50 (26.7%)
10 had gestational DM (GDM). Of the mothers with GDM, 50 (26.7%)
11 required insulin. Among the controls, 200 mothers had diabetes
12 (200/1,179, 15.8%), of whom 12 (0.9%) had ODM, and 188 (15.9%)
13 had GDM. Of the latter, 29 (14.5%) required insulin.
14
15
16
17
18
19
20

21 Maternal age over 40 years was high at 7% among mothers of babies
22 with CA compared to 3.6% among controls mothers (OR 2.09, 95% CI
23 1.43 to 3.05, $p=0.0002$) (table 4). This was mainly due to
24 chromosomal aneuploidy. Further subgroup analysis showed non-
25 chromosomal anomalies (NCA) was found in 55 mothers (4.6%)
26 compared to 3.6% among the controls mothers (OR 1.29, 95% CI 0.86
27 to 1.9, $p= 0.2$). The main NCA found were CHD in 22 (40%), 7 (12.7%)
28 were severe CHD and neural tube defects in 5 (9.1%).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Discussion

51 This longitudinal study of CAs in a pregnancy cohort in Saudi Arabia,
52 followed from mid-gestation through age 2 years, had three
53 integrated aims: to describe the population's risk factor profile,
54 document the associated birth prevalence of CAs, and assess survival
55
56
57
58
59
60

1
2
3
4 as a critical health outcome.⁷ Gathering information about these three
5
6 critical areas is crucial when planning and evaluating policies and
7
8 interventions, be they aimed at primary prevention (e.g., folic acid
9
10 fortification to prevent neural tube defects) or at improving care.
11
12
13

14
15 The burden of CAs was high in this population. The study
16
17 documented a remarkably high birth prevalence of CAs of 412 per
18
19 10,000 or 1 in 24 total births. This rate is higher than that reported in
20
21 studies from many high-income countries, as those reported by
22
23 EUROCAT (261/10,000 births),¹¹ BINOCAR (206/10,000 births),¹² and
24
25 the Bradford (BIB) study (305/10,000).¹³ This prevalence of CAs is also
26
27 higher than that previously reported from Saudi Arabia (115 to 257
28
29 per 10,000 live births).¹⁴⁻¹⁶ Although some studies report an even
30
31 higher prevalence, e.g., such as an antenatal CA prevalence of
32
33 521/10,000 pregnancies screened, and a prevalence among livebirths
34
35 of 465/10,000,¹⁷ these figures may be overestimates of the true
36
37 prevalence because of the inclusion of mothers referred from other
38
39 institutions. In the current study, we strove to obtain as complete an
40
41 ascertainment as possible by initiating follow-up in pregnancy and
42
43 extending it through the second year of life, by including stillbirths
44
45 and elective termination of pregnancies for foetal anomalies
46
47 (ETOPFAs), and by successfully including some genetic conditions that
48
49 tend to be diagnosed after the newborn period.
50
51
52 However, the high prevalence of CAs is likely to be due not only to
53
54 the completeness of the ascertainment but also to the high frequency
55
56
57
58
59
60

1
2
3
4 of adverse risk factors in the underlying population, as documented in
5
6 the controls of the nested case-control study. When focusing on
7
8 factors that are potentially modifiable, three such factors seem to
9
10 stand out. The first is insufficient folic acid use in this cohort (<10% in
11
12 the periconception period). The rate of neural tube defects was 19
13
14 per 10,000/births (table 2), at least three times higher than the rate of
15
16 6 per 10,000/births, which seems achievable by providing sufficient
17
18 folic acid to women of childbearing age.^{18 19} Although legislation
19
20 requiring the mandatory fortification of flour had been in place in
21
22 Saudi Arabia for years prior to this study (Kingdom of Saudi Arabia,
23
24 2000; Food fortification initiative, 2013),^{20 21} our findings suggest that
25
26 there are gaps in coverage or effectiveness, which could be evaluated
27
28 with nutrition or blood folate surveys. Such information would
29
30 provide important evidence to improve folate sufficiency in the
31
32 population, with its attendant health benefits, including a substantial
33
34 reduction in the burden of neural tube defects. Because of the
35
36 inclusion of stillbirths and pregnancy terminations, this study also
37
38 provides a fuller estimate of the potential benefits of primary
39
40 prevention than if only livebirths had been identified (representing
41
42 just over half of all cases, 30/54).
43
44
45
46
47
48
49
50
51

52 The second factor is maternal diabetes (tables 4 and 5). Diabetes is an
53
54 established risk factor for many CAs, and diabetes control before
55
56 conception has been shown to reduce and nearly normalize CA risk.⁹
57
58
59 ^{22 23} Several avenues for preventing diabetes and its health effects are
60

1
2
3
4 available, including population screening (many diabetic women are
5 undiagnosed), health care and counselling, and education on healthy
6 lifestyle and dietary choices starting from childhood. The current
7
8 reported prevalence in Saudi Arabia of overt diabetes in women
9
10 above age 40 years ranges from 7.7% – 21.7%.^{24 - 26} In the study
11
12 cohort, overt diabetes was observed in 2% of women and increased
13
14 in women 30 years old or older. Al-Nozha and colleagues²⁷ reported
15
16 a prevalence of overt diabetes of 11.6% in women aged 30-39 years
17
18 and >22% in women aged ≥40 years compared to 2.7% and 7.1% in
19
20 our study, respectively. Though lower than these estimates, the
21
22 prevalence of overt diabetes in the study cohort is alarmingly high.
23
24
25
26
27
28
29
30

31
32 Third, we observed a high rate of parental consanguinity (54.5%),
33
34 especially first-cousin marriages (48.0%). These marriages are
35
36 common in many parts of the Middle East, Africa, and the Indian
37
38 subcontinent,²⁸⁻³⁰ with one estimate suggesting that “one billion
39
40 people live in communities with a preference for consanguineous
41
42 marriage” (Hamamy, 2012).²⁹ This preference has deep social roots.
43
44 Nevertheless, education combined with preconception and premarital
45
46 counselling can be important prevention strategies by focusing on
47
48 increasing awareness to allow couples to make more informed
49
50 choices. Close consanguinity is a known risk factor for CAs,³⁰ as well
51
52 as Mendelian conditions such as inborn errors of metabolism
53
54 (occurring in 1 in 770 births in this study), as confirmed in prior
55
56 reports from Saudi Arabia and from the world literature.^{31 32}
57
58
59
60

1
2
3
4
5
6 Advanced maternal age (>40 years) was high (7%) among mothers of
7 babies affected with CA in the cohort studied. This is comparable to
8 6% among French mothers but higher than mothers from other 14
9 European countries (Loane et.al., 2009).³³ Advanced maternal age is
10 increasing over the last two decades^{33,34} and is affecting the
11 prevalence of aneuploidy. The risk for NCA were similar to controls
12 and recent reports suggest that it has a protective effect.³⁵ Several
13 reports have shown a higher prevalence of specific CA among babies
14 of mothers at this age group like neural tube defects, cleft lip,
15 oesophageal atresia with or without tracheal fistula. We found a high
16 prevalence of CHD and neural tube defects.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31
32 Structured health education programs at several levels should
33 emphasize the importance of planned pregnancies at the optimal age
34 (20-30 years), ensure adequate periconceptual folic acid intake (400
35 to 800 µg daily)³⁶ and detailed fetal anomaly scan. A nation-wide CA
36 registry will help to give a fuller picture and monitor the trends and
37 the results of any intervention.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 We did not diagnose cases of congenital rubella syndrome. This is
52 likely due to the active immunization programme in Saudi Arabia,
53 with a measles, mumps and rubella vaccine uptake of 97%. In
54
55
56
57
58
59
60

1
2
3
4 addition, preschool age girls are given a booster vaccine against
5
6 rubella.
7
8
9

10
11 In a prior publication, we reported a low regular (periconception) folic
12 acid (FA) intake (9.7%) in this study population ³⁷ and suggested
13 fortification of rice in addition to wheat, complemented by education
14 programmes supporting FA supplementation, as an efficient strategy
15 to achieve folate sufficiency in the population.
16
17
18
19
20
21
22

23
24 Finally, our findings emphasize the impact of CAs in this
25 population by documenting not only birth prevalence but also
26 the associated early mortality (table 1), which was 15.8% by the
27 second year of life (nearly all in the first year). Further
28 supporting the high impact of CAs are the findings by Majeed-
29 Saidan and colleagues ³⁸ who reported that 36% of deaths in a
30 large neonatal intensive care unit in Riyadh were due to lethal
31 CAs. These findings highlight the crucial importance and
32 urgency to improve care in addition to primary prevention.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 This study demonstrated the importance of the "triple
50 surveillance" programme, suggested by Botto and
51 Masteroiacova,⁴ for identifying the risk factors for CAs (causes),
52 estimating the burden of the disease (prevalence), and assessing
53 disease outcome (mortality). This will ultimately lead to disease
54
55
56
57
58
59
60

1
2
3
4 burden reduction or prevention by instituting appropriate
5
6 interventions.
7
8
9
10

11
12 The study has limitations. Because of the cohort design,
13
14 the resulting sample size did not allow a more detailed analysis
15
16 of specific CA groups. Estimates of some key risk factors, such
17
18 as folic acid insufficiency, were based on maternal reports (e.g.,
19
20 reported supplement use) rather than biomarkers. Furthermore,
21
22 the pregnancy cohort was mainly from families of Saudi army
23
24 personnel dependents. Although the Saudi Army recruits from
25
26 all sectors of Saudi society, a broader survey of the Saudi
27
28 population would provide additional information to better
29
30 assess gaps and opportunities for prevention and care
31
32 nationwide.
33
34
35
36
37
38
39
40

41 **Conclusion.** This longitudinal surveillance programme that
42
43 encompassed the causal chain from risk factors to health outcomes
44
45 documented several opportunities to reduce the burden of CAs
46
47 through primary prevention and better care. Folic acid fortification,
48
49 preconception diabetes screening, and consanguinity-related
50
51 counselling could have significant health benefits in this cohort and
52
53 arguably in the larger Saudi population, particularly if associated with
54
55 a national CA monitoring programme to support and track the impact
56
57 of interventions.
58
59
60

Acknowledgments

We thank the Medical Services Directorate of the Saudi Armed Forces and the PSMCMC directorate for their support during the initiation and execution of the study; the study's advisory board (Eduardo Castilla, Pierpaolo Mastroiacovo, Ester Garne, Fowzan Alkuraya, and Wesam Kurdi) for advice and guidance throughout the study; and the study secretaries for their commitment and enthusiasm.

Author's statement:

AMK study conception and design, revised the manuscript. **MAMS**, study conception and design, drafting and revising the manuscript., **MSR**, study design, data collection. **AMH**, data collection, revised the manuscript. **LDB**, study design, critically revised the manuscript for intellectual content. **HSB**, statistical analysis and revised the manuscript. **ANA**, study design, data collection, revised the manuscript. All authors approved the submission of the manuscript.

Written informed consent:

Consent for cord blood samples for future DNA analysis was obtained from the mothers in the nested case-control study only.

Data sharing statement:

1
2
3
4 Dataset can be obtained on request through a third party "King
5 AbdulAziz city for science and technology".
6
7
8
9

10 **Word count: 4,210**
11
12
13
14
15
16
17
18

19 **References**

- 20
21
22
23
24 1. World Health Organization. Sixty -Third World Health
25 Assembly. CA Report by the Secretariat, A63/10. Geneva,
26 Switzerland: World Health Organization, 2010.
27
28
29
30
31
32
33 2. World Health Organization. Global Health Observatory
34 (GHO) data. Under-five mortality 2016.
35
36 [http://www.who.int/gho/child health/mortality/mortality und](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/)
37 [er five text/en/](http://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/) (accessed 12 December 2017).
38
39
40
41
42
43
44
45
46 3. Christianson AL, Howson CP, Modell B. Global report on
47 CA: the hidden toll of dying and disabled children. White
48 Plains (NY): March of Dimes Defects Foundation 2006.
49
50
51
52
53
54
55 4. Tennant PWG, Pearce MS, Bythell M, *et al.*
56
57 20-year survival of children born with congenital anomalies:
58
59
60

1
2
3 a population-based study. *Lancet* 2010; 375: 649–56.
4
5
6

- 7
8 5. Wang Y, Hu J, Druschel CM, *et al.* Twenty-Five-Year
9 Survival of Children with Birth Defects in New York State: A
10 Population-Based Study. *Birth Defects Research (Part A)*
11 201;1 91:995-1003.
12
13
14
15
16
17
18 6. Ko HS, Kim DJ, Chung Y, *et al.* A national cohort study
19 evaluating infant and fetal mortality caused by birth defects
20 in Korea. *BMJ Open* 2017;7: e017963. doi:10.1136/bmjopen-
21 2017-017963
22
23
24
25
26
27
28 7. Botto LD, Mastroiacovo P. Triple surveillance: a proposal for
29 an integrated strategy to support and accelerate birth
30 defect prevention. *Ann. N. Y. Acad. Sci* 2018; (1414):126-36.
31
32
33
34
35
36
37
38 8. Avni FE, Maugey-Laulom B, Cassart M, *et al.* Foetal
39 genitourinary tract. In: Callen PW, ed. *Ultrasonography in*
40 *Obstetrics and Gynecology*. 5th Ed. New York: W.B.
41 Saunders 2007; 640-75.
42
43
44
45
46
47
48
49
50 9. Metzger BE, Gabbe SG, Persson B, *et al.* International
51 association of diabetes and pregnancy study groups
52 recommendations on the diagnosis and classification of
53
54
55
56
57
58
59
60

1
2
3
4 hyperglycemia in pregnancy. *Diabetes Care* 2010; 33(3):
5 676–82. doi: 10.2337/dc09-1848.
6
7
8
9

- 10
11 10. EUROCAT. Eurocat Guide 1.3. Instructions for registration
12 and surveillance of congenital anomalies. Belfast, Northern
13 Ireland University of Ulster 2005. [http://www.eurocat-
15 network.eu/content/Section%202.4-%2027%20Oct2016.pdf](http://www.eurocat-
14 network.eu/content/Section%202.4-%2027%20Oct2016.pdf)
16
17
18
19
20
21
22 11. EUROCAT. Prevalence Tables, 2011-2015
23 [http://www.eurocat-
26 network.eu/newprevdata/showPDF.aspx?winx=1896&winy=9
27 40&file=allsubgroups.aspx](http://www.eurocat-
24 network.eu/newprevdata/showPDF.aspx?winx=1896&winy=9
25 40&file=allsubgroups.aspx) 2015. (accessed 12 December
28 2017).
29
30
31
32
33
34 12. Springett A, Budd J, Draper ES, *et al.* Congenital Anomaly
35 Statistics 2012 England and Wales, London 2014.
36 [www.binocar.org/content/Annual%20report%202012_FINAL
38 nologo.pdf](http://www.binocar.org/content/Annual%20report%202012_FINAL
37 nologo.pdf).
39
40
41
42
43
44
45
46 13. Sheridan E, Wright J, Small N, *et al.* Risk factors for
47 congenital anomaly in a multiethnic birth cohort: an
48 analysis of the Born in Bradford study. *Lancet* 2013;
49 382(9901): 1350–9. doi: 10.1016/S0140-6736(13)61132-0.
50
51
52
53
54
55
56
57 14. Al Bu Ali WH, Balaha MH, Al Moghannum MS, *et al.* Risk
58 factors and birth prevalence of CA and inborn errors of
59
60

1
2
3
4 metabolism in Al Ahsa, Saudi Arabia. *Pan Afr Med J* 2011; 8:
5
6 14.
7
8
9

10
11 15. Fida NM, Al-Aama J, Nichols W, *et al.* A prospective study
12 of congenital malformations among live born neonates at a
13 University Hospital in Western Saudi Arabia. *Saudi Med J*
14 2007; 28(9): 1367–73.
15
16
17
18

19
20
21
22 16. Refat MY, Al-Moghanem M, McDonald, *et al.* Major CA at
23 King Fahd Hofuf Hospital: Prevalence, risk factors and
24 outcome. *Ann Saudi Med* 1995; 15(4): 339–43.
25
26
27
28

29
30
31 17. Sallout B, Obedat N, Shakeel F, *et al.* Prevalence of major
32 congenital anomalies at King Fahad Medical City in Saudi
33 Arabia: a tertiary care centre-based study. *Ann Saudi Med*
34 2015; 35(5): 343–51.
35
36
37
38
39

40
41
42
43 18. Kancherla V, Oakley GP Jr, Brent RL. Urgent global
44 opportunities to prevent CA. *Semin Foetal Neonatal Med*
45 2014; 19(3): 153–60.
46
47
48
49

50
51
52 19. Youngblood ME, Williamson R, Bell KN, *et al.* Update on
53 global prevention of folic acid-preventable spina bifida and
54 anencephaly. *CA Res A Clin Mol Teratol* 2013; 97(10): 658–
55 63. doi: 10.1002/CAra.23166. Epub 2013.
56
57
58
59
60

- 1
2
3
4
5
6 20. Kingdom of Saudi Arabia, Ministry of health, Nutritional
7 department directive. Number 652/1/26, 2000; 13/09/2000.
8
9
10
11
12
13 21. Food Fortification Initiative. (2013).
14 [http://www.ffinetwork.org/country_profiles/country.php?reco](http://www.ffinetwork.org/country_profiles/country.php?record=194)
15 [rd=194](http://www.ffinetwork.org/country_profiles/country.php?reco) (accessed 12 December 2017).
16
17
18
19
20
21
22 22. Kitzmiller JL, Wallerstein R, Correa A, *et al*. Preconception
23 care for women with diabetes and prevention of major
24 congenital malformations. *CA Res A Clin Mol Teratol* 2010;
25 88(10): 791–03. doi: 10.1002/CAra.20734.
26
27
28
29
30
31
32
33 23. Simeone RM, Devine OJ, Marcinkevage JA, *et al* Diabetes
34 and congenital heart defects: a systematic review, meta-
35 analysis, and modeling project. *Am J Prev Med* 2014; 48(2):
36 195–204. doi: 10.1016/j.amepre.2014.09.002.
37
38
39
40
41
42
43
44
45 24. Al-Nuaim AR, Al-Rubean K, Al-Mazrou Y, *et al*. Prevalence
46 of diabetes mellitus, obesity and hypercholesterolemia in
47 Saudi Arabia: national chronic disease survey. Riyadh (KSA):
48 Ministry of Health and King Saud University. ISBN: 1995;
49 9960-603-01-6.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 25. El-Hazmi M, Warsy A, Al-Swailem AR, *et al.* Diabetes
5
6 mellitus as a health problem in Saudi Arabia. East Mediterr
7
8 Health J 1998 (4): 58–67.
9
10
11
12
13 26. Warsy AS, el-Hazmi MA. Diabetes mellitus, hypertension
14
15 and obesity--common multifactorial disorders in Saudis.
16
17 East Mediterr Health J 1999; 5(6): 1236–42.
18
19
20
21
22 27. Al-Nozha MM, Al-Maatouq M, Al-Mazrou YY. *et al.*
23
24 Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25(11):
25
26 1603–10.
27
28
29
30
31 28. El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, *et al.*
32
33 Regional variations in the prevalence of consanguinity in
34
35 Saudi Arabia. Saudi Med J 2007; 28(12): 1881–4.
36
37
38
39
40 29. Hamamy H. Consanguineous marriages: Preconception
41
42 consultation in primary health care settings. J Community
43
44 Genet 2012; 3(3): 185–92.
45
46
47
48
49 30. Majeed-Saidan MA, Ammari AN, AlHashem AM, *et al.*
50
51 Effect of consanguinity on CA in Saudi women: results from
52
53 a nested case-control study. CA Res A Clin Mol Teratol
54
55 2015; 103(2): 100–4. doi: 10.1002/CAra.23331.
56
57
58
59
60

- 1
2
3
4 31. Mak CM, Lee HC, Chan AY, *et al*. Inborn errors of
5
6 metabolism and expanded newborn screening: review and
7
8 update. *Crit Rev Clin Lab Sci* 2013; 50(6): 142–62. doi:
9
10 10.3109/10408363.2013.847896.
11
12
13
14
15 32. Moammar H, Cheriyan G, Mathew R, *et al*. Incidence and
16
17 patterns of inborn errors of metabolism in the Eastern
18
19 Province of Saudi Arabia, 1983-2008. *Ann Saudi Med* 2010;
20
21 30(4): 271–7. doi: 10.4103/0256-4947.65254.
22
23
24
25
26
27 33. Loane M, Dolk H, Morris JK, a EUROCAT working group.
28
29 Maternal age-specific risk of non-chromosomal anomalies.
30
31 *BJOG* 2009; 116:1111-19.
32
33
34
35
36
37 34. Nabukrea S, Wingate MS, Alexander GR, et al. First -time
38
39 births among women 30 years and older in the United
40
41 States: patterns and risk of adverse outcome. *J Reprod Med*
42
43 2006; 9:676-82.
44
45
46
47
48
49 35. Goetzinger KR, Shanks AL, Odibo AO, st al. Advanced
50
51 maternal age and the risk of major congenital anomalies.
52
53 *Am J Perinatol*. 2017; 34(3):217-22.
54
55
56
57
58
59
60

- 1
2
3
4 36. U.S. Preventive Task force. Folic acid for the prevention of
5
6 neural tube defects: US preventive services task force
7
8 recommendation statement. *Ann Intern Med.* 2009;
9
10 150:626-31.
11
12
13
14
15
16 37. Al Rakaf MS, Kurdi AM, Ammari AN, *et al.* Patterns
17
18 of folic acid use in pregnant Saudi women and prevalence
19
20 of
21
22 neural tube defects — Results from a nested case–control
23
24 study. *Preventive Medicine Reports* 2 (2015) 572–576.
25
26
27
28 38. Majeed-Saidan MA, Kashlan FT, Al-Zahrani AA, *et al.*
29
30 Pattern of neonatal and postneonatal deaths over a decade
31
32 (1995--2004) at a Military Hospital in Saudi Arabia. *Saudi*
33
34 *Med J* 2008; 29(6):879-83.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Legend: Table 1 Distribution and rates of congenital anomalies (CA) among the cohort's pregnancy outcomes, and associated mortality.

	Total cohort		With CA			Timing of CA detection				Mortality among livebirths with CA					
	No	%	No.	%	Rate /10000	Prenatal		Postnatal		Overall (0-2 years)		1st week		Total 1 st year	
Birth outcome	No	%	No.	%	Rate /10000	No.	%	No.	%	No.	%	No.	%	No.	%
Live births	28 369	99	1 123	95.3	396	505	45.0	618	55	177	15.8	64	5.7	158	14.1
Stillbirths	259	0.9	38	3.2	1467	38	100								
ETOPFA	18	0.1	18	1.5	10000	18	100								
Total	28 646		1 179		412	561	47.6	618	52.4						

Footnote:

†ETOPFA, Terminations of pregnancy for foetal anomalies.

Stillbirth (foetal death at 20 weeks of gestation or greater).

Table 2 Prevalence and distribution of congenital anomalies, overall and by pregnancy outcome.

Birth defects	Number*	%	Prevalence per 1000 births (total births = 28646)	Live births		Prevalence per 10000 live birth (total live births = 28376)	Stillbirth		ETOPFA	
				No.	%		No.	%	No.	(%)
Any	1179	100	412	1123	95.3	396	38	3.2	18	1.5
Nervous system	160	13.6	56	129	80.6	45.7	18	11.3	13	8.1
Neural Tube Defects	54	4.6	19	30	55.5	10.6	11	20.4	13	24.1
Anencephalus	26	2.2	9	7	26.9	2.5	8	30.8	11	42.3
Encephalocele	11	0.9	4	9	81.8	3.2	1	9.1	1	9.1
Spina Bifida	17	1.4	6	14	82.4	4.9	2	11.8	1	5.9
Hydrocephaly	25	2.1	9	23	92.0	8.1	2	8.0		
Microcephaly	28	2.4	10	24	85.7	8.5	4	14.3		
Eye	33	2.8	12	33	100	11.6				
Anophthalmus/microphthalmus	11	0.9	4	11	100	3.9				
Congenital cataract	5	0.4	2	5	100	1.8				
Congenital glaucoma	9	0.8	3	9	100	3.2				
Ear, face and neck	7	0.6	2	7	100	2.5				

Anotia/microtia	7	0.6	2	7	100	2.5				
Cardiac	425	36.0	148	420	90.9	148	4	0.9		
Severe congenital heart defects *	91	7.7	32	89	97.8	31.4	2	2.2		
Common arterial truncus	3	0.3	1	3	100	1.1				
Transposition of great vessels	13	1.1	5	13	100	4.6				
Single ventricle	6	0.5	2	6	100	2.1				
Atrioventricular septal defect	17	1.4	6	15	88.2	5.3	2	11.8		
Tetralogy of Fallot	15	1.3	5	15	100	5.3				
Tricuspid atresia and stenosis	4	0.3	1	4	100	1.4				
Pulmonary valve stenosis	22	1.9	8	21	95.5	7.4	1	4.5		
Pulmonary valve atresia	9	0.8	3	9	100	3.2				
Aortic valve atresia/stenosis	5	0.4	2	5	100	1.8				
Hypoplastic left heart	15	1.3	5	15	100	5.3				
Hypoplastic right heart	5	0.4	2	5	100	1.8				
Coarctation of aorta	14	1.2	5	14	100	4.9				
Total anomalous pulmonary venous return	2	0.2	0.7	2	100	0.7				
Ventricular septal defect	171	14.5	60	171	100	60.2				
Atrial septal defect	214	18.2	74.7	214	100	75.4				
Oro-facial clefts										
Cleft lip with or without palate	42	3.6	14.7	35	83.3	12.3	5	11.9	2	4.8
Cleft palate only	11	0.9	3.8	11	100	3.9				
Respiratory	33	2.8	11.5	33	100	11.6				
Choanal atresia	5	0.4	1.7	5	100	1.8				

Digestive system	74	6.3	25.8	71	95.9	25.0	3	4.1		
Esophageal atresia with/without fistula	12	1.0	4.2	12	100	4.2				
Ano-rectal atresia and stenosis	26	2.2	9.1	25	96.2	8.8	1	3.8		
Diaphragmatic hernia	18	1.5	6.3	16	88.9	5.6	2	11.1		
Abdominal wall defects	7	0.6	2.4	6	85.7	2.1	1	14.3		
Gastroschisis	2	0.2	0.7	1	50.0	0.4	1	50.0		
Omphalocele	5	0.4	1.7	5	100	1.8				
Urinary	323	27.4	113	318	98.5	112.1	4	1.2	1	0.3
Bilateral renal agenesis	18	1.5	6.3	15	83.3	5.3	2	11.1	1	5.6
Renal dysplasia	60	5.1	21	58	96.7	20.4	2	3.3		
Congenital hydronephrosis	194	16.5	67.7	194	100	68.4				
Genital	127	10.8	44.3	126	99.2	44.4	1	0.8		
Hypospadias	108	9.2	37.7	108	100	38.1				
Indeterminate sex	3	0.3	1.0	2	66.7	0.7	1	33.3		
Limb	99	8.4	34.6	92	92.9	32.4	4	4.0	3	3.0
Limb deficiencies, all	17	1.4	5.9	17	100	6.0				
Upper limb deficiency	12	1.0	4.2	12	100	4.2				
Lower limb deficiency	7	0.6	2.4	7	100	2.5				
Club foot - talipes equinovarus	19	1.6	6.6	15	78.9	5.3	2	10.5	2	10.5
Hip dislocation and/or dysplasia	24	2.0	8.4	23	95.8	8.1			1	4.2
Polydactyly	23	2.0	8.0	23	100	8.1				
Syndactyly	9	0.8	3.1	9	100	3.2				
Musculo-skeletal	40	3.4	14	33	82.5	11.6	7	17.5		

Craniosynostosis	6	0.5	2.1	6	100	2.1				
Achondroplasia	3	0.3	1	2	66.7	0.7	1	33.3		
Thanatophoric dysplasia	2	0.2	0.7	2	100	0.7				
Jeune syndrome	2	0.2	0.7	1	50.0	0.4	1	50.5		
Other malformations	42	3.6	14.7	40	95.2	14.1	1	2.4	1	2.4
Situs inversus	10	0.8	3.5	10	100	3.5				
By underlying cause										
Chromosomal	82	7.0	8.6	79	96.3	27.8	3	3.7		
Down Syndrome/trisomy 21	63	5.3	22	62	98.4	21.8	1	1.6		
Edward syndrome/trisomy 18	8	0.7	2.8	7	87.5	2.5	1	12.5		
Patau syndrome/trisomy 13	2	0.2	0.7	2	100	0.7				
Turner syndrome	3	0.3	1	2	66.7	0.7	1	33.3		
Wolff-Hirschhorn syndrome	1	0.1	0.3	1	100	0.4				
Genetic syndromes (including microdeletions)	38	3.2	13.2	36	94.7	12.7	1	2.6	1	2.6
Teratogenic (Carbamazepine embryopathy)	1	0.1	0.3	1	100	0.4				
Conditions outside Q chapter of ICD-10										
Inborn error of metabolism	37	3.1	12.9	37	100	13.0				
Endocrine disorders	7	0.6	0.2	7	100	2.5				
Other	11	0.9	4	11	100	3.9				

Legend:

* The total number of birth defects is greater than the total number of affected births because some had more than one major CA.

§ Severe congenital heart disease (EUROCAT definition): common arterial trunk (Q200), double outlet right ventricle (Q201), transposition of great arteries (Q203), single ventricle (Q204), atrioventricular septal defect (AVSD) (Q212), tetralogy of Fallot (Q213), pulmonary valve atresia (Q220), Ebstein anomaly (Q225), hypoplastic right heart (Q226), aortic valve atresia and stenosis (Q230), mitral valve anomalies (Q232, Q233), hypoplastic left heart (Q234), coarctation of the aorta (Q251), aortic atresia / interrupted aortic arch (Q252), total anomalous pulmonary venous return (Q262).

Legend: Table 3 Common single congenital anomalies (CA) per body system involved

Body system	Total number Of CA	Isolated CA		Common isolated anomalies
		No.	%	
Cardiovascular	424	265	62.5	ventricular septal defects in 75 (28.3%). Atrial septal defects in 67 (25.3%). Pulmonary valve atresia and stenosis in 18 (6.8%). Sever CHD in 54 (20.4%)
Urinary	323	229	70.8	Congenital hydronephrosis in 147 (64.2%). Bilateral renal agenesis in 3 (1.3%).
Central nervous	161	68	42.8	Neural tube defects in 32 (47.1%). Encephalocele in 4 (5.9%)
Gastrointestinal	74	33	44.6	Ano-rectal atresia and stenosis in 16 (48.5%).

				Diaphragmatic hernia in 6 (18.2).
Limb	97	31	32	Total limbs reduction in 9 (29%). Upper limb reduction in 7 (22.6%). Lower limb reduction in 3 (9.7%).
Eye	32	14	43.8	Congenital glaucoma in 6 (42.9%). Congenital cataract in 4 (28.6%). Anophthalmia + microphthalmia in 3 (21.4%).

Legend: Table 4 Distribution of parental socio-demographic characteristics and association with congenital anomaly risk (univariate analysis).

Variable	Cases (total n=1179)		Controls (total n=1262)		Odds Ratio [‡]	95% CI		
	No.	%	No.	%		Lower	Upper	
Consanguinity								
Non-consanguineous	537	45.5	693	54.9	Ref	-	-	
Consanguineous	642	54.5	569	45.1	1.53	1.30	1.8	
Maternal age (years)								

<20	24	2.0	48	3.8	0.58	0.35	0.96
20-30	599	50.8	694	55.0	Ref	-	-
31-40	473	40.1	474	37.6	1.16	0.98	1.37
>40	83	7.0	46	3.6	2.09	1.43	3.05
Paternal age (years)							
20-30	341	28.9	403	31.9	0.92	0.76	1.10
31-40	548	46.5	593	47.0	Ref	-	-
41-50	240	20.4	225	17.8	1.15	0.93	1.43
> 50	50	4.2	41	3.2	1.32	0.86	2.03
Maternal body mass index [‡]							
<18.5	24	2.1	35	2.8	0.75	0.44	1.29
18.5-24.99	324	27.8	388	30.8	0.91	0.74	1.12
25.0-29.99	352	30.2	385	30.5	Ref	-	-
≥30	464	39.9	453	35.9	1.12	0.92	1.36
Previous deliveries (parity)							
Nulliparous	216	18.3	273	21.6	0.92	0.74	1.16
Para 1-2	374	31.7	436	34.5	Ref	-	-
Para 3-4	283	24.0	273	21.6	1.21	0.97	1.50
Para ≥5	306	26.0	280	22.2	1.27	1.03	1.58
Family monthly income Saudi riyals (US \$)							
<3,000 SR (<800\$)	19	1.9	12	1.0	1.87	0.89	3.92
10,000-14,000 SR (2667-3999\$)	235	23.2	277	22.3	Ref	-	-

3,000-6,999 SR (800-1866\$)	232	22.9	291	23.4	0.94	0.74	1.20
7,000-9,999 SR (1867-2666\$)	367	36.3	496	39.9	0.87	0.70	1.09
≥15, 000 (≥4000\$)	158	15.6	167	13.4	1.12	0.84	1.47
Maternal education							
Illiterate	391	33.2	333	26.4	1.50	1.26	1.80
Schooling up to high school	671	56.9	859	68.1	Ref	-	-
University	117	9.9	70	5.5	2.05	1.49	2.81
Folic acid intake							
Periconceptual	109	9.2	128	10.1	Ref	-	-
Improper use ^s	1070	90.8	1134	89.9	1.04	0.79	1.36
Parental Smoking							
Neither parent smoked	837	71.0	888	70.4	Ref	-	-
One or both parents smoked	342	29.0	374	29.6	0.97	0.82	1.16
Radiation exposure in pregnancy							
None	1161	98.5	1254	99.4	Ref	-	-
Radiation exposure in pregnancy	18	1.5	8	0.6	2.43	1.05	5.61
Diabetes mellitus (DM)							
No DM	956	81.1	1062	84.2	Ref	-	-
DM on insulin (all, overt & gestational	86	7.3	41	3.2	2.34	1.60	3.43
Gestational DM on diet only	137	11.6	157	12.6	0.91	0.62	1.16

Sibs of cases and controls (primiparous mothers excluded)							
No affected sibling	757	78.6	932	94.2	Ref-	-	-
Sibling with CA	85	8.8	58	5.7	1.61	1.14	2.27
Medication use in pregnancy							
None	792	67.2	951	75.3	-	-	-
Thyroxin	102	8.7	106	8.4	1.03	0.78	1.37
Insulin	86	7.3	40	3.2	2.34	1.59	3.45
Methyldopa	14	1.2	14	1.1	1.07	0.51	2.26
Maternal systemic illnesses							
None	808	68.5	971	76.9	Ref-	-	-
Mothers with Hypothyroidism	123	10.4	128	10.1	1.03	0.80	1.34
Mothers with Bronchial asthma	106	9.0	97	7.7	1.19	0.89	1.58
Mothers with depression	12	1.0	6	0.5	2.15	0.81	5.75
Mothers with essential hypertension	23	2.0	15	1.2	1.65	0.86	3.19

Footnote:

*BMI not available for 15 mothers

Some families declined reporting their income.

1
2
3
4 §Improper-use includes FA taken post conception and 49 mothers (43 case
5 mothers and 6 control mothers) who were not sure about their intake.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Legend: Table 5 multiple logistic regression model results for the significant risk factors on univariate analysis

Variable	ADJUSTED OR (from multiple logistic regression model) †			CRUDE OR (from univariate analysis)		
	OR	95% C.I.		OR	95% C.I.	
		Lower	Upper		Lower	Upper
Consanguinity, none (reference group)	-	-	-	-	-	-
Consanguinity, first degree	1.52	1.28	1.81	1.53	1.30	1.81
Maternal age, 20-30 years (reference group)	-	-	-	-	-	-
Maternal age, <20 years	0.54	0.32	0.91	0.58	0.35	0.96
Maternal age, >40 years	2.11	1.35	3.30	2.09	1.43	3.05

Maternal education, up to high school (reference group)	-	-	-	-	-	-
Maternal education, illiterate	1.41	1.17	1.70	1.50	1.26	1.80
Maternal education, university	1.74	1.24	2.44	2.05	1.49	2.81
Diabetes on insulin, overt or gestational (yes/no)	1.98	1.33	2.95	2.34	1.60	3.43
Sibling with anomalies (yes/no)	1.49	1.04	2.12	1.61	1.14	2.27

†: Adjustment for consanguinity, maternal age, maternal education, diabetes mellitus, sibling with anomalies.

Figures legend:


Legend: Figure _1 Catchment site and the study flow chart.

Legend: Figure _2 Study population and distribution of pregnancies and their outcomes.

1
2
3
4 Legend: Figure _ 3 Frequency among control subjects of selected risk factors for
5
6 CA.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1- Catchment site and the study flow chart.




Legend: Case catchment areas (A to E). A: antenatal clinic, B: at birth, C: the "one-month clinic, D: geneticist "one-month clinic", and E: other areas. 1,2,3 are postnatal, stillbirth and antenatal respectively. BD, Birth defect

Legend: Figure _1 Catchment site and the study flow chart.

150x120mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure_2 Study population and distribution of pregnancies and their outcomes.




Legend:

PSMMC, Prince Sultan Military Medical City; ETOPFA, Elective termination of pregnancy for foetal anomaly.

†Eight control foetuses were stillbirth.

Figure 3. Frequency among control subjects of selected risk factors for birth defects.



Legend:

BMI, pre-pregnancy maternal body mass index

BD, birth defect

*Frequency of prior child with BD computed among non-primiparous women

Legend: Figure _ 3 Frequency among control subjects of selected risk factors for birth defects.

99x79mm (300 x 300 DPI)

Supplement file

Appendix

Confidential



PSMMC

Booklet of

“Pattern of Fetal Malformations in a Saudi Population”

Study

Control

Local ID No.: _____ / Year 201

Mother’s Name:

Mother’s MRN:

Baby’s Name:

Baby’s MRN:

Date of Birth:

_____ / _____ / _____

Contact No: Mobile (husband)

Mobile (wife)

Home

Confidential

Keep in a safe place

Pattern of Malformations Study – PSMMC

(Baby and mother)

Local ID No _____

D.O.B. (dd/mm/yy): ____/____/____ Year: 201__

D. O. B./ Year Unknown Sex: Male Female indeterminate Not known

No. of babies delivered: Singleton 1 Twin 2 Triplet 3 Quadruplet 4
 Quintuplet 5 Sextuplet 6
 Not known 9

Specify twin type of birth, like or unlike sex, zygosity: _____

No. of malformed (in multiple set): No. ____ Not known Type of birth: Live Birth (LB). Still Birth (SB) Spontaneous Abortion TOP Not known Civil registration status LB SB No CR Not known Birth weight (g): _____ Confirmed Length of gestation (weeks): _____ Confirmed

Survival beyond one week of age:

Yes No Alive at discharge <1 Week Not known

Date of death (dd/mm/yy): ____/____/____ Year: _____

D. O. B. Mother (dd/mm/yy): ____/____/____ Year: _____ Confirmed

Age of mother at delivery: _____

Pattern of Malformations Study – RMH

(Baby and mother)

Local ID No _____

Mother's residence code at conception: Province _____ District _____

Mother's residence code at delivery: Province _____ District _____

Total No. of previous pregnancies: None Number (___) Not known

When discovered:

At birth Less than 1 wk 1-4 wk 1-12 m >12 m Prenatal diagnosis

At abortion (sp) or termination Not known Postnatal diagnosis, age not known

Condition at discovery: Alive Dead Not known

Gestational age at discovery (wk): _____

First positive prenatal test:

US at <14 wks US at 14-21 wks US at ≥ 22 wk US GA unknown
Serum/combined screening CVS Amniocentesis Other tests positive

No positive test, all results negative

Specify 'other' prenatal test: _____

Karyotype of infant/ fetus:

Performed, result known Performed, result unknown

Not performed Probe test performed Failed Not known

Specify karyotype: _____

Post mortem exam:

Performed, result known Performed, result unknown

Macerated fetus Not known Not performed

First surgical procedure:

Performed (or expected) in the first year of life

Performed (or expected) after the first year of life

Prenatal surgery No surgery required

Too sever for surgery Not known

Pattern of Malformations Study – PSMMC

(Prenatal Malformations)

Local ID No _____

	Code	Text
Syndrome:		
Malformation 1:		
Malformation 2:		
Malformation 3:		
Malformation 4:		
Malformation 5:		
Malformation 6:		
Malformation 7:		
Malformation 8:		

1
2
3 **Pattern of Malformations Study – RMH**

4
5 (All Malformations)

6
7 Local ID No _____

8
9

	Code	Text
11	Syndrome:	
12		
13	Malformation 1:	
14		
15	Malformation 2:	
16		
17	Malformation 3:	
18		
19	Malformation 4:	
20		
21	Malformation 5:	
22		
23	Malformation 6:	
24		
25	Malformation 7:	
26		
27	Malformation 8:	
28		

29

30
31 **McKusick code:** _____

32
33 **Aetiology:**

34
35 Chromosome **C** Familial **F** Isolated **I** Multiple **M**

36
37 New Dominant **ND** Other Genomic **OG** Syndrome **S** Teratogens **T** Inborn

38
39 Error of Metabolism **IEM** Control **Co**

40
41
42
43

44 **View anomaly subgroup(s):**

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – RMH

Local ID No _____

Assisted conception: No Induced ovulation only Artificial insemination
 In vitro fertilization Gamete intrafollopian transfer
 Intracytoplasmic sperm injection Egg donation Other
 Not known

Mother's occupation: House wife Teacher Student Other

Maternal Systemic illnesses;

None EHT Hypothyroidism CHD
 RHD CRF Asthma SCA SLE
 IDA Anxiety Depression Epilepsy
 Other (specify) _____

Weight before pregnancy (Kg) _____

Current weight (Kg) _____

Mother's height (m) _____

Body Mass Index: <18.5 18.5 – 24.9 25 – 29.9
 30.0 – 34.9 35.0 – 39.9 ≥ 40.0

True DM: Yes No

Gestational DM on Diet (GDOD)

Gestational DM on Insulin (GDOI)

Diabetes screening: GTT (result) 0 time: _____ 1hour: _____ 2 hours: _____

Booking RBS: _____

HbA1c _____

Infectious disease:

Tuberculosis: Before pregnancy During pregnancy 1st T 2nd T 3rd T

Rubella Before pregnancy During pregnancy 1st T 2nd T 3rd T

CMV Before pregnancy During pregnancy 1st T 2nd T 3rd T

Toxoplasmosis Before pregnancy During pregnancy 1st T 2nd T 3rd T

Syphilis Before pregnancy During pregnancy 1st T 2nd T 3rd T

UTI Before pregnancy During pregnancy 1st T 2nd T 3rd T

Fever Before pregnancy During pregnancy 1st T 2nd T 3rd T

FLU Before pregnancy During pregnancy 1st T 2nd T 3rd T

Others Before pregnancy During pregnancy 1st T 2nd T 3rd T

(Specify others) _____

Previous surgical history: Obstetrical/Gynaecological

Specify; _____

Non Obstetrical

Specify; _____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pattern of Malformations Study – PSMMC

Family history & sociodemographic

Local ID No _____

Folic acid supplementation:

At least 0.4 mg folic acid supplement taken regularly, starting periconceptionally

Folic acid supplement taken irregularly or starting post-conceptionally

No folic acid supplement taken or not recorded

ATC code

Text (**only** drugs taken in the 1st trimester of pregnancy)

Drugs 1:		
Drugs 2:		
Drugs 3:		
Drugs 4:		
Drugs 5:		

Consanguinity: Not related or relationship more distant than second cousin

Relationship of second cousin or closer Not known

Specific information on consanguinity:

Sibs with anomalies: Same Other Same and other No Not known

Previous sibs notified to the Saudi Malformations Registry: Yes No Not known

Local ID of previous sibs notified to the SMR (1): _____

Local ID of previous sibs notified to the SMR (2): _____

Local ID of previous sibs notified to the SMR (3): _____

Mother's family with anomalies: Same Other Same and other No

Not known Specify _____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Father’s family with anomalies: Same Other Same and other No

Not known Specify _____

Maternal education: Illiterate Elementary and lower secondary

Upper secondary Tertiary Not known

Family monthly income (SR): _____

(husband or combined husband and wife income)

Nationality: Saudi None Saudi Only father Saudi Only mother Saudi

General additional comments:

1
2
3
4
5
6
7
8 **Pattern of Malformations Study – PSMMC**

9 Local Vars. (1)

10
11
12 Local ID No _____

13
14 **Place of birth:** _____

15
16 **Birth order (in multiple set),** (please write as 1st, 2nd, 3rd and so on): _____

17
18 **Date of discovery (dd/mm/yy):** ____/____/____ **Year:** _____

19
20 **Amniocentesis:** Performed result positive Performed result not known

21
22 Not performed Performed result negative Failed Not known

23
24 **Ultrasound:** Performed result positive Performed result not known

25
26 Not performed Performed result negative Failed Not known

27
28 **Chorionic villous sampling:** _____

29
30 **Other techniques:**

31
32 Performed result positive Performed result not known Not performed

33
34 Performed result negative Failed Not known

35
36
37
38
39 **Specify other technique for prenatal diagnosis:** _____

40
41 (Cordocentesis,..etc)

42
43 **No. of previous spontaneous abortions:** None 1 2 3 4

44
45 5 6 7 8+ Not known

46
47 **No. of previous TOP:** None 1 2 3 4 5

48
49 6 7 8+ Not known

50
51 **No. of previous live births:** please write the exact No (1-20) _____ Unknown

52
53 **No. of previous stillbirths:** None 1 2 3 4

54
55 5 6 7 8+ Not known

56
57 **Mode of transmission:** Familial De novo Not known

Habitual exposures: Smoking F179 Oude F159
 Other (specify) _____

Unusual exposures: X-ray during pregnancy (any) Nuclear medicine during pregnancy
 (Radiation & chemical)

Date of birth of father: ____/____/____ **Year:** _____ **Age of father:** _____

Occupation of father: Soldier Officer Civilian

Pattern of Malformations Study – RMH

Local Vars. (2)

Local ID No _____

Date of last LMP: ____/____/____

Certainty of LMP: Certain Uncertain No LMP Not known

Labor: Spontaneous Induced No labor

Delivery: Spontaneous EMLSCS ELSCS ABD
 Instrumental

Sources of information 1:

Notes in routine scan Birth notification or notification of malformation at birth

Hospital case notes Death or stillbirth certificate Prenatal diagnosis

Lab. report (cytogenetic ... etc) Postmortem exam Other Not known

Sources of information 2: please insert as in one _____

Sources of information 3: please insert as in one _____

Sources of information 4: please insert as in one _____

Sources of information 5: please insert as in one _____

Racial information Mother, Tribe code _____ Father, Tribe code _____

Same tribe Different tribe

Otaibi 1, Mutairi 2, Shuhri 3, Asiri 4, Shamrani 5, Onazi 6, Shahrani 7, Zaharani 8, Harbi 9, Qahatni 10, Ghamdi 11, Shamari 12, Asmari 13, Ahmari 14, Amri 15, Dawsari 16, Harthi 17, Subaie 18, Ajman 19, Not known (99)

Other 20, specify: _____

Chronic illness of father (including drug abuse): _____

Confirmation of diagnosis:

Follow up needed for further confirmation Confirmed at <6 months
Confirmed at 6-12 m Confirmed at 12-18 m Confirmed at 18-24 m
Not confirmed, lost for follow up

Source: Booked Un booked Referred

Checklist

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	Observational, prospective cohort design with a nested case-control study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Abstract Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a CA, for an overall prevalence of 412/10000 total births, or 1 in 24 births.
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	<p>Congenital anomalies(CA) are increasingly recognized as a global health priority because of their lifelong impact on health and survival.^{1,2}</p> <p>CA affect approximately an estimated 1 in 33 newborns, contribute each year to 300,000 deaths in the first month of life, and are associated with 3·2 million birth-related disabilities.³ Accordingly, the World Health Assembly has emphasized the urgent need for action to help prevent, diagnose, and provide timely intervention.¹</p>
Objectives	3	State specific objectives, including any prespecified hypotheses	4,5	In this study, we implemented an integrated approach to generate these data in well-defined cohort of women, tracked from mid-gestation through the second year of life of their children, to assess concurrently the burden of potentially modifiable risk factors, the occurrence of CA, and survival of affected children, as a basis for better prevention and care. ⁴
Methods				
Study design	4	Present key elements of study design early in the paper	5	Observational, prospective cohort design with a nested case-control study.

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group		n/a
Bias	9	Describe any efforts to address potential sources of bias	5,6	Pregnancies referred from other hospitals because of a diagnosis of a foetal anomaly, and babies with CA delivered elsewhere and referred to PSMHC for evaluation and management
Study size	10	Explain how the study size was arrived at	5	All mother delivered at PSMHC during the study period were included
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9,10	Odd ratios for CA were computed first via univariate logistic regression, then with a multiple logistic model. The latter was developed by first including uncorrelated significant factors ($p < 0.05$) from the univariate analysis, then reducing the number of variables by stepwise backward elimination for a more parsimonious model.
		(b) Describe any methods used to examine subgroups and interactions		n/a
		(c) Explain how missing data were addressed		
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	n/a randomization n/a

		(e) Describe any sensitivity analyses		n/a
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9 -11	All mothers and their offspring were included. For details see Figure 2.
		(b) Give reasons for non-participation at each stage		n/a
		(c) Consider use of a flow diagram		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	29 - 32	All demographic data were shown in Tables 4 and 5
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure		
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8	2 – 5 years. Follow up. Case-infants (with CA) and control-infants were examined in the dedicated study clinic at 1, 6, 12, 18 and 24 months of age
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time		
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	9	1179 as cases and 1262 as controls
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	9-11	Of the 28 646 eligible pregnancy outcomes, 1179 were diagnosed with a CA, for an overall prevalence of 412/10000 total births, or 1 in 24 births. Of these 1179 cases, 38 (3.2%) were stillbirths and 18 (1.5%) were electively terminated because of lethal malformations

		which confounders were adjusted for and why they were included		(13 with anencephaly, 3 with severe hydrops foetalis and cystic hygroma, 1 with Meckel-Gruber syndrome and 1 with bilateral renal agenesis). The antenatal detection rate among women who has had antenatal ultrasound screening examination was 70.6%(561/795), tables b 1,2,3
		(b) Report category boundaries when continuous variables were categorized		
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		n/a
Discussion				
Key results	18	Summarise key results with reference to study objectives	2	In this cohort of women, the burden of potentially modifiable risk factors included high rates of diabetes (7.3%), maternal age >40 years (7.0%), consanguinity (54.5%), and lack of periconceptional folic acid use (90.8%). The birth prevalence of CA was 41.2/1,000 births (1179 cases / 28646 live births and stillbirths), driven mainly by congenital heart disease (14.8 per 1000), renal malformations (11.3), neural tube defects (1.9), and chromosomal anomalies (2.7). Mortality for live births with CA at 1 and 2 years of age was 14% and 15.8%, respectively.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15	Single centre study, Army personnel household only
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15	High prevalence of CA, multiple modifiable risk factors.

Generalizability	21	Discuss the generalizability (external validity) of the study results	15	Since it's a single centre study, it should be generalized with caution as mentioned in the discussion.
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2	This project was supported by King Abdul-Aziz City for Science and Technology (KACST) through the National Science, Technology and Innovation Plan (NSTIP). Project No: 09-MED748-21. The funder has no role in this study.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.